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Cell therapies are typically limited by the rapid dispersal of cells on delivery. Scaffolds offer an 
approach of enhancing therapeutic efficiency and efficacy as a delivery vehicle and implantable niche. 
This project aimed to combine the bio-intelligent properties of fibrin-based scaffolds with the 
potential of MSC cell therapies for activating healing in chronic wounds.  
A highly porous fibrin-based biomaterial scaffold was developed using an optimised emulsion 
templating technique. Templating enables reproducible manufacture of materials with a regular, 
highly porous structure with a high degree of pore interconnectivity and consistent pore size 
distribution. The method was optimised to generate a range of pore diameters suitable for skin tissue 
engineering, but it could be adjusted for other purposes. What differentiates this method is that the 
emulsion is amenable to incorporation of protein monomers without causing any denaturation, which 
allows the creation of a native-like structure during fibrin formation. The initial structure is then 
stabilised by glutaraldehyde cross-linking. The resulting scaffold is suited to cell ingress and supporting 
angiogenesis and allows fluid and nutrient exchange between the scaffold and the wound 
environment.  
The experimental work undertaken to design a suitable emulsion produced results which, to the 
authors’ knowledge, have not been reported elsewhere. The two distinct patterns of behaviour 
identified suggest specific surfactant traits that make certain kinds of surfactants extremely useful in 
supporting high internal phase emulsions. The reason(s) for this are unclear, but the overall trend has 
potential utility in emulsion formulation. ‘Oil carrying capacity’ (OCC) is proposed as an index for 
ranking surfactants by the oil fraction (in an oil-in-water emulsion) for which stability is greatest. 
This project is divided into two main sections: emulsion formulation and using the optimised emulsion 
to template a scaffold that was then refined to produce a material with appropriate structural, 
mechanical, and biochemical properties for skin tissue engineering. Emulsion design encompassed 
degradation kinetics and achieving appropriate internal phase droplet size, packing and size 
distribution for cell and blood vessel ingress. Successful emulsions were then tested for protein 
compatibility and used to template various fibrin-based scaffolds. By iterative redesign, refined and 
reproducible scaffolds were produced that were characterised by various means to assess their 
suitability as skin tissue engineering scaffolds. 
This work describes a novel biocompatible fibrin scaffold with optimised microstructure for cell ingress 
and angiogenesis, excellent handling capabilities in both freeze-dried and rehydrated forms and 
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Skin is the largest organ of the body and is instrumental in homeostatic regulation as well as forming 
a physical barrier to infection (Percival, 2002; Walters and Roberts, 2002). When skin is wounded and 
this protective barrier is breached, it is important to repair the damage quickly to restore function 
(MacNeil, 2007). However, some wounds do not heal readily, leaving patients in pain and at risk of 
secondary illnesses (Ehrlichman et al., 1991; Guest et al., 2015). These non-healing wounds may be 
chronic wounds such as ulcers, but another example is extensive partial- or full-thickness burns. The 
normal wound healing mechanism may not be impaired in the same way that it is in chronic wounds, 
but the extent of severe burn injuries means that the time required to restore the epidermal layer can 
be excessively long (Papini, 2004; Percival, 2002). There may also be insufficient healthy tissue 
remaining for graft repair, the current gold standard (Atiyeh and Costagliola, 2007; Dai et al., 2018; 
Hrabchak et al., 2006).  
In these cases, intervention is required to facilitate healing. Where conventional therapies fail, tissue 
engineering strategies may be deployed (Boyce and Lalley, 2018; Garcia-Gareta, 2019; Vig et al., 2017; 
Yu et al., 2019). This may take the form of transplanted cells, growth factors or biomaterial scaffolds 
of various composition (Bhardwaj et al., 2017; Chua et al., 2016; Frueh et al., 2016; Whang et al., 2000; 
Yu et al., 2019).  
The aim of the project is to produce an appropriate scaffold to support regeneration of skin tissue 
damaged by burns or chronic wounds, such as diabetic ulcers. It is generally accepted that tissue 
engineering scaffolds must fulfil a series of biological, structural and mechanical requirements to 
achieve in vivo efficacy (Garcia-Gareta, 2019; Hutmacher, 2001; Jones et al., 2002; Yannas and Burke, 
1980). As a minimum, the scaffold produced for this project must meet the following requirements.  
1) The scaffold must be capable of physically filling the defect caused by the tissue damage (or 
the excised wound site) and integrating with the healthy surrounding tissue (Schulz et al., 2000; 
Yannas and Burke, 1980). This may be achieved by either ingress of migratory cells and 
migration of wound margin keratinocytes, or cellular colonisation of the scaffold before 
implantation; or a combination of the two (Zhong et al., 2010).  
2) Engineering approaches to scaffold manufacture have sought to integrate the scaffold with the 
surrounding tissue by matching their elasticity and tensile strength (Janson and Putnam, 2015; 
Sander et al., 2014; Vidal et al., 2019). The scaffold must have a high degree of porosity with 
good interconnectivity to allow for the movement of cells and diffusion of nutrients and waste 
(Busby et al., 2001; Thomson et al., 1995; Whang et al., 2000). Pores must be of an appropriate 
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size to host cells and allow them to develop an appropriate morphology and proliferate 
(Bokhari et al., 2007; Busby et al., 2001; Dagalakis et al., 1980; Sultana and Wang, 2008).  
3) The biomaterial must be non-cytotoxic and biocompatible with the host tissue to avoid an 
inflammatory response that could lead to rejection (Hutmacher, 2001; MacNeil, 2007). 
Appropriate material selection (or coating) may even be beneficial to the healing wound. The 
scaffold must persist long enough to adequately support the fragile wound site but degrade in 
line with the rate of tissue repair to safe, readily metabolisable products (Busby et al., 2001; 
Langer and Vacanti, 1993).  
The project is industrially sponsored and is intended for eventual commercialisation. This influenced 
decisions about both method and materials from the outset to ensure the scaffold had the potential 
for straightforward technology transfer. Ease of manufacture and potential scalability are therefore 
additional, though secondary, considerations. So too is the cost/benefit ratio of the scaffold, the 








Scope of thesis 
This thesis discusses the design, development, and characterisation of a biomaterial scaffold from first 
principles. It aims to explain the rationale for such a material, given the large number of commercially 
available ‘wound healing’ products and attempt to summarise the overwhelming and at times 
contradictory literature surrounding these products. The experimental work encompasses the design 
of the scaffold and also of the emulsions used to template them. These processes were not mutually 
exclusive and were performed concurrently in an iterative manner. For the sake of clarity, the work is 
not presented chronologically and is instead arranged to follow a logical narrative.   
The thesis comprises four chapters, the first of which provides an overview of the normal structure 
and function of skin; the pathology of normal wound healing and the instances where wound healing 
is impaired. It further discusses the clinical and socioeconomic need to resolve recalcitrant wounds, 
and introduces the role of tissue scaffolds in addressing this need. 
The second chapter summarises the relevant literature, covering the development of tissue 
engineering scaffolds; their successes and limitations; the relative merits of different manufacturing 
techniques and the scaffold properties arising. Emulsion templating is evaluated in more depth as a 
method of manufacturing scaffolds. The ‘ideal’ biological, structural, and mechanical scaffold 
properties are discussed, as is the relevance of fibrin as a scaffold material to achieve these criteria.   
Chapter three presents the experimental work in four different sections. Firstly, emulsions were 
prepared, evaluated, and refined for stability and droplet size. Secondly, emulsions with appropriate 
stability were used to template scaffolds, with fibrinogen and thrombin incorporated into the 
continuous phase. The emulsions were further optimised, taking into account salinity of the buffer 
and concentration of the aqueous phase, to maintain stability while increasing the oil fraction to 
generate stable emulsions capable of producing highly interconnected porous materials. In the third 
section, candidate materials were evaluated for mechanical strength (tensile and bulk compression 
testing), cytocompatibility and degradation in storage as well as wound environments. Assessment of 
the angiogenic potential of optimised scaffolds and commercial products is presented in the fourth 
section of the experimental chapter. This work was performed using fertilised hens’ eggs in an in 
vitro/in vivo bridge model. 
The fourth and final chapter presents the conclusions arising from this project and presents 
suggestions for future work. The scaffolds produced for this project have only been manufactured in 
a small laboratory setting and would require extensive and rigorous testing to meet regulatory 




Chronic wounds, such as diabetic ulcers, affect 200,000 people in the UK alone (Posnett and Franks, 
2008), and cost the NHS an estimated £3bn a year to treat (D McColl et al., 2009). There are an 
estimated 24,000 UK hospital admissions for diabetic foot ulcers alone. With NICE estimating the 
number of people living with diabetes to almost double between 2013 and 2025, this figure is only 
expected to increase (NICE, 2015). Amid growing pressures on health services and care provision, 
there is a requirement to move towards treatment, rather than management, of chronic wounds. This 
would not only reduce the economic burden of such wounds, but also more importantly improve 
patient outcome and quality of life. 
Biomaterials have long been investigated as a means of supporting regeneration of tissue damaged 
by burns or chronic conditions. The use of scaffolds for tissue grafting and repair using allogenic cells 
has been under development for the last 25 years (Langer and Vacanti, 1993); however, few scaffolds 
are being produced and marketed at the scale, cost and speed required to seriously tackle the burden 
of chronic wounds.  
A scaffold is a substrate material into which cells may be loaded for transplantation. Much like building 
scaffolding, it creates a supportive structural framework which plugs a physical gap in the injured 
tissue, while providing an internal microenvironment that houses cells (such as stem cells), allowing 
them to communicate, produce extracellular matrix and ultimately regenerate the wound by 
producing healthy tissue that integrates into its surroundings. The scaffolding material itself may 
promote wound healing by direct interaction with ingressing cells, or by release of bioactive agents. 
This may be achieved by selection of a compatible, bioactive material such as a native protein, or an 
inert substrate functionalised with a bioactive coating. 
While scaffolds may be applied acellularly (de la Puente and Ludeña, 2014), and rely on colonisation 
by cell ingress and vascular invasion from the wound margin (Klin et al., 2007); it is generally accepted 
that successful wound regeneration by tissue regeneration requires suitable scaffolds to be used in 
combination with a cellular component and/or a bioactive component (Ahmed et al., 2008; Whang et 
al., 2000). The bioactive component may promote proliferation and differentiation of cells 
transplanted in the scaffold or host cells. 
In the last century there has been enormous development in the treatment of serious skin injuries, 
particularly with the advent of modern tissue engineering. However, there has always been a lag 
between laboratory developments and improved clinical outcomes. Historically this has been due to 
lack of detailed knowledge of the pathophysiology in these complex wound environments. More 
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recent challenges include how to promote regeneration (newly formed matrix resembling native 
tissue, with total function and no scarring) as opposed to loss of tissue or healing with scarring, 
contracture, or other loss of function.  
Successful future therapies should draw on the successes of the past and combine to create a 
treatment that promotes regeneration or at least improved healing. Research has shown that supply 
of stromal cells and/or biochemical agents such as growth factors have the potential to achieve this. 
Biomaterial scaffolds offer the opportunity to replicate the success of autologous cell therapies with 
a single biopsy rather than several painful harvesting surgeries which further expose immune-
compromised patients to risk of infection.  
This project was a collaboration between The Open University and Consorcio Regenero/Cells for Cells, 
a stem cell company based in Chile. The goal of the project is to design and create suitable scaffolds 
to support stem cells, provided by Regenero, in order to deliver them into wound environments and 
promote their proliferation and differentiation into skin-type cells that can remodel damaged tissue.  
The particular focus was on healing skin damaged by burns or chronic wounds.  
Scaffold samples were sent to Chile for testing with Regenero’s cells. The results are held by Regenero 
and are not discussed or disclosed in this thesis. The work therefore focused on development of the 
scaffold material and manufacturing techniques. There were two novel aspects to this work: firstly, 
the pattern of emulsion behaviours described in Chapter 3.1 have not, to our knowledge, been 
reported previously. Secondly, the manufacturing process here enables tightly controlled templating 
of highly porous protein scaffolds with their native structure retained. This is an important distinction 
from other protein scaffolds made from comparable methods, as the conditions and/or reagents 





Skin and its structure 
Skin forms a barrier over almost the entire surface of the body and is a vital barrier to the environment 
that protects against infection. The various structures and components of skin together give rise to its 
global physiology. These structures are illustrated in Figure 1 and described below. 
The outer epidermal layer confers barrier function. The underlying dermis provides mechanical 
support and thermal regulation. It contains a wide variety of cells types and supporting structures. 
Under the dermis is the hypodermis which acts as an energy reserve, releasing fats from its adipocytes 
when required. 
 
Fig. 1: Cross-sectional view of full thickness human skin. Skin comprises three distinct layers: 
the epidermis, dermis, and hypodermis. The epidermis comprises five sub-strata, culminating 
in the stratum basale, which forms the boundary with the underlying dermis. The dermis is 
the thickest layer of skin. It contains two sub-strata; one of loosely packed collagen and one 
of thicken collagen bundles. Elastin and proteoglycans are also present, providing elasticity 
and hydration to the extracellular matrix surrounding the dermal fibroblasts. The deepest 
layer of skin is the hypodermis, or subcutaneous layer. This is largely composed of 
subcutaneous fat tissue. Image adapted from Rook’s Textbook of Dermatology (McGrath et 




The outermost layer, the epidermis, constantly renews by sloughing off dead cells and replacing them 
with cells migrating upwards from lower levels. These cells change in their characteristics to become 
keratinized (hardened and senescent) as they migrate to the surface. 
The epidermis comprises five sub-strata, the first of which, the stratum corneum, consists of a layer 
of these keratinized cells and forms a waterproof barrier to the environment. The stratum lucidum, 
most notable in thicker epidermis, is a thin layer of dead cells. These slough off and are replaced by 
underlying cells as part of the dynamic skin renewal process. The stratum granulosum is a thin layer 
formed by keratinocytes migrating up from the stratum spinosum underneath. This layer is so named 
due to its spiny appearance (Montagna and Parakkal, 2012), arising from microfilaments between 
desmosomes shrinking when stained for histological imaging (Bensouilah and Buck, 2006). The 
stratum basale is the lowest layer of the epidermis and forms the boundary with the dermis below.  
The epidermis is primarily composed of keratinocytes. Small numbers of other cells types with a 
diverse array of functions are also present. These include Langerhans cells, antigen-presenting 
immune cells, present in all layers except the stratum corneum. Together with the barrier function of 
the stratum corneum, these cells help protect the skin from infection. Present in the stratum basale 
are melanin-producing melanocytes, and Merkel cells (‘light touch’ mechanoreceptors) (Kamel et al., 
2013; Montagna and Parakkal, 2012; Szabo, 1967). Melanocyte density is dependent on the location 
– for example, it is higher on the face and other regions frequently exposed to sunlight (Szabo, 1967). 
Below the epidermis is the dermis, the thickest of the three layers of skin, composed of connective 
tissue. The dermis supports the derivative structures of skin, such as hair follicles and sweat glands 
(Bensouilah and Buck, 2006). It is highly vascularised by the dermal plexus, a dense capillary network 
(Schulz et al., 2000). This capillary network is supported by venules and arterioles in the hypodermis. 
The epidermis, however, is avascular. 
The dermis comprises two sub-layers: a thin papillary layer, and a thicker reticular layer. The papillary 
layer lies next to the stratum basale of the epidermis and contains a loose mesh of collagen fibres. 
Underneath, thicker bundles of collagen lie parallel to the various strata – this is the reticular layer 
(Bensouilah and Buck, 2006; Montagna and Parakkal, 2012).  
These collagen fibre meshes provide mechanical strength and structural integrity to the dermis. They 
allow the dermis to provide structural support to the epidermis and underlying tissues. The thickness 
of the hydrated dermis also helps provide thermal insulation. The primary cell type present is 
fibroblasts, but some immune cells (mast cells and macrophages) are also present. Dermal fibroblasts 
produce collagen, elastin and proteoglycans – the components of extracellular matrix (ECM) (Tessmar 
23 
 
and Göpferich, 2007). The principal component is collagen (70%) which gives the dermis mechanical 
strength and toughness. Elastin improves flexibility and elasticity. Proteoglycans impart hydration and 
a degree of viscosity to the dermal ECM (Bensouilah and Buck, 2006). 
The dermis also carries motor and sensory nerve endings. Nerve density varies with location. Sensory 
nerves in the skin serve to sense pain, temperature, and pressure. Conditions in which sensory 
function is impaired, such as diabetic neuropathy or traumatic injuries which destroy nerve endings, 
can cause delays in detecting wounds and seeking treatment (Sidawy, 2006). An example is diabetic 
ulcers, another co-morbidity of diabetes which may occur alongside diabetic neuropathy and which 
arises from venous insufficiency. These ulcers commonly occur in less visible locations, such as the 
soles of feet. Neuropathic patients who cannot feel pain from the ulcer may not realise there is a 
wound. Intervention is delayed, during which time the ulcer is likely to worsen. Neuropathic patients 
are also more likely to obtain traumatic injuries like burns as their autonomic aversion response (for 
example, to extremely high temperatures) is impaired (Falanga, 2005). Nerves are therefore a vital 
component of skin in normal homeostasis and in early detection and response to wounds. 
The third, deepest, layer is the hypodermis; composed of loose connective tissue and adipose tissue 
(Bensouilah and Buck, 2006). Some deeper sweat glands also extend into the hypodermis (Montagna 
and Parakkal, 2012).  
 
Classification of wound type and severity 
Wounds may be classified by the type of injury, their depth, and propensity to heal in a defined 
timeframe. Wounds are broadly divided into acute wounds, which heal in a timely fashion according 
to a classical model of wound healing; and chronic wounds – recalcitrant wounds that heal very slowly 
or may not heal at all without appropriate intervention (Li et al., 2007; Robson, 1997). Such wounds 
may not be as immediately severe as acute wounds, but the longer a chronic wound remains unhealed 
the more susceptible it is to infection (Landis, 2008). This results in increased pain for the patient and 
may lead to sepsis. A summary of different types of both chronic and acute wounds is given in Tables 






Thin wounds made with a sharp edge. Wounds may be deep, but narrow 
enough to suture to allow healing by primary intent. Little damage to 
surrounding soft tissue; little disruption to vasculature. 
Burns 
Burns are classified according to depth. Superficial burns may heal easily; 
partial burns are increasingly damaging with depth into the dermis. 
Maintaining a clean, moist wound is vital. Full thickness burns are excised 
to remove necrotic tissue to promote healing. Scarring is common. 
Degloving 
Injuries caused by a shearing force to the skin edge. Skin may appear 
mottled. Disruption to skin surface may be minimal but de-vascularisation 
to skin and soft tissue can be significant. This can lead to tissue necrosis, 
leading to infection and slowed healing. Excision is vital before suturing.  
Crushing 
Skin may not be broken, but crushing force may cause cell death. Wound 
may require excision or debridement to remove necrotic tissue. Wound 
closed with non-viable tissue left in situ will result in excessive scarring. 









(also known as bed 
sores, decubitus ulcers 
and ischemic ulcers) 
Pressure sores are common in patients with limited or no mobility 
where skin is compressed under body weight. Regions of 
compressed tissue may receive insufficient blood supply, causing 
damage and eventually becoming necrotic. Once the epidermis is 
necrotised, the ulcer is susceptible to infection as supply of white 
blood cells is reduced by impaired vasculature. Pressure ulcers are 
most common on bony areas of the body – heels, ankles, hips, and 
coccyx.  
Diabetic ulcers 
Patients with severe or poorly managed diabetes are at risk of a 
subset of pressure ulcers, known as diabetic ulcers. Reduced 
capillary perfusion in the extremities, often coupled with 
atherosclerotic arteries, can lead to microangiopathy. Blood flow 
and perfusion are further compromised by pressure, so diabetic 
ulcers commonly occur on the soles of the feet. Patients with 
diabetic neuropathy do not feel pain from the injured region, 
allowing injuries to progress undetected.  
Venous ulcers 
Venous ulcers arise from venous insufficiency, for example due to 
impaired venous valves that causes blood to pool in the vein. Fluid 
leakage from the vein into surrounding tissue can cause necrosis and 
lead to ulceration. Ulcers typically occur on the lower leg or ankle. 
Venous ulcers are the most common form of leg ulcers (70-90%).  
Table 2: Examples of chronic skin injuries (Belcaro et al., 2006; Callam et al., 1987; Cullum et 
al., 2001; Harding et al., 2002; Mustoe, 2004; Shea, 1975; Snyder, 2005). 
 
Skin is a dynamic system that constantly renews by sloughing off dead cells and replacing them with 
cells migrating outwards from lower levels. Therefore, the epidermis has an inherent mechanism for 
self-repair and renewal, supported by migration of keratinocytes from the wound margin (Gurtner et 
al., 2008; Papini, 2004). As such, the depth of a wound is a critical factor in the healing outcome. 
Wounds that extend deeper than the epidermis cannot heal in this way without intervention. 
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Clinically, a ‘healed’ wound is simply one in which the epidermal barrier is restored. ‘Regeneration’ is 
a more rigorous term referring to the restoration of the structure and function of the injured tissue 
are restored to their uninjured state.  
First degree, or partial thickness, injuries affect only the outer layer of skin. Breaching the epidermis 
impairs the barrier function of skin, but the dermis below remains intact. The mechanical support 
provided by the dermis prevents the wound gaping or distorting and helps limit the size of the defect. 
In the case of superficial burn injuries, the epidermis is injured but remains intact (Papini, 2004). The 
barrier function of skin remains, so the risk of infection is low and the wound remains hydrated, 
enabling healing to occur more quickly (Cope et al., 1947). 
Injuries restricted to the epidermis are capable of total regeneration with no noticeable change from 
the uninjured tissue, as long as there remains a dermal substrate over which these keratinocytes can 
migrate (Schulz et al., 2000; Yannas et al., 1989). No scar tissue forms as the underlying dermis is not 
damaged no extracellular matrix (ECM) deposition occurs in response to the injury (Shevchenko et al., 
2009).    
However, adult human dermis is not generally thought to be capable of spontaneous regeneration 
(Yannas et al., 1989). As a result, deeper injuries are not able to fully regenerate and instead proceed 
through a process of healing and remodelling, but original tissue structure is not fully restored.   
Partial thickness wounds extend into the dermis. Superficial partial thickness injuries are painful, as 
nerves in the upper dermis are exposed in the wound (Papini, 2004). Healing of the epidermis occurs 
by migration of keratinocytes from the wound margin and dermis adnexa (Ito et al., 2005). 
Regeneration is slower than in superficial injuries, and the rate is determined by the density of adnexa. 
Thicker, hairier skin heals more quickly than thinner hairless skin. Deeper partial thickness wounds, 
where most of the dermis is affected, heal more slowly as the density of dermal adnexa reduces with 
depth (Papini, 2004).  
In superficial, partial thickness burn wounds, cooling the wound and maintaining a moist environment 
are important in preventing progression of the injury to deeper tissue. Deeper partial thickness 
wounds that are not cooled in this way may be still capable of healing in healthy individuals where a 
warm, moist, clean wound environment are maintained; however, bad scarring is likely (Cuttle et al., 
2006; Papini, 2004). To promote better healing, deep partial thickness burns are often excised to 
remove damaged and necrotic tissue and present an amenable surface for healing. The excised wound 
is commonly treated with grafting (Kaufman et al., 1990).  
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In full thickness wounds, all three layers of skin are damaged. Adnexa and native structures capable 
of supporting regeneration are damaged or destroyed in the wound and there is no remaining 
supportive tissue underneath the wound (Schulz et al., 2000). Therefore, healing can only occur by 
migration of cells from the wound margin, which slows down the healing process considerably. As 
migration only occurs laterally, the rate of healing is also strongly dictated by the diameter of the 
wound. Wounds greater than 1 cm in diameter contract strongly and in doing so impair function of 
the tissue (Papini, 2004).  
Full thickness wounds can occur due to trauma (Graham et al., 2013; Weigert et al., 2011); necrotising 
infection (which may require excision) (Akhtar et al., 2006); following surgery (i.e. tumour resection) 
(Tufaro et al., 2007) or as a result of severe burns (Böttcher-Haberzeth et al., 2010; Pham et al., 2007). 
Clinically, these wounds are often treated by application of split-thickness skin graft (STSG) (Frueh et 
al., 2016). This approach is clearly limited – it contains only epidermal keratinocytes and therefore 
lacks the potential to regenerate the complex arrangement of ECM and dermal cells in the deeper 
tissue. The dermis will instead fill with granulation tissue as a defensive mechanism to cover the 
wound (Schulz et al., 2000). Scarring ensues, leading to contraction and a poor cosmetic and functional 
result. Additionally, harvesting STSG results in donor site morbidity so it is not desirable to harvest a 
large quantity of skin graft for patients with extensive injuries (Boyce et al., 2017). In practice, full 
thickness wounds are not considered to be capable of restorative healing by conventional techniques 
(Shevchenko et al., 2009).  
Burn wounds are commonly classified in the same way as other wounds, but using a different 
terminology: first, second or third degree. First degree burns are superficial, second degree burns 
affect the dermis, and third-degree burns affect the full thickness of skin. 
 
A brief history of burns and their classification 
Burns have affected mankind since Neanderthals learnt to create and control fire. Early records of 
their treatment date back to 1500 BC during the time of the ancient Egyptians (Artz, 1970; Liu et al., 
2016). Subsequent civilisations throughout history have created their own remedies using materials 
at hand. These treatments range from the bizarre (wine and myrrh) to the truly unpleasant (cattle 
dung and bees wax) but many ancient treatments contained materials and principles that are still used 
today (Liu et al., 2016). The Chinese were using tea leaves to treat burns over 2500 years ago; recent 
research suggests that green tea leaves provide useful antioxidants to promote healing and may 
stimulate angiogenesis (Liu et al., 2016; Qin et al., 2013; Wang et al., 2004). Hippocrates reportedly 
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applied pig skin mixed with bitumen resin and vinegar solution – an early example of a biological 
xenogeneic skin substitute, with acid perhaps to sterilise the wound. That Hippocrates chose pig skin 
is interesting, as it closely resembles human skin and pigs are still commonly used as model systems 
in clinical trials today.  
Maggots were widely used for debridement to prepare the wound bed. Whilst unpleasant, maggots 
specifically target necrotic tissue and are therefore highly effective at preparing a wound bed (for 
burns or other types of wounds requiring excision) without removing healthy tissue – something that 
would be extremely difficult to achieve by surgical or chemical means without advanced knowledge 
and equipment.   
Early treatments were limited by a lack of fundamental understanding of the pathophysiology. 
Guillaume Dupuytren (1777-1835), an eminent French surgeon, was the first to create a formal 
classification system to assess the severity of burns according to their depth. His six-stage system 
categorised wounds by increasing severity (Androutsos et al., 2011): 
1) Skin redness 
2) Blisters 
3) Partial destruction of the skin 
4) Total destruction of the skin 
5) Charring of muscle tissue 
6) Charring of bones  
His treatment regimen included debridement and application of silver nitrate (a solution which 
blackens the wound on oxidation but provides broad spectrum antimicrobial action) as well as 
“perforated compresses spread with cerate, lint, emollient cataplasms, and calming drinks”. 
Dupuytren importantly recognised the importance of postoperative care and rehabilitation, using 
immobilisation and traction devices to restore the position and function of limbs after injury. He was 
also the first to describe lines of skin tension (Langer lines) which dictate the way that wounds grow 
following incision (Langer, 1861). A practical application is the deliberate orientation of surgical 
incisions to minimise wound size. Though Dupuytren did not use skin grafting in his own work, his 
legacy heavily influenced future reconstructive plastic surgery practices (Goldwyn, 1969).  
Dupuytren’s attempt at burn classification was a useful contribution to the field, but was cumbersome 
and thus superseded by Boyer’s three-stage classification system: erythema, blistering and eschar 
formation (Jackson, 1970; Sneve, 1906).  
A common system for definition and categorisation of burns, with agreed and precise terms, is 
essential for assessment and comparison of injuries. Historical systems like Boyer’s and Dupuytren’s 
classified burns by criteria such as appearance, depth of necrosis or circulatory state. Assessments like 
these fail to take account of the fact that while the surface appearance of new burns indicates the 
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intensity of skin burning, but this may not align with the depth of necrosis and therefore the range of 
tissues damaged (Jackson, 1970). This has implications for prognosis, treatment options and 
postoperative care. As such, the system most commonly used in recent years classifies wounds by 
depth. 
 
Normal wound healing 
Wounds may heal by primary or secondary intention. Healing by primary intention involves the wound 
edges being drawn together, for example with the aid of surgical staples or sutures. Wounds in which 
necrotic tissue is debrided prior to suturing are said to heal by ‘delayed primary intention’. In both 
cases, epidermal closure may be achieved by keratinocyte migration across the narrowed wound site. 
If a wound is too large to close, healing by secondary intention occurs instead. The defect remains 
open throughout the healing process and is therefore prone to infection. The large defect size means 
wound repair is slower and more complex than for healing by primary intent (Beldon, 2010). The 
typical process of healing by secondary intention is outlined below.  
There are three stages of repair in the classic model of wound healing by secondary intention: 
inflammation, formation of new tissue and remodelling of the new tissue (Broughton et al., 2006; 
Gurtner et al., 2008). There may be some overlap between each phase; and the duration and success 
of each stage is specific to the health and environment of the injured individual (Falanga, 2005).  
The response to skin injury is immediate. Inflammatory pathways, cellular components of the immune 
system and the coagulation cascade (discussed in detail below) are all activated (Gurtner et al., 2008). 
Keratinocytes at the wound periphery release IL-1 and TNF-α, signalling to the surrounding cells that 
the epidermis is injured (Kondo and Ishida, 2010). The priority is to seal the defect to prevent blood 
loss. Vasoconstriction occurs, reducing vessel lumen diameter (Broughton et al., 2006). Thrombin-
activated endothelial cells cease production of anticoagulant materials and instead produce von 
Willebrand factor. Thrombin also activates platelets, which become ‘sticky’ and adhere to each other 
and the site of the vessel defect (Marder et al., 2012). Once the wound is stabilised, the inflammatory 
process dilates blood vessels and increases their permeability to support movement of inflammatory 
cells, such as neutrophils attracted by TNF-α and IL-1 (Broughton et al., 2006; Kondo and Ishida, 2010). 
The damage to blood vessels limits the supply of oxygen to the wound bed, creating a hypoxic 
environment (Chen et al., 2008; Falanga, 2005). This hypoxic effect stimulates the progress of healing 
by promoting keratinocyte migration, proliferation of fibroblasts and synthesis of growth factors such 
as PDGF-B, endothelin and TGF-β1  (Falanga, 2004, 2005; Falanga et al., 1991; Kourembanas et al., 
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1990, 1991). These growth factors recruit dermal cells and circulating monocytes to the wound 
environment over the following 2 to 3 days. When sufficient numbers of each are present, neutrophils 
interact with platelets in the wound, causing platelets to release lipoxin A4 or A5 (Broughton et al., 
2006). Lipoxin can resolve inflammation processes in a variety of cell types (Chandrasekharan and 
Sharma-Walia, 2015). It counteracts the pro-inflammatory cytokines to prevent the inflammatory 
response persisting unnecessarily, as doing so may be detrimental. 
The fibroblasts that migrate into the wound bed deposit a disorganised, loosely packed collagen 
matrix. Granulation tissue fills defects but lacks the functionality of intact tissue. It is visually different 
from healthy tissue and may appear unsightly, and it lacks the mechanical strength and elasticity of 
surrounding healthy tissue. This makes granulation tissue more susceptible to further damage or 
injury as it cannot respond to mechanical stress in the same way as the intact tissue surrounding it. 
In an ideal wound healing scenario, tissue is restored to the same level of structural and functional 
integrity as it held prior to injury. Whilst this is not achievable by current methods, and injured adult 
skin will never regain its initial strength, it is possible to restore some native structure and function 
(Levenson et al., 1965). This is achieved during the third and final stage of wound healing in which the 
temporary granulation tissue is remodelled to resemble intact tissue more closely. Remodelling begins 
two to three weeks after injury and can last for a year or even longer. Any residual activity from the 
inflammatory and new tissue formation stages reduces and ceases during the remodelling process. 
Most of the endothelial cells, macrophages and myofibroblasts that were recruited during these 
earlier stages cease activity in the wound area – either migrating away from the area or undergoing 
apoptosis (Gurtner et al., 2008).  
Following this reduction of cell mass in the dermis, a quantity of tissue – comprised largely of type III 
collagen and other ECM proteins – remains in the injury site (Gurtner et al., 2008). Collagen III provides 
tensile strength in the dermis (Cen et al., 2008). A few cells remain, such as fibroblasts and 
mesenchymal stem cells, which are thought to interact to regulate homeostatic function of the 
remodelling skin (Szabowski et al., 2000). The remaining fibroblasts, macrophages and endothelial 
cells that were recruited to the wound in early stages secrete matrix metalloproteinases, which 
gradually remodel the disorganised type III collagen matrix to a matrix composed primarily of type I 
collagen (Lovvorn et al., 1999). Type I collagen is the primary component of intact skin. It is arranged 
in randomly oriented bundles, loosely interwoven in a ‘basket weave’ structure. Tissue remodelling, 
replacing disorganised type III with more structured type I collagen and accompanied by secretion of 
ECM proteins, allows for the tissue to withstand greater strain. Remodelled tissue has greater 
elasticity and strength than transitional (granulation) tissue.  
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Meanwhile, the recruited monocytes differentiate into macrophages. These are thought to be 
involved in coordinating the later stages of healing, although their role is not understood (Gurtner et 
al., 2008). In addition to inflammatory cells, progenitor and stem cells may potentially also be recruited 
(Chen et al., 2008). These, in turn, release a cocktail of growth factors. Recruited fibroblasts and 
endothelial cells begin to form granulation tissue (Falanga, 2005).  This begins wound contraction. 
Contraction occurs when these growth factors stimulate fibroblasts to differentiate into 
myofibroblasts (Mirastschijski et al., 2004). Myofibroblasts contract by an actin-myosin mechanism, 
collectively acting to cause wound contracture. ECM proteins such as collagen, fibronectin and 
vitronectin support the new tissue and provide guidance for cellular movement and contraction 
(Falanga, 2002). Myofibroblasts can cause a wound to contract to less than 10% of its initial size. While 
this effectively reduces the exposed wound surface, the result is a scarred defect with permanent loss 
of function (Schulz et al., 2000).  
The duration of the remodelling phase is influenced by management of the wounds and the general 
health of the patient. By the end of the remodelling phase, the epidermis is restored, and the defect 




















Figure 2: Schematic diagram illustrating the chronological events of wound healing. The 
three major phases of wound healing are distinct in their action, but may overlap as events of 
wound healing are controlled by soluble factors, such as cytokines and growth factors, which 
take time to secrete, diffuse and stimulate a response from target receptors. Overlap of 
phases ensures a continuous, persistent movement towards healing an injury. The major cells 
types involved in each phase are shown alongside their role in wound healing. Chronology 
diagram adapted from Li et al (2007); healing stages image adapted from Opneja et al. (2019).  
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2. Literature Review 
Current treatments 
There are various strategies to achieving wound healing. Narrow incision-type wounds may be cleaned 
to prevent infection and sutured to promote healing by primary intent. This is the best-case scenario, 
as keratinocyte migration and support from the undamaged surrounding dermal appendages allows 
for total regeneration. Wound edges must be clean, in close proximity and not necrotic or otherwise 
unviable for this mode of healing. 
Larger defects must be assessed according to their width and depth to determine an appropriate 
method of treatment. Wounds with a large surface area but shallow penetration, such as abrasions, 
may heal readily by keratinocyte migration and support from underlying dermal structures. However, 
the loss of epidermis impairs barrier function in the wound and the area is susceptible to infection by 
environmental pathogens. Keeping the wound clean is important in preventing infection and 
supporting timely healing.  
In deeper, wider wounds, healing will occur by secondary intention and the wound will fill with 
granulation tissue. Such wounds may be actively treated, or simply covered to keep clean and allowed 
to progress through healing by secondary intent. This may be the case for small, acute wounds where 
healing is expected and the scar will be small and unobtrusive.  
Active treatment is desirable in larger wounds or those expected not to heal without intervention, 
such as recalcitrant chronic wounds. This may be achieved by seeking to seal the epidermis to restore 
the barrier function (i.e. by the application of keratinocytes or a synthetic silicon covering) and 
allowing the underlying tissue to form granulation tissue. The graft may be initially applied using 
surgical staples, sutures or adhesive, but gradually adheres to the wound bed by ingrowth of 
granulation tissue (Jones et al., 2002). Alternatively, constructs may seek to support both epidermal 
and dermal repair by provision of biological stimuli or of a construct designed to support native cells 
and ECM structures.    
The strategies for treating superficial and deeper wounds by tissue engineering constructs are 
discussed briefly below. 
When the epidermis is breached in a superficial wound, keratinocytes migrate from the wound 
periphery and bed, leading to total regeneration with no visible scar. For larger epidermal defects, 
keratinocyte migration from the wound margins alone is not sufficient to cover the wound and restore 
the epidermal barrier (Jones et al., 2002). A single sheet layer of cultured keratinocytes can be used 
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to replace irreparably damaged epidermis (MacNeil, 2007). However, in deeper wounds that extend 
into the dermis, the dermal structures that support healing are compromised and tissue will scar 
rather than regenerate.  
The dermis is not capable of regeneration so this technique is insufficient to adequately replace a full-
thickness defect, either cosmetically or functionally (Schulz et al., 2000). To replicate the thickness, 
durability, and difference in both anatomical and mechanical structures, a second ‘dermal’ layer is 
required.  
Early synthetic scaffolds sought to restore epidermal barrier function by creating a seal to prevent 
infection and fluid loss. The materials used were typically bioinert organic polymers which adhered to 
the wound and provided no stimulus to influence or promote wound healing (Burke et al., 1981). The 
recognition of biocompatible and bioactive materials led to the creation of more ambitious constructs. 
These aimed not only to replace missing epidermis, but also to support the damaged dermis by 
provision of a bilayered construct. (Burke et al, 1981). This tenet provided the basis for Integra® 
(Integra LifeSciences; Plainsboro, NJ, USA); comprising a temporary Silastic outer layer and a porous 
collagen-chondroitin ‘dermis’. The silicon ‘epidermal’ layer is initially bonded to the ‘dermis’ once the 
porous dermal component has integrated with host tissue, the Silastic may be peeled away, allowing 
the epidermis to heal from the wound margin and burgeoning dermal wound bed, or by the 
application of autograft. The porous collagen-chondroitin scaffold supports in-migration of cells from 
the surrounding dermis, and was found to vascularise within 3 to 5 days of implantation (Burke et al., 
1981). Integra® was an important development in the treatment of burn wounds, arguably the most 
significant since the Second World War, as it represented a shift in thinking from merely sealing the 
wound to reduce mortality, to healing the wound and restoring appearance and functionality (Cope 
et al., 1947; Jones et al., 2002; Yannas and Burke, 1980). First patented in the 1980s, Integra® remains 
a leading commercial product in the field.  
More recently, Boyce et al (1999) showed that cultured autologous keratinocytes and fibroblasts, 
seeded onto a collagen-based sponge, could be used in conjunction with Integra® in place of an 
autograft. This approach requires a biopsy to harvest autologous cells, but removes the necessity for 
repeated autograft harvests. If the biopsy is taken early, the cells may be sufficiently expanded to 
apply when the Silastic layer is ready for removal. There is no need to wait for re-epithelialisation of 
graft sites to harvest autografts, and the smaller area and duration of exposed tissue from biopsy 
reduces the risk of infection.  
MySkin (Regenerys, Cottenham, Cambridge, UK) also uses the concept of in vitro expansion of 
autologous keratinocytes to avoid the need for extensive and repeated autograft harvest in burns and 
35 
 
chronic wounds patients. Traditionally taking a similar form to the cultured skin substitute described 
by Boyce et al (1999), keratinocytes are expanded in vitro and delivered to the wound on a polymer 
carrier dressing, allowing a convenient patch method of applying cells to the wound (Moustafa et al., 
2007). MySkin is also available as a spray, where keratinocytes are delivered in a suspension and may 
be applied by spraying directly onto the wound bed. 
Some existing skin replacement constructs present both dermal and epidermal components that 
interact dynamically with each other during in vitro maturation (Stark et al, 2006) and also after 
transplantation (Klingenberg et al, 2010).   
Dermal scaffolds are designed to support cells that will mimic the native dermis. The dermis is highly 
vascularised; it supports the keratinised avascular epidermis by nutrient exchange diffusion (Jones et 
al., 2002; MacNeil, 2007). As such, a key feature of dermal scaffolds – as opposed to typical dressings 
or epidermal scaffolds – is the ability to induce, encourage, or support angiogenesis into the wound 
site (Frueh et al., 2016). This will sustain the regenerating tissue and allow the damaged dermis to 
continue to support the regenerating epidermis above. Dermal scaffolds may be optimised to enhance 
angiogenic potential by modifying the size, number and interconnectivity of pores; using bioactive 
materials, releasing agents or coatings to stimulate angiogenesis; or by chemically modifying the 
scaffold to present a more biocompatible surface to the wound margin (Cam et al., 2015; Frueh et al., 
2016; Wilcke et al., 2007).   
It is worth noting that although human skin comprises three distinct layers, tissue-engineered skin 
substitutes currently available for clinical and commercial use lack the subcutaneous layer (i.e. 
hypodermis) (Monfort et al., 2013).  Whilst it may not be as important as an epidermal or dermal 
replacement in terms of filling the defect and causing cellular regeneration of the wound, the 
hypodermal layer contributes to the mechanical durability and thermal regulation capability of skin. 
Current commercial skin substitutes and scaffolds only comprise two layers, so the functionality of the 
third, hypodermal, layer is lacking. This may be a factor in their disappointing clinical performance.  
However, there is limited literature on the creation or performance of tri-layered skin substitutes. 
While published results are encouraging, (Monfort et al., 2013; Perng et al., 2008; Trottier et al., 2008) 
there has been no move towards commercialisation and little clinical data exists on in vivo efficacy. 
Further evidence is required to demonstrate sufficient improvement over a bilayered product to 





Classification Usage Example product 
i. Anatomical structure Epidermal 
Dermal 
Dermo-epidermal (composite) 
Split-thickness skin graft 
MatriDerm®; Hyalomatrix® 
Apligraf® 




Analogue material; graft 
Material later remodelled 
(e.g. Suprathel®) 
Biobrane® 





Nylon- and silicon- backed 
materials (e.g. EpiDex®) 
e.g. MatriDerm® 










Cadaveric skin graft; OrCel 
Porcine skin graft 
e.g. Dermagraft® 
Nylon- and silicon- backed 
materials 
v. Skin substitute composition 





vi. Primary biomaterial loaded 





Table 1: Classification of currently available skin-substitute products. Collated from 
multiple sources (Atiyeh et al., 2005; Atiyeh and Costagliola, 2007; Clark et al., 2007; Horch 
et al., 2005, 2005; Jones et al., 2002; MacNeil, 2007; Patel and Fisher, 2008; Shevchenko et 





Skin substitutes have been commercially available since the advent of modern tissue engineering in 
the 1970s (Yannas and Burke, 1980). This began with the pioneering of autograft techniques, providing 
a rapid wound covering without the need for donor screening or the risk of immune rejection. 
However, the procedure is painful and may cause donor site morbidity and exposes additional surface 
area to infection in an already compromised patient. Autograft is therefore unsuited to treatment of 
extensive injuries. The use of artificial skin overcomes the drawbacks of the use of autograft and 
allograft/xenograft. There is no donor site morbidity and no wait for donor recruitment and screening. 
Synthetic products can be engineered to render them non-immunogenic.  A range of products, for 
treatment of both chronic wounds and burns, is now commercially available for therapeutic use in 
patients where autograft is not a tenable solution (Jones et al., 2002).  
While autograft remains the gold standard, skin substitutes have the potential match their 
performance without the requirement for painful graft harvesting.  
The application of skin substitutes has been shown to reduce morbidity in patients with severe burns 
(>50% total body surface area burnt) (Boyce et al., 2017). Treatment of these burns requires that 
necrotic tissue be removed to create a viable wound bed and prevent excessive inflammation. This 
cannot be achieved using standard wound dressings alone (Hansbrough, 1990). The use of autograft 
or allograft provides immediate, but temporary, coverage to sustain patients while repair takes place. 
Synthetic dermal substitute products (see Tables 2 and 3) offer not just coverage but depth, structure, 
and support to the regenerating tissue.   
As a minimum, a skin substitute should replace the basic barrier function of the wounded skin, 
preventing dehydration and infection as well as aiding thermoregulation (Kamel et al., 2013). 
However, this only restores epidermal function. The goal is regeneration of the full thickness of the 
damaged tissue. The challenge of skin substitutes is to replace or promote repair of the dermal layer 
that would not otherwise regenerate. This would restore the thickness and function of skin to the 
wound area. However, quality of healing is vital. Excessive contracture or scarring achieves physical 
wound closure but the new tissue is both functionally and cosmetically impaired (Frueh et al., 2016). 
In their pioneering work during the early days of skin tissue engineering, Yannas and Burke (1980) 
identified two goals of artificial skin – to achieve wound closure, and to replace lost or damaged tissue. 
In the short term, substitutes must stabilise patients by establishing a barrier to infection and fluid 
loss. However, preventing functional skin loss requires intervention to reduce scarring and 
contraction.  
Skin substitutes may be excised donor skin (autograft, allograft or xenograft) synthetic or bio-synthetic 
(Pham et al., 2007). Autograft remains the gold standard for re-epithelialisation of critically damaged 
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skin with best restoration and least contracture of the wound site (Boyce, 2001; Mahjour et al., 2015). 
However, limited availability and high risk of donor site morbidity present a need for alternative 
therapy (Böttcher-Haberzeth et al., 2010). Allograft and xenograft (commonly porcine tissue) counter 
these issues, but present problems of graft rejection, ethical issues and the risk of disease transmission 
(Eisenbud et al., 2004; Yannas and Burke, 1980). Non-cellular components of skin grafts – primarily 
ECM proteins and collagen – have low immunogenicity. However, the difficulty of removing 
immunogenic cellular components of these grafts mean that allogenic grafts are ultimately rejected 
and are only suitable for temporary use (Wainwright, 1995). 
    
 

















Wound cavity fills 
and remodels over 
time to restore 
function 
Fig. 1: The use of artificial skin substitutes for repair of injured tissues. Adapted from 
MatriDerm® promotional materials from the MedSkin Solutions Dr. Suwelack website, 
http://www.medskin-suwelack.com/en/matriderm. Page last accessed 16th August 2017. 
 
Current commercial bioengineered skin substitutes do not match the results achieved by autograft, 
but they do achieve some restoration (Klingenberg et al., 2010). They may be used in combination 
with split-thickness autograft, significantly reducing the area of graft tissue required (Boyce et al., 
2006). This reduces both donor morbidity and the number of surgeries required. Bioengineered skin 
substitutes combine biocompatible polymers with cultured cells such as fibroblasts and keratinocytes 
(Klingenberg et al., 2010). There are now a number of commercially available temporary and 
permanent skin substitute products available (Schulz et al., 2000). These are summarised in Table 2 
(products made with naturally derived products) and Table 3 (products based on synthetic materials). 
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Product name Manufacturer Material(s) Indications 





Semi-permeable transparent film of HYAFF®11, a benzyl 
ester of hyaluronic acid (HA derived from bacterial 
fermentation).  
Indicated for management of superficial 
moderately exudating wounds (i.e. venous, 
pressure, diabetic and chronic vascular ulcers; 




New York, NY, USA 
Bilayered allogeneic product used in combination with 
STSG. Fibroblasts seeded on porous side of bovine 
collagen sponge; keratinocytes seeded on non-porous 
side. 
Originally designed to treat epidermolysis 
bullosa. 
OrCel has been used for burns also.  




Derived from cadaveric human skin from tissue banks. 
Epidermis and all cellular components removed, leaving 
dermal matrix. Freeze-dried; rehydrate to use. 
Contains intact collagen fibres to support ingrowth of 
new tissue, elastin filaments to provide strength, and 
hyaluronan and proteoglycans for cell attachment and 
migration.  
Burns, traumatic or oncologic wounds with deep 
structure exposure, hernia repair, breast, and 
other tissue reconstruction. 
Apligraf® 
Organogenesis, Inc.; 
Canton, MA, USA 
Living bilayered skin substitute comprising an 
‘epidermal’ layer of human keratinocytes and a ‘dermal’ 
Intended for use in conjunction with compression 
treatment of partial and full-thickness venous 
skin ulcers (>1 month duration). 
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layer of human fibroblasts in a bovine type I collagen 
matrix. 
Cells are originally derived from donated human 
neonatal male foreskin tissue. 
Contraindicated for use in infected wounds and 
patients with known hypersensitivity to bovine 




Injectable micronized particulate form of AlloDerm.  
Dry form, packaged in syringe, rehydrated prior to use 
with either normal saline or lidocaine for injection.  
Cosmetic soft tissue augmentation and treatment 
of vocal cord paralysis by injection laryngoplasty.  
Hyalomatrix® 
Anika Therapeutics, 
Inc.; Bedford, MA, 
USA 
Hyaluronic acid-based dressing consisting of a 
biomaterial (esterified hyaluronic acid materials). 
Indicated for use in the management of partial 
and full-thickness wounds, second degree burns, 
ulcers (pressure, venous, diabetic, and chronic 
vascular), surgical wounds, tunnelled wounds, 
trauma wounds and draining wounds. 
MatriDerm 
Dr. Suwelack Skin & 
Health Care, 
Billerbeck, Germany 
3D matrix consisting of native structured collagen from 
bovine dermis, and elastin from bovine nuchal ligament. 
Available in different sizes and thicknesses, selected 
according to the demands of the wound. 




Cook Biotech, Inc.; 
West Lafayette, IN, 
USA 
ECM derived from porcine sub-mucosal small intestine, 
primarily composed of collagen, proteoglycans cell 
adhesion proteins, ECM proteins, growth factors and 
GAGs. 
Indicated for use in chronic vascular, diabetic, 
pressure and venous ulcers; trauma wounds, 
management of partial and full thickness wounds. 








Inc.; Mundelein, IL, 
USA 
Silver containing version also available (‘Puracol Plus 
Ag+). 
Bovine collagen (predominantly type I) processed to 
retain a higher degree of tertiary triple helix structuring 
than more heavily processed collagen products. 
Indicated for the management of partial and full 
thickness wounds; pressure, venous, diabetic, 
and mixed vascular aetiology ulcers; first- and 
second-degree burns; donor sites and bleeding 
wounds; abrasions, trauma wounds and surgical 
wounds. 
Not suitable for third degree burns. 
Contraindicated for patients with known 
sensitivity to collagen.  
Table 2: Examples of current commercial scaffolds for skin tissue engineering made using natural materials. This includes both cryopreserved and 
decellularised tissue, as well as scaffolds synthesized from naturally occurring organic polymers such as collagen. Information sourced from Frueh et 




Product name Manufacturer Material(s) Indications 
Products for superficial/epidermal repair 
MySkin Regenerys Ltd.; 
Cottenham, 
Cambridge UK 
Autologous keratinocytes seeded onto a plasma 
polymerised carrier dressing. Keratinocytes may also 
be sprayed directly on the wound. 
Product maturation takes 2-3 weeks from biopsy to 
application.  
Used for severe extensive burns, or chronic wounds 
and ulcers. 
Required biopsy size 4c m2; 0.5 mm thickness 







Bilayered product comprising a thin outer semi-
permeable silicone membrane, bonded to a matrix of 
knitted fabric with adherent purified peptides from 
porcine dermal collagen. 
Native blood clots in the nylon/collagen matrix, 
providing additional adherence 
Debrided superficial to ‘mid-partial’ thickness burns 
with viable wound beds. 




Cryo-preserved 3D human dermal substitute 
composed a bioabsorbable scaffold of polyglactin 
mesh with human fibroblasts seeded. These are 
intended to proliferate to fill the mesh interstices and 
Indicated for treatment of full thickness diabetic 
foot ulcers (>6 weeks duration), in conjunction with 





Sciences Inc.; La 
Jolla, San Diego, 
CA, USA). 
produce ECM and other physiological factors prior to 
cryo-preservation, so the final product resembles 
dermal matrix. 
Contraindicated for infected wounds, wounds with 
insufficient blood supply or ulcers with sinus tracts; 
and in patients with known hypersensitivity to 
bovine products (may contain traces from 
manufacturing and storage media). 
DermaMatrix Synthes CMF, 
West Chester, 
PA, USA 
Cadaver human skin from tissue banks. 
Donor skin is processed to remove all cellular 
components, including epidermis, and then is freeze-
dried. Rehydrate to use. 
Soft tissue repair, breast reconstruction, abdominal 






Autologous keratinocytes (from stem cells of follicular 
outer root sheath of anagen hair) cultured on silicone 
sheets to form a multi-layered epidermal equivalent. 
Production of EpiDex takes 6 weeks after hair 
plucking to harvest keratinocytes. 50-200 hairs are 
required per patient.  
Chronic wounds – those where the wound has not 
healed with optimum standard of care within 3 
months. 








Bilayered product comprising a thin outer layer of 
silicon and the thick inner matrix layer of pure bovine 
collagen and glycosaminoglycans (derived from shark 
collagen). 
Post-excisional treatment of full-thickness or deep 
partial thickness burns; repair of scar contractures. 
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Contraindicated for infected wounds and patients 







Semi-permeable PLA-based elastic membrane. Indicated for use with superficial and deep 
dermal/partial thickness skin loss diseases, or small 
full thickness areas (e.g. burns, STSG donor sites, 
large abrasions, reconstructive surgery, scar 
corrections and dermabrasion, and non-healing 







San Diego, CA, 
USA 
Synthetic epidermis consisting of fibroblasts (donor 
allogenic cells) cultured on a nylon mesh and 
cryopreserved in situ. 
Indicated for use for treatment of partial- and full- 
thickness venous skin ulcers (>1 month duration) 
and diabetic foot ulcers (>3 weeks duration) which 
extend through, but no deeper than the dermis.  
Contraindicated for use on infected wounds and in 
patients with known allergies to bovine collagen or 
agarose shipping medium. 
Table 3: Examples of current commercial scaffolds for skin tissue engineering made using synthetic materials. This includes scaffolds also 
incorporating a naturally derived element, such as bilayered products; synthetic scaffolds supplied seeded with cells; and composite scaffolds 




Pipeline products and clinical trials 
The market for wound products for skin is vast. As the largest and outermost organ, skin is not only 
the most susceptible to injury but also the most visible. Products therefore span those that seek to 
address immediate threat to life, for example by preventing infection, to products that address 
cosmetic concerns. At the time of writing, there are over 3,300 trials regarding wounds and skin 
injuries listed on ClinicalTrials.com (last accessed September 2019). These trials encompass new 
products, new and expanded uses of existing products (particularly those already well established on 
the market, such as Biobrane (Table 3, Table 4), StrataGraft® (Table 4) and Hyalomatrix® Hyaluronic 
Acid Regenerative Matrix (Table 5)) and the use of non-product based therapies (such as behavioural 
and peri- and postoperative care approaches to supporting wound healing).  
Despite a wealth of research in the field and advances in materials, technology and rehabilitative 
therapies, the number of innovative new products coming to market is relatively small compared to 
the number of clinical trials (Table 6). This may be attributed to the cost and time required to develop, 
test, and achieve regulatory approval for new products. This system is biased in favour of large 
commercial entities marketing products with close similarities to existing regulated products.   
This gives rise to a large number of similar products modified and marketed for highly specific 
applications rather than a diverse range of products, or those custom-designed to best treat different 
types of wounds. 
Given the overwhelming number of products available to treat a broad spectrum of types and 
severities of skin injury, there is some confusion and hesitancy on the part of many physicians to adopt 
new bioengineered products for use. Inertia with clinical and commercial uptake is a further 
commercial barrier to new and innovative or niche products, particularly those produced by SMEs, 
microenterprises and start-ups that lack the resources, networking capabilities and marketing 
experience of established companies. 
As yet, off-the-shelf, full-thickness skin replacements (as a medical device or as a template to promote 
tissue regeneration) are not available, despite the marketing claims of some current commercial 
products. However, there are many products on the market that go some way to meeting these 
requirements. These materials may be used as vehicles, incorporating various cell types (such as 
keratinocytes, fibroblasts and stromal cells) or other growth-enhancing substances like cytokines and 
growth factors to improve the biological functionality and relevance of the scaffolds (Branski et al., 
2009). Using well-known materials and well-characterised cell lines, or expanded autologous cells, 
would reduce regulatory requirements and therefore time and financial barriers to market. 
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Gene transfer technology is another interesting future avenue for therapy. Delivery by scaffold in 
direct contact with the wound bed is advantageous to topical delivery as it offers greater control over 




































Sufficient healthy skin for 
donor site in case 
StrataGraft site requires 
autografting 
Complex skin defects of up 
to 49% TBSA (can come 
from >1 area) 
Full thickness complex skin 
defects requiring excision & 
autografting 
Treatment sites on torso 
and limbs may be up to 200 
cm2 (cohort 1) or 400 cm2 
(cohort 2) 
For thermal burns only, 
first excision &grafting of 
treatment sites 
Pregnant women and 
prisoners 
Subjects receiving systemic 
immunosuppressive 
therapy 




Expected survival <3 
month 
Suspected infection at 
anticipated treatment sites 
Treatment sites adjacent 
to unexcised eschar 
Chemical & electrical burns 




Safety, tolerability and 
efficacy of single or 
multiple applications  for 
healing excised full 
thickness defects from 



































possibly due to 
SG. One probable 
– rash vesicular 
(1/30) 
As above, but: 
3-49% TBSA 
Deep partial thickness 
thermal burn(s) with total 
area 88-880 cm2 
Treatment sites with 
exposed tendon or bone 
Face, head, neck, hands, 
buttocks, perineum and 
over-joint areas 
Chronic wounds 
Current conditions at 
discretion of investigator 
Phase 1b open-label, 
dose-escalation 
Safety, tolerability and 
efficacy  
2 cohorts receive product 
stored by refrigeration; 1  
receives cryopreserved, 






































(both – to 
different areas on 
the same patient) 
≥18 y/o w/ thermal burn(s) 
on torso, arms or legs – 
first excision and grafting of 
study treatment sites 
Sufficient healthy skin 
reserved for donor site if 
needed 
Clinical expectation donor 
site will heal without 
grafting 
Complex skin defects 3-
49% TBSA (≥1 area) 
Thermal burns with intact 
dermal elements for which 
excision + autografting are 
clinically indicated.  
Prisoners, pregnancy, 
expected survival <3 
months; subjects receiving 
systemic immuno-
suppressive therapy, with 
a known history of 
malignancy, pre-admission 
insulin-dependent 
diabetics; other concurrent 
conditions (discretionary); 
participation in treatment 
group of another study 
within 90 days prior to 
enrolment 
Chronic wounds or full-
thickness in the treatment 
area; treatment sites 
immediately adjacent to 
unexcised eschar; signs of 
infection at anticipated 
treatment sites; treatment 
sites on the face, head, 
neck, hands, feet, buttocks 
or over joints. 
Phase III 


























access at specific 
study sites 
(StrataCAT) 
 StrataGraft skin 
tissue 
Applied once to 
no more than 3 
separate burn 
sites, totalling a 
max. study 
treatment area of 
no more than 
1000 cm2, and 
using no more 
than 10 tissues 
Provide written informed 
consent 
Have enough health skin to 
reserve as donor site(s) in 
case autografting becomes 
necessary 
Have protocol-defined 
thermal burns on torso, 
upper extremities and 
lower extremities: 
- The right size for 
treatment areas 
- With intact dermal 
elements for which 
excision and autografting 
are clinically indicated 
- Wounds have not been 
previously excised and 
grafted 
Pregnant, prisoner, or 
expected to live less than 3 
months 
Has any other condition 
that, per protocol or in the 
opinion of the investigator, 
may compromise the 
patient’s safety or the 
study objectives 
Has participated in an 
investigational study 
within 90 days before 
enrolment  
Provide expanded access 
to StrataGraft for 
thermally induced deep 
partial-thickness burns 
that contain intact 
dermal elements and for 
which surgical excision 
and autograft are 
clinically indicated 
Multi-centre, open-label 












































in a split-wound 
design 
3 serious and 10s 





Aged 18+, with complex 
skin defects requiring 
sequential debridement 
under anaesthesia with 
temporary biological 
dressing (allogeneic 
grafting) prior to 
autografting 






Venous stasis ulcers of the 
lower leg; diabetic foot 
ulcers; donor site wounds 
Wounds of <5% BSA; 
wounds of the hands, face 
and feet  
Prior entry into this study 
Expected survival <3 
months 
Concomitant processes 
sustained at time of 
dermal injury (i.e. cardiac/ 
respiratory damage; 
destabilised organs from 
trauma) 
Active malignancy 
Phase I/IIa clinical trial 
Open-label, randomised, 
comparative study with 
max. 15 patients 
Sequential surgical 
procedures involving 
surgical debridement and 
temporary cadaveric 
allografting and various 




Table 4: Selected clinical trials regarding use of StrataGraft™ from ClinicalTrials.gov. Last accessed October 2019. StrataGraft™ (Stratatech, a 
Mallinckrodt company) skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix 
(containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells). The standard of care for temporary coverage of full thickness skin 
















































Age 21-90 (18-85) 
Chronic venous 
insufficiency and the 
presence of venous 
ulceration for >2 
months 
Subjects and/or 
caregiver willing and 




Must be reliable, 
responsible, and 
able to visit the clinic 
weekly to the full 16-
week period 
Non-venous ulcers; sensitivity to HA; 
presence of wound infection; peripheral 
arterial disease 
Has received growth factor therapy (e.g. 
autologous platelet-rich plasma gel, 
becaplermin, bilayered cell therapy, 
dermal substitute, ECM) within 2 weeks  
Pregnancy or lactation at time of 
treatment 
Currently (or within 3 months of 
randomisation) receiving/ed radiation 
or chemotherapy 
Currently enrolled in another 
investigational device, drug of biological 
trial (or within 30 days of baseline) 
History or alcohol or drug abuse  
Allergic to primary & secondary dressing 
materials and adhesives, including 
occlusive dressings  
Randomised, 
comparative study to 
determine whether 
Hyalomatrix is as 
effective as Integra™ 
Meshed Bilayer Wound 
Matrix when used in 
subjects who receive 
concurrent treatments 
with both products on 
their first- and/or 
second-degree burns 
located on both hands. 
Interventional, 
randomised, parallel 
assignment, open label, 


































on both hands) 
Written consent 
First and/or second 
degree burns on 
both hands 
Subject must be 
enrolled within 48 
hours of the injury 
occurrence 
Breastfeeding, pregnancy (current or 
planned)  
Prognosis indicating unlikely survival 
past the study period 
Third degree burns 
Electrical/chemical or frostbite burns 
Inhalation-related burn trauma 
On-going bone fractures 
Known sensitivity to silicone, 
hyaluronan, bovine collagen, 
chondroitin and/or derivatives  
Prior treatment that may affect study 
outcome 
Medical condition that may impede 
wound healing beyond what would be 
typically expected 
Randomised, 
comparative study to 
determine efficacy of 
Hyalomatrix compared 
to Integra™ Meshed 






































tissue) in place 
of autograft). 
Age up to 17 years 
Patients requiring 
syndactyly release 
surgery with skin 
grafting for one or 
more web spaces on 
their hand(s) 
 
Previous surgery on the web that 
requires a subsequent syndactyly 
release 
Diagnosis of macrodactyly 
Those who otherwise do not meet the 
inclusion criteria 
Study purpose: compare 
effectiveness, wound 
healing, scar formation 
and potential associated 
complications of current 
skin graft technique 





blind (by location of 
each comparator 
material) 
Table 5: Select clinical trials regarding use of Hyalomatrix® Tissue Reconstruction Matrix (Anika Therapeutics) listed on ClinicalTrials.gov.  Last 
accessed October 2019.  Hyalomatrix® is a bi-layered, sterile, single-use and flexible ‘advanced’ wound dressing.  It is composed of a non-woven pad 
with a contact layer of fibrous-form hyaluronic acid derivative with an outer layer of a semi-permeable silicone membrane.
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  New products by development stage 
 
New products by route of administration  
 
Table 6: An overview of the status and development of new burns products registered on the World 
Health Organisation Research Observatory database. Despite a wealth of academic research, few 
products translate to market. The duration and high cost of clinical trials may be a barrier, particularly 
to small companies and spinouts. Of those that do translate, most are classified as ‘topical’, which 
carry the lowest regulatory requirements. Data available online at https://www.who.int/research-
observatory/en/ last accessed October 2019.  
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Stem cells and wounds 
Stem cells can be defined as pluripotent or multipotent, depending on the number of cell types they are 
capable of differentiating into. Mesenchymal stem cells (MSCs) are multipotent, and can differentiate into a 
range of lineages, including bone, cartilage, fat, tendon, ligament and muscle (Oreffo et al., 2005; Pittenger et 
al., 1999). This plasticity renders MSCs of great interest in the field of regenerative medicine as their potential 
applications are wide ranging.  
MSCs are primarily located in adult bone marrow, as well as in umbilical cord, adipose tissue and menstrual 
blood. Marrow is also a major reservoir for hematopoietic stem cells, which synthesise blood cells to renew 
those in circulation (Pittenger et al., 1999). MSCs can also migrate from bone marrow and circulate through 
blood vessels. In the context of skin tissue regeneration, MSCs in circulation may be chemically recruited to a 
wound by inflammatory cytokines (Chen et al., 2008).   
One study found that the provision of IL-1α to in vitro cultured mesenchymal stem cells increased their 
expression of various growth factors (G-CSF, M-CSF, IL-6 and IL-11) (Haynesworth et al., 1996). In a wound 
environment, keratinocytes are known to release IL-1, so MSCs may be able to support regeneration by 
influencing and recruiting other cell types in the wound by growth factor expression (Kondo and Ishida, 2010). 
Controlling the environment of stem cells influences their differentiation. In a wound environment, MSCs may 
differentiate into fibroblasts to directly aid wound repair, or endothelial cells and perivascular smooth muscle 
cells to form new blood vessels and support the wound (Pittenger et al., 1999). MSCs derived from adipose 
tissue have been shown to elicit a strong angiogenic response from host tissue. Their implantation in scaffolds 
improves vascularisation compared to comparable avascular scaffolds (Laschke et al., 2013). This 
vascularisation is important in the integration of an implanted scaffold and integral to the viability of resident 
cells. The oxygen diffusion limit has been observed to be approximately 150-200 µm from the nearest blood 
vessel (Folkman and Hochberg, 1973). Scaffolds are designed to aid repair in large defects, where the centre 
of the scaffold could reasonably be in the order of several times this range from the wound bed and 100 times 
the range from the lateral wound margins. The ability to quickly vascularise a scaffold is therefore essential as 
a large area is isolated from intact vasculature and is susceptible to necrosis. While this has been achieved by 
seeding endothelial cells, harvesting autologous cells is difficult (i.e. HUVECs from umbilical cord); yield is low 
and in vitro expansion difficult (Laschke et al., 2013; Tremblay et al., 2005).   
Adipose-derived stem cells are of interest as they are readily available in adults and relatively straightforward 
to harvest (i.e. by liposuction) (Aust et al., 2004; Cheng et al., 2012). The ease of extraction makes adipose 
tissue a useful autologous source of MSCs. Using autologous adipose MSCs avoids the ethical implications that 
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are associated with the harvest of stem cells from other sources (i.e. embryonic; umbilical). The yield from 
harvest is also significantly higher than stem cell yield from bone marrow (Laschke et al., 2013).  
It has been shown that human MSCs respond to signals from keratinocytes – migrating towards them, or 
towards conditioned media and away from keratinocytes (Mishra et al., 2012). This demonstrates a precedent 
for use of MSCs in scaffolds, as they may be more disposed to colonise a scaffold and migrate outwards 
towards signals from the keratinocytes in the surrounding healthy tissue.  
MSCs have been shown to have important effects via regulation of the immune system, making it possible for 
allogenic cells to evade the host immune system (Koç et al., 2000). The mechanisms for this are not 
understood, but the theory is supported by a small number of studies. For example, Koç et al. (2002) found no 
evidence of alloreactive T cells in patients treated with MSCs. 
This creates new avenues of opportunity for cellular tissue engineering, moving away from the requirement 
for autogenic cells. However, precise understanding of the physiological behaviour and mechanisms of 
differentiation is lacking, hindering the development of more sophisticated, targeted therapies (Sasaki et al., 
2008). Tuan et al (2002) similarly suggest that more understanding is required to unlock the therapeutic 
potential of MSCs, and further that the key to their success may be the ability to successfully control, 
manipulate and expand them in vitro.   
 
Therapeutic use of stem cells 
Stem cells retain their ability for self-renewal. They are also able to differentiate into mature cells of a range 
of lineages depending on physical, chemical and biological environment signals from surrounding tissues in 
vivo (Arwert et al., 2012; Jiang et al., 2002) or under simulated conditions in vitro (Sasaki et al., 2008). After 
injury, stem cells utilise both of these capabilities in turn: proliferating to replenish the damaged or missing 
cells, then differentiating into an appropriate lineage (Watt and Driskell, 2010) – for example, myofibroblasts.  
Differentiated cells are responsible for secretion of extracellular matrix components (Tessmar and Göpferich, 
2007). The successful creation of new tissue, similar in composition to healthy native tissue, requires the cells 
in the scaffold to differentiate into appropriate lineages. This may be achieved by the provision of an 
appropriate microenvironment alongside biochemical triggers such as cytokines (e.g. SDF-1, IL-8, IL-6, VEGF 
and CXCL-5) (Mishra et al., 2016; Nissen et al., 1998). 
Bone marrow-derived stem cells  (BM-MSCs) secrete greater quantities of some of these cytokines, including 
VEGF and keratinocyte growth factor, than dermal fibroblasts (Chen et al., 2008). Interestingly, they also 
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secreted lower amounts of other cytokines, such as IL-6, which are implicated in various diseases when found 
in elevated quantities.  
“Enhanced” growth factor secretion, either by up- or down-regulation, contributes to the enhanced wound 
healing capability of BM-MSCs compared to differentiated cell lineages such as dermal fibroblasts (Wu et al., 
2007). Cancer cells also express elevated levels of growth factors, which may explain their ability to proliferate 
and colonise rapidly (Goldman, 2004).  
Applying this principle to healing of chronic or recalcitrant wounds by delivering growth factors to the wound, 
directly or indirectly using BM-MSCs, has therapeutic potential. BM-MSCs have been shown to migrate to 
epithelial wounds, suggesting they do indeed support wounds healing by this mechanism in model systems. 
In one such system, the BM-MSCs were principally located in the upper dermis, below the wounded 
epithelium, suggesting a paracrine mode of action whereby BM-MSCs do not enter the wound, but express 
growth factors into it to promote healing (Chen et al., 2008; Yamaguchi et al., 2007).   
 
Scaffolds: a structured approach to soft tissue repair 
Porous scaffolds are widely used in in the treatment of injured or diseased tissue (Sultana et al, 2008; Bannasch 
et al, 2003). They may be used as a physical plug to fill an extensive cavity and prevent excessive contraction 
or scarring. Principally, however, they are used to provide a suitable structure to allow for cell infiltration and 
encourage tissue regeneration.  
Porous materials are highly desirable as scaffolds as interconnected cavities provide space for vascularisation 
and angiogenesis, and aid the supply of nutrients and chemical stimuli and removal of waste from the 
regenerating tissue (Thomson et al, 1995; Busby et al, 2001; Whang et al. 2000). A highly porous material will 
allow for increased and more uniform infiltration of cells (Brauker et al, 1995; Carnachan et al, 2006; Glowacki 
et al, 1983; Klawiter and Hulbert, 1971; Lu et al, 2012; Mooney et al, 1991; Nade et al, 1983; Whang et al, 
2000). 
Current commercial scaffolds display very different microstructures to ideal characteristics cited in the 
literature. This may relate to reduced plasma diffusion and cell or blood vessel motility within the scaffold and, 
in turn, reduced in vivo performance. Porosity is created in Integra® Dermal Regeneration Template (Integra 
Lifesciences) by snap-freezing a dispersion of liquid particles within their matrix (Yannas et al., 1985). While 
porosity is high (Figure 2A) – the patent claims up to 95% porosity by this method – the material suffers from 
low interconnectivity between pores (Figure 2B). Additionally, the space between droplets in the dispersion 
results in impenetrable protein walls which restrict cellular or vascular migration. Matriderm® (Dr. Suwelack 
Skin and Health Care) also displays porosity with low interconnectivity (Figure 2D). In this case, porosity is 
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generated by the freeze-drying process (Schoof et al., 2001; Wieland and Haas, 2013). In both cases, the 
method of producing porosity is scalable and amenable to use with protein-based materials, but the 
conservative approach fails to achieve the high degree of interconnected porosity and low density that would 













Fig. 2: Scanning electron micrographs showing cross-sections of commercially available skin 
scaffolds, Integra® Dermal Regeneration Template (Integra Lifesciences) and Matriderm® (Dr. 
Suwelack Skin & Health Care). Integra is shown at [A] 200 times and [B] 1,500 times magnification 
(images taken from (Jeremias et al., 2014)). Matriderm is shown at [C] 500 times and [D] 5,000 times 
magnification (primary images).  
 
Vascularisation is key to the success of a tissue engineered construct – insufficient vascularisation results in 
impaired exchange of nutrients and waste and impedes immune response. As such, infection, localised 
necrosis or even loosening and rejection of the implant may occur (Sahota et al, 2003; Hendrickx et al, 2010).  
Vascularisation of acellular scaffolds may be encouraged by modification of the structural or physicochemical 
properties of the scaffold or biological activation by release of growth actors (Frueh et al, 2016). Indeed, 
enrichment with VEGF/bFGF has been shown to accelerate vascularisation of the collagen scaffold Integra® 
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The size of pores is important to properly accommodate cells, enabling them to adhere to and interact with 
the scaffold (Bokhari et al, 2007). The degree of porosity, and the size of the pores, can greatly affect the 
behaviour of cells in a scaffold. Pore size is therefore an important criterion when developing a scaffold for 
use with any cell type, but especially stem cells as the implications may be profound (Viswanathan et al, 2012).  
Work by Choi et al (2013) suggests that pore sizes larger than 200 µm tend to give rise to the formation of a 
low-density network of large blood vessels which are capable of penetrating deep into the scaffold. Pore sizes 
less than 200 µm give rise to high-density networks of small blood vessels, but penetration depth is reduced. 
As such, large pore sizes are desirable for large 3D scaffolds, whereas smaller pore sizes are more suited to 
smaller, thinner scaffolds such as those required for skin substitutes (Choi et al, 2013). Existing products 
Integra® (Integra Life Sciences, Plainsboro, NJ) and Matriderm® (Dr. Suwelack Skin & Health Care AG, 
Billerbeck, Germany) both fall into the latter category (Frueh et al, 2016).  
Optimum pore sizes for skin scaffolds quoted in literature vary, but authors commonly quote pore sizes from 
a few microns ranging to 200 or 300 µm (Busby et al, 2001; Sultana et al, 2008).  
Further to pore size, the size of the interconnections is almost important is promoting vascularisation of the 
scaffold. Large interconnections (~150 µm) show enhanced vascularisation compared to comparable scaffolds 
with smaller interconnections (Bai et al, 2010). This is likely a direct result of growing blood vessels being 
presented with a more open, less tortuous path into the implanted scaffold. 
High porosity is achieved by maximising the surface area: volume ratio. Very little bulk material is therefore 
required to create a scaffold, rendering the scaffold fairly fragile. The scaffold must be sufficiently tough to be 
readily handleable, but also must provide a suitable physical environment for cell ingress and formation of 
new tissue in vivo.  
Scaffolds may be applied acellularly, relying on native cells to migrate in and colonise. They may also be pre-
populated with relevant cell types (such as fibroblasts, keratinocytes, or stem cells capable of differentiating 
into these cells).  
There is evidence to suggest that implanting cellularised scaffolds may result in improved or accelerated 
healing. Lu et al., 2012 reported that their PLLA-collagen and PLLA-gelatin scaffolds, implanted in nude mice 
with full-thickness dorsal skin injuries, produced a thicker epidermis after 28 days than the same scaffolds 
used acellularly. A similar result was produced by (S. B. Lee et al., 2003) using gelatin/glucan scaffolds.  
Alternative strategies to enhance wound healing may be achieved in either cellularised or acellular scaffolds 
by incorporating proteins, such as growth factors, to create a ‘smart’ or ‘physiologically active’ scaffold 
(Tessmar and Göpferich, 2007). The proteins may be adherent to the surface, encouraging the surrounding 
tissue to integrate with the scaffold edge, or released in a controlled manner (Bryant et al., 2007; Kim et al., 
62 
 
2003; Whang et al., 2000). This type of carrier scaffold may be used to administer therapeutic doses of drugs 
to the wound over a defined period.  
Once the wound has regenerated, scaffold materials remaining in the wound may often separate and elicit an 
inflammatory response (Lu et al., 2012). This is a particular problem with some polymeric materials, such as 
PLLA, PGA and PLGA, which degrade into acidic by-products (Li and Chang, 2005; Taylor et al., 1994). 
Appropriate material selection, degree of cross-linking, and scaffold dimensions (i.e. wall thickness) help 
ensure scaffold materials do not persist in the healed wound. Scaffolds for tissue regeneration should instead 
degrade steadily during healing and leave no debris (Busby et al., 2001; Langer and Vacanti, 1993; Tessmar 
and Göpferich, 2007). This allows space for generation of new ECM products (Vepari and Kaplan, 2007). 
Tissue engineering scaffolds combine materials science with a biological element (i.e. a polymeric scaffold 
seeded with cells ex vivo, or intended to integrate with native cells in vivo). As such, the ideal scaffold must 
have both mechanical and biochemical properties optimised in order to perform well as an engineered 
construct and support living cells in a wound environment.  
Scaffolds must be capable of maintaining a moist wound environment, replacing the hydrating properties of 
intact dermis. This may be beneficial in reducing formation of bad scars (Chang et al., 1995). Hydration must 
be held in balance; it is also beneficial for scaffolds to have the capacity to absorb wound debris such as 
exudate (Choi et al., 1999). Absorption of exudate is an additional advantage of the porous sponge-like 
structure most scaffolds adopt.   
Mechanical strength is vital for the survival of a scaffold, not only to withstand gross movement and external 
impact, but also to counter contractile forces exerted by cells within the scaffold (Dado and Levenberg, 2009; 
Lu et al., 2012). Cell-mediated contraction can lead to shrinkage of the scaffold that may alter the structure, 
and will also prevent the scaffold from creating an effective seal of the wound bed. 
However, excessive mechanical strength of a scaffold may also be detrimental. Increased strength is often 
associated with reduced flexibility of the scaffold, reducing its ability to conform to the wound as it repairs. 
Limited flexibility and elasticity of the scaffold will impair the elasticity of the ECM in contact with the scaffold. 
Mesenchymal stem cells have demonstrated a high level of sensitivity to matrix elasticity in differentiating to 
different cell lineages (Engler et al., 2006). As the mechanical properties of ECM and gross tissue are closely 
linked, the flexibility and elasticity of the scaffolding material is therefore very specific to the target tissue 
(Dutta et al., 2017; Janson and Putnam, 2015).      
Additionally, strength may be associated with a longer proteolytic degradation time. A scaffold should be 
optimally tuned to degrade at the same rate that a wound repairs, to maintain a steady volume in the wound 
cavity. The inherent strength of synthetic polymers makes them well suited as biomaterials for tissue 
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engineering of ‘hard’ tissues (Dutta et al., 2017). It could be suggested, therefore, that natural polymers are 
better suited to applications in soft tissue engineering, such as the regeneration of skin.  
Mechanical strength derives from the physical (e.g. microstructure, porosity, and homogeneity) and 
mechanical (e.g. elasticity, stiffness, and isotropy) properties of the scaffolding material (Dutta et al., 2017). 
Given that many of these characteristics have tight optimal parameters for defined scaffolding applications, 
altering the strength without detriment to other features can be challenging. One method of increasing 
strength without affecting the bulk material is fibre reinforcement (Lu et al., 2012). The fibres may be randomly 
dispersed to achieve anisotropy. The surface area to volume ratio is very high for thin fibres, increasing the 
area for degradation, so unwanted in vivo persistence is avoidable.   
The internal structure of a scaffold is vital to its effectiveness. What differentiates a bioinert structure from a 
truly biocompatible, integrative structure is its ability to support the regenerating tissue. Scaffolds must 
encourage cells to infiltrate, proliferate and communicate. These cell colonies require the support of a vascular 
network to apply the supply of nutrients and physiological cues (i.e. growth factors) and removal of waste 
(Thomson et al., 1995; Whang et al., 2000). Insufficient vascularisation impairs exchange of waste and 
nutrients, which is detrimental to healing, and impedes immune response. This may lead to necrosis of the 
wound area, loosening of the scaffold and even rejection from the wound bed (Hendrickx et al., 2010; Sahota 
et al., 2004).  
Vascularisation may be encouraged biochemically, by the provision of growth factors (Frueh et al., 2016). 
Indeed, the use of VEGF and bFGF has been shown to accelerate the vascularisation of the collagen scaffold 
Integra® Dermal Regeneration Template (Integra Life Sciences, NJ, USA) (Wilcke et al., 2007).  
Alternatively, the internal architecture of the scaffold may encourage its vascularisation. High porosity and 
interconnectivity between pores allow for pervasion of capillaries from the wound periphery, and their 
distribution throughout.  This connects the scaffold to the infrastructure of the surrounding tissue and is 
therefore vital to creating an integrative scaffold (Bannasch et al., 2003; Busby et al., 2001; Hollister, 2005). 
Porosity enhances the permeability of a material, promoting release of bioactive materials loaded onto a 
scaffold and diffusion of native soluble factors into the scaffold and the cells supported within (Leach and 
Schmidt, 2005). These materials allow for increased and more uniform infiltration of cells into the implanted 
scaffold (Brauker et al., 1995; Carnachan et al., 2006; Klawitter and Hulbert, 1971; Lu et al., 2012; Nade et al., 






A scaffold’s structure should closely mimic the tissue it is designed to replace to encourage native or near-
native behaviour. It is known that porosity and topography directly influence cultured cell behaviour, such as 
migration (Frueh et al., 2016). Bokhari et al (2007) found pore diameters of 100 µm and interconnect 
diameters (diameter of connections between larger pores) of 25 µm optimal for penetration of osteoblastic 
cells into a scaffold. Close control of the microstructure is crucial to optimise these parameters, and to achieve 
homogeneity throughout the scaffold so that cells are likely to interact in the same way regardless of their 
position. Thus, the cells are disposed to act as a single population, rather than small colonies each responding 
to different microenvironments (Bokhari et al., 2007).   
Pore size is a critical parameter in the success of a tissue engineering scaffold, especially those designed to 
support angiogenesis into the wound site (Linnes et al., 2007). In engineering of soft tissue, such as skin, 
scaffolds with pores of 35 µm diameter showed enhanced angiogenesis compared to scaffolds with smaller or 
larger pores (Marshall et al., 2005), although vascularisation occurred throughout more of the scaffold with 
70 µm diameter pores (Marshall et al., 2004).  
Choi et al. (2013) further demonstrated that scaffolds with larger pores (>200 µm diameter) promote the 
formation of low-density networks of larger blood vessels. Conversely, scaffolds with smaller pores (<200 µm 
diameter) promote the formation of high-density networks of smaller blood vessels. However, these networks 
do not penetrate deeply into the cultured construct. As such, smaller pore diameter scaffolds are more suited 
to smaller, thinner tissue substitutes, such as skin (Choi et al., 2013; Frueh et al., 2016).  
Scaffolds with a narrow pore size distribution are typically favoured. However, as the literature suggests 
different sizes for pore and interconnect diameter for different purposes, it may be desirable to achieve 
narrow distributions at two pore diameters. This would encompass pore sizes optimised for angiogenesis, 
vascularisation and cell migration and settlement. 
The spatial distribution of these differently sized pores may have to be optimised to support formation of 
homogenous tissue, and this could prove challenging using current methods. 
However, interconnect size may be a more dominant parameter than pore size. Optimised interconnect 
diameter promotes vascularisation by promoting proliferation, adhesion and migration of endothelial cells 
through scaffolds (Xiao et al., 2015). Scaffolds with larger interconnections have been shown to exhibit 
improved vascularisation over those with smaller diameter interconnections, up to a maximum of 400 µm 
beyond which no significant difference is observed (Bai et al., 2010). However, the optimal pore sizes 
suggested above are many times smaller than this value. Scaffolds with interconnect diameters exceeding 
pore diameter are clearly meaningless, so direct application of this data is not useful. In vitro verification for 
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specific cell types in defined scaffolds is advisable to confirm optimum pore and interconnect diameters. 
However, the results suggest that wider interconnect diameters enhance vascularisation by provision of a 
more open and direct route through the scaffold. 
The shape of pores may also affect scaffold interaction with cells. Funnel-shaped porous structures have been 
shown to improved fibroblast adhesion, and allow for high cell seeding efficiency (Lu et al., 2012). 
The number and distribution of pores is directly linked to the cell-loading capability of a scaffold, and also the 
spacing between these cells. The density of cells in a scaffold affects the rates of cell proliferation and 
deposition of new ECM (Cheng et al., 2006; Lu et al., 2012). These two factors play a major role in the 
properties of the resultant tissue.     
The bulk material is selected for both its engineering properties and its biocompatibility. There is an arsenal 
of such materials, approved for use in a variety of biomedical applications by the FDA and other international 
regulatory bodies, including natural and synthetic polymers. Treating the surface of the bulk material affects 
the way it interacts in vivo. Surface treatment can be used to enhance in vivo performance, or to broaden the 
selection of appropriate materials by providing a biocompatible surface to a less favourable substrate.  
Chemically modifying the material surface has been shown to influence cellular adhesion, allowing control in 
the way cells interact with the implant (Viswanathan et al., 2012). Biomaterial surfaces may also be biologically 
treated, for example with the immobilisation of growth factors, to promote or otherwise influence cell 
adhesion, proliferation and behaviour (LeBaron and Athanasiou, 2000). Cells respond in a very sensitive 
manner to biomaterial surfaces. Topography can govern the mode of adhesion, the extent and direction of 
migration, and even differentiation (Bokhari et al., 2007).  
 
The role of fibrin in wound repair 
After injury, the coagulation and fibrinolytic cascades are important in providing rapid and appropriate 
haemostasis to minimise blood loss. If the vascular system is damaged, the coagulation cascade is activated, 
leading to the release and activation of thrombin (Factor IIa). Thrombin then acts to polymerise soluble 
fibrinogen (Factor I) to fibrin. The fibrin fibrils that form cross-link and recruit other proteins to aid stability. 
Together, these actions form a clot, or thrombus, to seal the puncture and prevent further blood loss 
(Blombäck, 2000; Standeven et al., 2005).  
Fibrinogen is one of the most abundant proteins in human plasma (Anderson and Anderson, 2002). It is 
synthesized by hepatocytes at a rate of approximately 1.7 – 5 g/day (Takeda, 1966). It then leaves the liver 
and circulates the body in blood plasma at a typical concentration of 2.5 – 3 mg/ml. When circulating cytokines 
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such as IL-6 are provoked (i.e. in response to epidermal breach), pro-inflammatory agents are released which 
strongly upregulate the plasma concentration of fibrinogen. Elevated levels increase the potential for 
coagulation to occur (Blake and Ridker, 2001; Sidhu et al., 2003).  
Fibrinogen is a large soluble glycoprotein (approximately 330 kDa in size) with an unusual tri-nodular structure, 
arising from the fact that it possesses the properties of both fibrous and globular proteins (Standeven et al., 








Fig. 3: Primary structure model of human fibrinogen. This simplified diagram shows the primary 
protein structure of fibrinogen, with the six chains arranged in order, and the N-terminals facing 
towards the central E domain. A, B and γ refer to the paired protein chains; α and β refer to 
fibrinopeptides FpA and FpB located at the C-termini of the A and B chains, respectively. Image 
adapted from Henschen et al., 1983. 
 
The fibrinogen molecule comprises six chains with three identical pairs. These are denoted as Aα, Bβ and γ. 
The N-termini of all these chains face towards the centre of the fibrinogen molecule, the E domain. These 
chains intertwine from the central E domain, forming α-helical coiled-coil structures that are supported by 
disulphide bridges. This results in a generally linear molecule. However, while the Bβ and γ chains extend the 
length of fibrinogen, ending distally at one of two D regions, the Aα chains instead loop back towards the E 
domain (Standeven et al., 2005; Weisel and Medved, 2001). This tertiary structure, and its common bending 
conformations, are illustrated in Figure 4, below. 
N termini C termini C termini N termini 
D domain D domain E domain 





Fig. 4: Tertiary structure and bending conformations of the fibrinogen molecule, with the hinge 
region coloured yellow. The Aα, Bβ and γ chains are coloured blue, red and green respectively; 
carbohydrates are shown in orange. The bending angle γ is the angle that the hinge region forms 
between the E domain and the D region. φ is the torsion angle. This is defined by two different parts 
of the E domain, the hinge region, and the D region. Image adapted from Köhler et al., 2015. 
 
During the coagulation cascade, fibrinogen polymerises to fibrin. This occurs when thrombin cleaves the N-
terminal sequences on the Aα and Bβ chains by proteolysis, releasing the surface-bound fibrinopeptides FpA 
and FpB, and in doing so exposing specific binding sites (Bailey et al., 1951; Riedel et al., 2011; Standeven et 
al., 2005). The chain cleavage and release of FpB causes a drop in solubility that causes the molecules to 
aggregate laterally and increases the availability of α-chains to cross-linking by Factor XIII (Gorkun et al., 1994; 
Standeven et al., 2005; Weisel, 1986).  
The precise roles of FpA and FpB are not fully understood, as lateral protofibril aggregation can occur without 
FpB, but equally clot formation can occur with only FpB. However, this latter mechanism is unlikely to occur 
in vivo, as thrombin preferentially cleaves the N-terminal of the Aα first. Cleavage of both Aα and Bβ, releasing 
FpA and FpB respectively, likely works synergistically to strengthen the bonding between the aggregating 
molecules, producing stronger fibres (Shainoff and Dardik, 1983; Weisel, 1986). FpB is also associated with 
faster fibrin formation and increased rate of lateral aggregation (Blombäck, 2000; Shainoff and Dardik, 1983).  
As well as Aα and Bβ, fibrinogen contains two γ chains. These are cross-linked at the branch points of higher 
molecular weight molecules, such as trimers and tetramers (Mosesson et al., 1989; Standeven et al., 2005). 
The formation of these γ polymers is favoured in certain conditions, such as high Ca2+ concentration or slow 
polymerisation of fibrinogen to fibrin (Mosesson et al., 2001). Additionally, two species of fibrinogen exist: 
fibrinogen 1 and fibrinogen 2. Fibrinogen 1 contains two identical γ chains, whereas fibrinogen 2 contains a γ 
and a γ’ chain. γ’ has a different C-terminal sequence. While cross-linking of both resultant fibrinogens is 
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comparable, fibrinogen 2 is found to produce finer branched fibre networks than fibrinogen 1 (Siebenlist et 
al., 2005). This is likely due to the delayed release of FpA resulting from the altered thrombin binding site at 
the C-terminal of γ’ on fibrinogen 2. This indirectly supports, and gives physiological relevance, to the findings 
of the in vitro work of Shainoff and Dardik (1983), who found that release of both FpA and FpB gave rise to 
stronger protofibril and fibre binding.    
During cross-linking, protofibrils of fibrin begin to form. When these protofibrils reach a critical length, they 
start to assemble into double-stranded twisted fibrils. The thickness of these fibres is limited by the degree of 
twisting, as the constituent protofibrils are also twisted and this limits the distance they can stretch (Standeven 
et al., 2005; Weisel, 1986). These fibrils branch out, by a combination of two proposed mechanisms, to create 
intricate networks (Weisel, 1986). In the first, the fibrils align adjacent to one another and form a branch point 
of two or four molecules. This lends mechanical strength to the clot. In the second, most likely occurring when 
proteolytic cleavage of fibrinogen is slow, three fibrin molecules bind three protofibrils (Standeven et al., 
2005).     
Haemostasis and thrombus formation are achieved so rapidly because as fibrin forms, the cleavage of Factor 
XIII activation peptides by thrombin is accelerated. This ensures that the level of Factor XIII available in the 
wound site is sufficient to maintain rapid cross linking of the polymerised fibrin protofibrils (Curtis et al., 1983; 
Lewis et al., 1985).  
Eventually, an elastic gel forms (Blombäck and Bark, 2004). The structural and mechanical characteristics are 
highly dependent on a number of factors. In vitro experiments revealed that clotting time remained the 
dominant factor in clot structure determination through varying ionic strength, fibrinogen concentration and 
H+ concentration (Blombäck and Okada, 1982; Okada and Blombäck, 1983). A faster clotting time correlates 
to a short gelling time, with more lateral fibre aggregation (Weisel, 1986).  
Additionally, pH, ionic strength and the presence of various ions and proteins are capable of modifying clot 
structure. Calcium and chloride ions, albumin and collagen have all been shown to alter clot structure 
(Standeven et al., 2005). 
The presence of calcium ions shortens the clotting time of fibrinogen and gives rise to the production of fibrils 
with increased mass: length ratios. The resultant fibrin fibres are therefore thicker and stronger (Carr et al., 
1986; Hardy et al., 1983). Type IV collagen, typically found in the basement membrane of skin, likewise 
influences fibrinogen polymerisation. Jones and Gabriel (1988) found that when type IV collagen is present 
during fibrinogen coagulation, the fibrin fibres produced are thicker for a given fibre length than when collagen 
is not present.    
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 Conversely, the presence of chloride ions leads to the production of thinner, less stiff, fibrin fibres. This is due 
to the ions inhibiting lateral aggregation of protofibrils during coagulation (Di Stasio et al., 1998). Human 
albumin similarly limits lateral growth of fibrils by an alternate mechanism of steric hindrance (Galanakis et 
al., 1987; Wilf et al., 1985).   
Whilst these molecules are all physiologically relevant, the work cited above was all performed in vitro. It is 
therefore more pertinent to tissue engineering work for generation of fibrin constructs, rather than to in vivo 
mechanisms. For example, while isolated fibrinogen and thrombin are capable of causing thrombus formation, 
the fibres formed are of smaller diameter than fibrin fibres formed by the interaction of fibrinogen and 
thrombin in plasma (Carr, 1988).      
Increasing pH leads to creation of a finer, more friable, clot structure composed of thinner fibrils. Perhaps 
counter-intuitively, given the evidence that shorter clotting time produces thicker fibrils in the presence of 
Ca2+ and collagen, this occurs in conjunction with a reduced clotting time (Ferry and Morrison, 1947).  
Finally, the relative concentrations of fibrinogen and thrombin themselves have a significant influence on 
polymerisation and resultant clot structure. Increased concentration of thrombin reduces the lag period 
during which protofibrils grow before aggregation. Therefore, when thrombin concentration is increased, the 
protofibrils produced will be thinner (Hantgan and Hermans, 1979). An in vivo study by Wolberg (2007) 
showed that this is true only at prothrombin concentrations above physiological levels. At very low 
prothrombin levels (<10% plasma levels) clots were weak and malformed (Wolberg, 2007). As prothrombin is 
the precursor molecule to thrombin, it is reasonable to draw the same conclusions about the effect of 
thrombin concentration. These results indicate that there exists an optimum thrombin concentration range 
that must be achieved for appropriate coagulation. 
Conversely, an increased concentration of fibrinogen increases the lag time, giving more time for protofibrils 
to grow laterally prior to aggregation. The fibrils and resultant fibres are longer and thicker with increased 
fibrinogen concentration, and the maximum rate of fibre assembly also increases (Weisel and Nagaswami, 
1992). However, when the concentration of fibrinogen exceeds the concentration of thrombin by a factor of 




Fibrin scaffolds  
Fibrin has been widely investigated as a scaffold for a diverse range of tissue engineering applications including 
engineering of small blood vessels and heart valve prostheses, cartilage, bone and skin, and as a carrier for 
transplanted stem cells (Bensaıd̈ et al., 2003; Geer et al., 2002; Jockenhoevel et al., 2001; Perka et al., 2001; 
Swartz et al., 2005; Yasuda et al., 2009). The use of fibrin composite tissue engineering constructs, with 
materials such as fibrin-agarose, fibrin-collagen, fibrin-alginate, fibrin-PCL, fibrin-PLLA-PLGA and fibrin-
polyurethane has also been described (Carriel et al., 2012; Collen et al., 2003; S. B. Lee et al., 2003; Lesman et 
al., 2011; Levenberg and Lesman, 2014; Ma et al., 2012, 2003; Schagemann et al., 2010; Serbo and Gerecht, 
2013; Shikanov et al., 2009; Swieszkowski et al., 2007; Weinberg, 1989).   
Fibrin scaffolds have been used as vehicles for controlled-release drug delivery (Catelas et al., 2008; Jeon et 
al., 2005; Lee et al., 2003). Fibrin products are also used as adhesives (Borst et al., 1982; Brennan, 1991; Brown 
et al., 1992; Currie et al., 2001; Dahlstrøm et al., 1992; Rose and Dresdale, 1986), making use of the high tensile 
strength of bound fibrin constructs. This strength of adhesion derives from the ability of fibrin to bind to cells 
(de la Puente and Ludeña, 2014) either directly, via integrin receptors, or indirectly via ECM proteins such as 
fibronectin (binding to fibroblast and phagocyte receptors) (Makogonenko et al., 2002) and vitronectin 
(binding to collagen and endothelial cell receptors) (Preissner and Jenne, 1991).  
Fibrin has been used as a haemostatic agent for over 100 years (Loeb, 1909). Its therapeutic use was inspired 
by its native action in the coagulation cascade, and it is used to rapidly seal a wound and prevent blood loss in 
extreme scenarios, such as battlefield injuries (Borst et al., 1982; Granville-Chapman et al., 2011; Vournakis et 
al., 2003). This versatility in application may derive from the characteristic structure of fibrinogen, and the 
many ways of producing fibrin from fibrinogen. 
Fibrin gels match other biomaterials, such as collagen, for high cell seeding efficiency and the uniform 
distribution of cells achieved therein and is thus proposed as a candidate scaffold material (Swartz et al., 2005). 
Further, fibrin offers many advantages over other protein-based biomaterials. For example, processing does 
not damage protein functionality. Conversely, extraction and processing of collagen to make it suitable for 
implantation irrevocably damages the higher protein structure. Extraction of fibrin is from whole blood, which 
may be harvested readily from an autologous donor without incurring donor site morbidity. Allogenic or 
xenogenic (bovine) blood may also be used. 
In normal physiology, the persistence of natural fibrin constructs – blood clots – is regulated by the interplay 
between the coagulation and fibrinolysis cascades (Clark, 2003; Standeven et al., 2005). Regulation of artificial 
fibrin scaffolds is likewise tuneable by mechanical or enzymatic means. The number, diameter and density of 
fibrin fibrils affects degradation rate; as does the biochemical environment, including proteolytic enzymes.   
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One problem with the use of fibrin for implantable biomaterials is its rapid degradation in vivo. Protease 
inhibitors like aprotinin or tranexamic acid can delay proteolytic degradation, prolonging the persistence of 
implanted fibrin constructs as required to support the repairing tissue (de la Puente and Ludeña, 2014; 
Jockenhoevel et al., 2001).  
In vivo, cross-linking of newly-formed soluble fibrin fibrils by activated coagulation factor XIII stabilises the 
fibrils to form a strong, elastic insoluble clot  (Standeven et al., 2005). The same effect may be achieved in 
artificial fibrin constructs by chemical cross-linking with reagents such as genipin (Dare et al., 2009; Linnes et 
al., 2007), glutaraldehyde (McManus et al., 2006) or carbodiimides such as EDC in NHS buffer (Grasman et al., 
2012); or by photo crosslinking with the aid of a ruthenium catalyst (Bjork et al., 2011).   
Fibrin and fibrinogen can be used to make an extensive and varied range of scaffold constructs, including 
microspheres, micro- and nanofibres, microtubes, nanoparticles and hydrogels (Rajangam and An, 2013).   
 
Scaffold preparation techniques 
 
Fig. 5: Summary of manufacturing approaches to produce porous scaffolds for tissue engineering, 
classified by method of generating porosity. 
 
Scaffolds are designed with the intention of supporting cells within the matrix, by guiding migration and 
promoting adhesion. They must also support a vascular network to support these cells, and allow the supply 
of nutrients and physiological cues (i.e. growth factors) and removal of waste. As such, highly porous structures 




Some materials, such as foams, are inherently porous (Baldwin and Saltzman, 1996), as are fibrous materials 
that form an interwoven mesh. This may be accomplished by weaving, knitting or electrospinning. For other 
materials, porosity may be achieved by a variety of means (Figure 5).  
However, certain limitations (e.g. pH, temperature, toxicity) may apply to retain the integrity of the material 
used and ensure its biocompatibility. This is particularly true of biological polymers, such as proteins, whose 
structure and functionality is highly dependent on their environment (Tessmar and Göpferich, 2007). At 
elevated temperatures, proteins are likely to denature, which may alter their structure such that their desired 
function is impaired or lost. This is supported by a study from Lu et al. (2012) who found that in scaffolds made 
of gelatin, a denatured form of collagen, cell proliferation was lower than in comparable scaffolds of a less 
processed form of collagen. Thus, they suggested that increased bioactivity of the matrix protein may confer 
increased proliferative activity to the cells it supports. Care should therefore be taken to process proteins 
within tolerable physiological ranges of temperature (37°C) and pH (~pH 7).  
Scaffolds are typically formed from solutions, whose structure is formed during solidification. Porosity may be 
introduced by a number of methods, such as particulate leaching, gas bubbling, phase separation, melt 
moulding, foaming and emulsion templating (Dutta et al., 2017; S. Yang et al., 2001). 
Particulate leaching employs solid particles as porogens. These porogens are dispersed through the liquid 
scaffold mixture and the scaffold is solidified with the porogens trapped inside. The scaffold is then treated, 
for instance by washing, to remove the porogen, leaving a cavity in its place. The size and shape of the porogen 
determines the size and shape of the resultant pore. The density and packing arrangement of the porogens 
determines the number, spacing and interconnectivity of the pores.  
Traditional porogens include soluble materials such as salt and glucose, but porogen selection is only limited 
by ability to establish a means of its non-destructive removal from the scaffold (Busby et al., 2001; Holy et al., 
1999).  
Several groups have used hydrocarbons, such as paraffin and beeswax, as porogens (Shastri et al., 2000). These 
hydrocarbon porogens may be accurately sized and shaped to offer control over scaffold porosity. Removal of 
the porogen is only possible through interconnected pores, so this method is only suitable for an open pore 
system. Heat must be applied to melt the waxes in order to remove them, which may not be suitable for 
protein scaffolds to avoid denaturation and compromised tertiary structure. However, the melting points of 
paraffin and beeswax are relatively low (61-65°C) so  the method is suitable for a range synthetic polymers 
widely used in tissue engineering, such as PLLA, PLGA, PMMA and PEO (Bogdanov, 2004; Shastri et al., 2000).  
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Kang et al. (1999) created porous scaffolds by using ice in swollen gelatin hydrogels. This simple method offers 
advantages of low porogen cost, no biocompatibility issue in case of incomplete porogen removal and no 
aggressive leaching treatment is required.  
The use of particulate leaching to induce porosity is typically limited to production of very thin scaffolds up to 
3 mm thick, owing to the difficulty of ensuring porogen removal (S. Yang et al., 2001). In practise, such thin 
scaffolds have limited applications for in vivo tissue engineering.  Additive manufacturing may be applied to 
build up a multi-layered scaffold. For example, by creating many thin scaffolds and layering them to create a 
thicker three-dimensional construct. This also introduces a possibility for controlled variable porosity 
throughout the scaffold. 
Bubbling inert gas through the liquid scaffold is another method of introducing porosity. Polymer emulsions, 
such as PLGA in methylene chloride, are saturated with supercritical gas (such as carbon dioxide) in a sealed 
vessel. The supersaturation replaces the solvent with carbon dioxide. The vessel is rapidly vented, causing the 
gas to form bubbles. At the same time, the polymer precipitates, leaving behind a solid porous scaffold (Hile 
et al., 2000). This method may be used in combination with other methods, such as particulate leaching, to 
enhance the scaffold porosity or to introduce a subset of pore sizes within the scaffold (Shea et al., 1999).    
Freeze drying is widely used to preserve scaffold architecture and create a stable, dehydrated product to 
extend shelf life prior to implantation. It is used as a final processing step in the  manufacture of scaffolds with 
both synthetic (PLGA, PLA, PLLA) and natural polymers (gelatin, fibrin, collagen) (Kang et al., 1999; Nam and 
Park, 1999; Tessmar and Göpferich, 2007; Whang et al., 2000; Yayon et al., 2010). 
In some instances, perhaps where the system is less stable (i.e. soft polymer constructs), snap freezing super-
cools water to prevent its crystallisation to ice. The crystallisation process may cause the liquid to pull away 
from the scaffold, and the shape of the ice crystals may distort the round pores. ‘Snap’ freezing may be 
achieved using liquid nitrogen or a -80°C freezer prior to freeze drying. This process was originally devised for 
manufacture of pure polymer scaffolds but has since been used more widely, for example in the lyophilisation 
of synthetic and composite (HA/PHBV, PLLA, PLGA) or natural polymer (chitosan, collagen/chitosan, fibrin) 
scaffolds (Kim et al., 2003; Liu and Ma, 2004; Ma et al., 2003; Rapp, 2002; Sultana and Wang, 2008; Whang et 






An emulsion is a mixture of two or more immiscible phases, typically an oleic and an aqueous phase. Upon 
mixing, these liquids form a dispersion of droplets (the dispersed phase) in a continuous phase (Hentze and 
Antonietti, 2001; Tadros, 2013).  
Emulsions are thermodynamically unstable systems and inevitably tend towards phase separation (Wang et 
al., 2010). The stability of the emulsion is determined by the rate at which it decays; i.e. the droplets change 
size and distribution by processes such as creaming and sedimentation, coalescence and flocculation (Kato et 
al., 1985; Prinderre et al., 1998; Yarranton et al., 2007) (fig. 6). Gravitational separation occurs when the 
dispersed particles migrate upwards (“creaming”) or downwards (“sedimentation”) depending on their 
relative density to the continuous phase. Droplets may also clump together to form aggregates. If these 
droplets retain their original integrity, this process is known as flocculation. If the droplets merge together and 
grow, the process is coalescence. Ostwald ripening is another process of droplet growth, whereby smaller 
droplets feed larger ones by mass transport through the continuous phase. Phase inversion occurs when the 
continuous and dispersed phases swap (i.e. an oil-in-water emulsion becomes water-in-oil, or vice versa). 
Emulsions can destabilise by one or many of these processes. Technological advances, such as the 
development of automated light scattering equipment, allow real-time data collection to monitor the change 
in dispersed droplet diameter and spacing at different heights in the sample (Mengual et al., 1999). This allows 




Fig. 6: Mechanisms of emulsion instability and breakage. Image adapted from (McClements, 2007). 
In stable emulsions, the internal phase droplet number, diameter and spacing remain unchanged. This 
is thermodynamically unfavourable; emulsions have a tendency to separate to reduce the interfacial 
area and hence energy. Emulsions can break by migration of the denser phase (creaming or 
sedimentation, depending on whether the internal phase is more or less dense than the continuous 
phase). Emulsions can also break by droplets coming together, displacing the continuous phase. 
Droplets may adhere as floccs (flocculation), merge into larger droplets (coalescence) or feed larger 
droplets by mass transport (Ostwald ripening).  
 
In general, emulsions with smaller droplet diameters in the dispersed phase are more stable. The change in 
viscosity of an emulsion system is also a good indicator of its stability. Small variations in viscosity are indicative 
of emulsion stability (Friberg et al., 1968). An amphiphilic molecule, such as a surfactant, may be added to 
promote stability of the emulsion (Hentze and Antonietti, 2001). Surfactants have both lipophilic and 
hydrophilic regions, allowing organised assembly at the interface between the oil and aqueous phases. The 
barrier they create slows instability. The ratio between the size of the hydrophilic and lipophilic regions of a 
surfactant molecule is expressed by as HLB (hydrophilic-lipophilic balance) (Boyd et al., 1972; Davies, 1957).  
A water-in-oil emulsion (w/o) has oil droplets dispersed in an aqueous continuous phase. An oil-in-water (o/w) 
emulsion has aqueous droplets dispersed in an oleic continuous phase (Tadros, 2013). The propensity for 
formation of a w/o or o/w emulsion is determined by the balance of hydrophobicity and hydrophilicity of the 
solutions in the mixture (Davies, 1957). This may be simply determined using the HLB scale (Griffin, 1955). 
Oleic phase reagents are assigned an HLB number, determined experimentally, that allows for selection of an 
appropriate surfactant to cause emulsification with the aqueous phase (Aulton, 1988). This is not a precise 
method; factors such as temperature, and salt content of the aqueous phase, alter the required HLB. 
Required HLB numbers may be indirectly confirmed using conductivity measurements, by determining the 
nature and temporal stability of a protein emulsion (Prinderre et al., 1998). Emulsion conductivity increases 
significantly after homogenisation then reduces as the emulsion decays. The rate and duration of the 
reduction of the conductivity is therefore an indicator of emulsion stability (Kato et al., 1985). Further, 
experimental data from o/w emulsions has shown that by plotting emulsion conductivity against HLB, the 




Common name Chemical designation  HLB Emulsifying character 
- Sorbitan tetra stearate 0.5 
Lipophilic (oil soluble) 
Span 85 Sorbitan tri oleate 1 
Span 65 Sorbitan tri stearate 2.1 
GMS Glycerol mono stearate 3.8 
Span 80 Sorbitan mono oleate 4 
Arlacel P135 Polyethylene-30 dipolyhydroxystearate 5.6 
Span 40 Sorbitan mono palmitate 6.7 
- n-butanol 7 
Water dispersible 
Span 20 Sorbitan mono laurate 8.6 
Arlatone T PEG-40 sorbitan peroleate 9 
Tegosoft GC PEG-7 glyceryl coacetate 10 
Tween 81 Polyethylene sorbitan mono oleate 11 
Hydrophilic (water 
soluble) 
Synperonic NP8 Nonylphenol polyglycol ether 8 EO 12.3 
Tween 21 Polyethylene sorbitan mono laurate 13.3 
Tween 60 Polyethylene sorbitan mono stearate 14.9 
Tween 80 Polyethylene sorbitan mono oleate 15 
Tween 40 Polyethylene sorbitan mono palmitate 15.6 
Tween 20 Polyethylene sorbitan mono laurate 16.7 
Na oleate Sodium oleate 18 
K oleate Potassium oleate 20 
Synperonic PE/F 68 Tri-block copolymer of ethylene oxide and 
propylene oxide 
29 
SDS Sodium dodecyl  40 
Table 7: Common emulsifying surfactants arranged across the HLB range from lipophilic to 
hydrophilic in character. The hydrophilic-lipophilic balance (HLB) scale is a semi-quantitative method 
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for assessing the relative contributions of the hydrophilic and lipophilic regions of non-ionic 
surfactants by molecular weight. HLB 2-3 are antifoaming agents; HLB 3-6 are w/o emulsifying agents, 
HLB 7-9 are wetting agents, HLB 8-16 are o/w emulsifying agents, HLB 13-15 are detergents and HLB 
15-18 are solubilising agents. The overlap shows that behaviour is highly dependent on the emulsion 
system and surfactant used. Adapted from Davies (1957); Griffin (1955); Kang et al (2010); Lee et al 
(2005); Pays et al (2002) and Sobisch and Lerche (2005).  
 
The average diameter of dispersed droplets in an emulsion is typically in the order of several µm. The droplet 
size distribution is often broad. However, additional processing, such as fractionation, may be employed to 
separate and remove droplets with diameters outside the desired range (Zhang and Cooper, 2005). Emulsion 
droplet size can be controlled and varied by altering the interfacial tension between the oleic and aqueous 
phases. For example, increasing surfactant concentration reduces interfacial tension between the dispersed 
and continuous phase leads to a reduction in the diameter of the droplets of the dispersed phase (Ho et al., 
1994). 
Homogenisation of an emulsion system, for example by shear mixing, reduces droplet size to a minimum after 
which no further decrease is observed. The smallest droplets are achieved by mixing at the highest speed for 
the shortest time, until the theoretical minimum droplet size is achieved, then the mixing time has no further 
effect (Prinderre et al., 1998; Solans et al., 2005). Ultra-high speed/frequency mixing can be used to make very 
small droplets in nano-emulsions (Floury et al., 2000; Leong et al., 2009).   
The minimum droplet size is governed by interfacial tension and the availability of surfactant in the emulsion 
system. Homogenisation promotes droplet formation by distributing surfactant throughout the system to 
enable assembly around a greater number of interfaces. This can also be achieved by, or in conjunction with, 
increasing the concentration of surfactant.  
In addition to affecting the droplet size of the dispersed phase, mixing time also has a strong effect on viscosity, 
even after droplet size is minimised (Prinderre et al., 1998). (Floury et al., 2000) suggest that this occurs 
because at high homogenisation pressure, flocculated particles are disrupted. The viscosity reduces until all 
droplets exist as discrete spheres, or the number of ‘floccs’ reaches a minimum. Further, they observed that 
at increasing homogenisation pressures, emulsions exhibit Newtonian behaviours, whereas they show shear-
thinning behaviours at lower homogenisation pressure. 
The density of droplets in the dispersed phase is varied by changing the ratio between the continuous and 
dispersed phases. There is a theoretical maximum dispersed phase ratio, beyond which the continuous phase 
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is insufficient to surround all the droplets of the dispersed phase. In practise, instability results in breakdown 
of the emulsion before this is achieved.  
Emulsions offer an attractive method of manufacture for tissue engineering scaffolds. The dispersed phase 
acts as a set of liquid phase porogens. Thus, the emulsion creates a ‘template’ for the scaffold (Kimmins and 
Cameron, 2011; Thomas et al., 2008). The versatility of emulsion templating arises from the ability of 
emulsions to form readily controllable droplets. Either hydrophilic or hydrophobic polymers may be used 
depending on the emulsion type used. Hydrophilic polymers dissolve in the aqueous phase to form a scaffold 
matrix around oil droplets in an o/w emulsion.  
 
Emulsion templating 
The ability of emulsions to form droplets of readily controllable size gives many applications in cell and tissue 
engineering, from micelles or microbeads used to deliver proteins (Tessmar and Göpferich, 2007), drugs (Ho 
et al., 1994) and DNA/RNA (Kulkarni et al., 2011) (where the dispersed phase is the desired functional output) 
to templated scaffolds (where the continuous phase creates a porous sponge-like structure after removal of 
the dispersed phase).  
Emulsion templating is a widely used and highly versatile method of introducing porosity (Kimmins and 
Cameron, 2011; Zhang and Cooper, 2005). The dispersed phase acts as a set of liquid phase porogens. Thus, 
the emulsion creates a ‘template’ for the scaffold (Kimmins and Cameron, 2011; Thomas et al., 2008). The 
versatility of emulsion templating arises from the ability of emulsions to form readily controllable droplets. 
Either hydrophilic or hydrophobic polymers may be used depending on the emulsion type used. Hydrophilic 
polymers dissolve in the aqueous phase to form a scaffold matrix around oil droplets in an o/w emulsion.  
Methods of using emulsions to create porosity include:  
• traditional o/w or w/o emulsions  
• TIPS (thermally induced phase separation) (Whang et al., 1995)  
• polyHIPEs (poly high internal phase emulsions, where the dispersed phase exceeds 74% total emulsion 
volume) (Busby et al., 2001; Cameron and Sherrington, 1996) 
• polyHIPEs combined with porogens, whereby some of the monomer in the continuous phase is 
replaced with an inert solvent (porogen) that is immiscible with the dispersed phase. On 
polymerisation, a series of much smaller pores forms in the walls of the larger ones (Busby et al., 2001; 











Fig. 7: A simple emulsion comprises an oleic and an aqueous phase. A surfactant may be added to 
improve stability by assembly at the interface, with hydrophobic regions in the oil phase and 
hydrophilic regions in the aqueous phase. Porous scaffolds may be produced by dissolving monomers 
in one phase and initiating polymerisation while the emulsion remains stable. The structure of the 
emulsion is preserved in the solid scaffold, giving rise to the term ‘templating’.  
 
Alternatively, the polymer may be dissolved into the dispersed phase (i.e. a hydrophobic polymer in an o/w 
emulsion) to form micelles or template microbeads. These polymer microbeads may be used to deliver a 
variety of substances in vivo, such as proteins, drugs and DNA/RNA  (Ho et al., 1994; Kulkarni et al., 2011; 
Tessmar and Göpferich, 2007).  
In a porous templated scaffold, the volume fraction of the dispersed phase of the emulsion dictates scaffold 
porosity and also influences wall thickness by closeness of adjacent droplets. Droplet diameter gives pore 
diameter. The average diameter of dispersed droplets in an emulsion is typically in the order of several µm. 
The droplet size distribution is often broad. However, additional processing, such as fractionation, may be 
employed to separate and remove droplets with diameters outside the desired range (Zhang and Cooper, 
2005). Emulsion droplet size can be controlled and varied by altering the interfacial tension between the oleic 
and aqueous phases. For example, increasing surfactant concentration reduces interfacial tension between 
the dispersed and continuous phase leads to a reduction in the diameter of the droplets of the dispersed phase 
(Ho et al., 1994). 
Homogenisation of an emulsion system, for example by shear mixing, reduces droplet size to a minimum after 
which no further decrease is observed. The smallest droplets are achieved by mixing at the highest speed for 
the shortest time, until the theoretical minimum droplet size is achieved, then the mixing time has no further 
effect (Prinderre et al., 1998; Solans et al., 2005). Ultra-high speed/frequency mixing can be used to make very 
small droplets in nano-emulsions (Floury et al., 2000; Leong et al., 2009). The minimum droplet size is governed 
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by interfacial tension and the availability of surfactant in the emulsion system. Homogenisation promotes 
droplet formation by distributing surfactant throughout the system to enable assembly around a greater 
number of interfaces. This can also be achieved by, or in conjunction with, increasing the concentration of 
surfactant.  
In addition to affecting the droplet size of the dispersed phase, mixing time also has a strong effect on viscosity, 
even after droplet size is minimised (Prinderre et al., 1998). Floury et al. (2000) suggest that this occurs because 
at high homogenisation pressure, flocculated particles are disrupted. The viscosity reduces until all droplets 
exist as discrete spheres, or the number of ‘floccs’ reaches a minimum. Further, they observed that at 
increasing homogenisation pressures, emulsions exhibit Newtonian behaviours, whereas they show shear-
thinning behaviours at lower homogenisation pressure. 
The density of droplets in the dispersed phase is varied by changing the ratio between the continuous and 
dispersed phases. There is a theoretical maximum dispersed phase ratio, beyond which the continuous phase 
is insufficient to surround all the droplets of the dispersed phase. In practise, instability results in breakdown 
of the emulsion before this is achieved. 
Stability of emulsions is key for templating. An emulsion that breaks by creaming or sedimentation will 
produce a heterogeneously porous scaffold, with one surface having much lower porosity than the other. 
Instability arising from coalescence or flocculation will give rise to irregular pore size and non-homogeneous 
pore distribution. This would produce varied wall thicknesses, with some too thin and liable to rupture, and 
others too thick to allow diffusion and potentially thick enough to provoke an adverse immune response.  
However, engineered and well-characterised emulsions are capable of generating scaffolds with tunable and 
reproducible properties from a variety of materials. It is therefore an interesting technique for producing 
tissue engineering scaffolds. The batch-to-batch reproducibility is well suited to satisfying regulatory 
requirements. There is no need for costly and specialised equipment to produce the emulsions, making 





3.0 Experimental work: polyHIPEs for skin tissue engineering 
This chapter is presented in four sections: surfactant selection for o/w emulsions (section 3.1), optimisation 
of the emulsion to template fibrin from solubilised fibrinogen (3.2), characterisation and refinement of fibrin 
polyHIPEs (polymerised structures from high internal phase emulsions) (3.3) and a study of their angiogenic 
potential (3.4). 
The work is presented in a logical, rather than strictly chronological, order for the sake of clarity. Emulsion 
stability experiments and surfactant selection were carried out in tandem with templating trials. These were 
initially performed at low internal volume fractions (50 or 60%) before gradually increasing to high internal 
phases in order to ascertain the best surfactant for templating as well as inherent emulsion stability. As such, 
some surfactants and formulations are not described in all sections, as earlier experiments (which may for 
clarity be presented in subsequent sections) demonstrated lower suitability for templating. 
The first section (3.1) presents a strategy for surfactant selection by ‘oil carrying capacity’. A series of 
systematic experiments, testing stability of multiple different families, was used to establish the oil fraction at 
which peak stability was observed. Two distinct categories of behaviour were observed. 
In section 3.2, surfactants with oil carrying capacity in the HIPE (high internal phase emulsion) regime (≥74% 
internal phase) were considered as potential candidates and trialled in templating. Their performance was re-
assessed with protein (for stability of emulsion and function of protein). Oil fraction was gradually increased 
to create scaffolds with the most desirable microstructure in terms of porosity, interconnectivity, fibre 
diameter and density and wall thickness. These experiments were carried out alongside work presented in 
sections 3.1 and 3.3. 
Having established a working protocol to templating, the resulting highly porous scaffolds (made from HIPEs 
with an internal phase comprising ~90% total emulsion volume) were evaluated for mechanical and biological 
properties in vitro. The scaffold recipe was then refined to improve the performance based on initial in vitro 
results. The effects of different scaffold compositions on microstructure, bulk mechanical behaviour, cyto-
compatibility and degradation rate are presented in section 3.3. 
The final section, 3.4, describes the effect of different scaffold structures and compositions on blood vessel 
interactions in a chick chorioallantoic membrane assay. This in vitro-in vivo bridge model was deployed to gain 
an understanding of scaffold performance in a dynamic system. Scaffolds were evaluated against well 
established, clinically used scaffolds (Matriderm® and Integra® Dermal Regeneration Template). This tested 
angiogenic potential of the scaffold materials. More data is required; this will be a priority if future work is to 
be undertaken.    
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This experimental section summarises scaffold development from template design and refinement through 
to early compatibility studies. It will form the basis of future investigations including in vivo clinical studies.  
An overview of the iterative design process for template design, revisited throughout sections 3.1 and 3.2, is 
shown in fig. 1 below. 
 
Fig. 1: Overview of experimental work, from surfactant selection and emulsion design to scaffold 





3.1 Characterising emulsion stability 
 ABBREVIATIONS 
HIPE High internal phase emulsion 
HLB  Hydrophilic-lipophilic balance 
O/W Oil-in-water emulsion 
OCC  Oil carrying capacity 
POE  polyoxyethylene 
RI   Refractive index 
TSI   Turbiscan™ stability index 
TX   Triton™ X 
W/O emulsion Water-in-oil (inverse)  
________________________________________________________________________________________ 
ABSTRACT 
Emulsions are used in myriad applications, from paint to petroleum; mayonnaise to medicines. The properties 
of these products, including density and viscosity, are directly governed by the emulsion. Increasing the oil 
content, especially beyond 74% of the total volume, greatly changes the behaviour of the emulsion. This can 
be exploited to generate useful structures or generate higher product yields. However, stability is the limiting 
design factor and requires careful selection of stabilising surfactants.  
The HLB system is the principle quantified method for selecting appropriate (non-ionic) surfactants. It assigns 
numeric value to the lipophilic and hydrophilic portions of surfactants, attempting to quantify the 
‘contribution’ to stabilising a given oil. While a useful measure, surfactant HLB is only one measure and is not 
robust enough to accurate select surfactants. This remains a ‘dark art’ with lengthy experimentation and 
personnel experience hugely important in formulation. 
We propose a novel supplementary surfactant screening tool, “oil carrying capacity”. Using a test emulsion 
comprising decane, aqueous buffer and common industrial surfactants, we assessed short-term dynamic 
emulsion stability at increasing oil fractions using static multiple light scattering. Surfactants included Tweens, 
Tergitols, Brijs and Tritons from HLB 9.8 to 17.6.  
Emulsion stability data was used to rank surfactants for their ability to generate high internal phase oil-in-
water emulsions in the test system. Two distinct patterns of behaviour were observed among the surfactants 
tested. Branched chain and reduced forms of surfactants displayed enhanced stability at extremely high oil 
fractions and less contribution of HLB compared to other surfactants of the same family.  
This system of determining the oil fraction at which optimum emulsion stability occurs, the ‘oil carrying 
capacity’ of each surfactant, is intended as a tool for surfactant selection in a system where the desired oil 
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fraction is known. Equally, it may be used to optimise oil fraction ‘carried’ in the emulsion when a particular 
surfactant is required. 
________________________________________________________________________________________ 
INTRODUCTION 
Achieving stable emulsions of known oil: aqueous volume fractions is highly desirable in a broad range of 
applications. In the petroleum industry, emulsifying heavy oil may improve flow for transportation. The 
production of reduced fat foodstuffs, such as ice cream or mayonnaise, requires low internal phase (oil) 
fraction (McClements and Demetriades, 1998). In the pharmacology and biomedical industries, emulsions may 
be used to template porous scaffolds to support cells in regenerating tissues, or to produce microbeads for 
delivery of drugs or cellular therapies (Chen et al., 2011; Ho et al., 1994; Tan and Takeuchi, 2007; Zhang et al., 
2013). Emulsion templating of delicate structures such as scaffolds requires an extremely high internal phase 
volume fraction. 
The range of emulsions for industrial application is huge and diverse, and the requirements of internal 
(dispersed) phase volume fraction and duration of stability are equally wide-ranging. Emulsions are inherently 
thermodynamically unstable, so operational stability must simply exceed shelf life or the duration of a 
processing step. It is therefore highly specific to the recipe, storage conditions and application.  
A robust system of screening surfactants is required to minimise dependence on lengthy experimentation and 
improve efficiency of emulsion formulation. The purpose of this work was to systematically evaluate 
surfactant efficacy and efficiency in a high internal phase emulsion (HIPE) system of decane and aqueous 
buffer. The goal was to identify surfactants that could adequately stabilise high internal phase oil-in-water 
emulsions with a minimum concentration of non-ionic surfactant. 
For non-ionic surfactants, the best screening method remains the HLB system, devised by Griffin in 1955 
(Griffin, 1955). This is a semi-quantitative measure of the relative molecular weights of the hydrophilic and 
lipophilic regions of a surfactant molecule assigned on a scale from 0.5 (extremely lipophilic) to 19.5 (extremely 
hydrophilic) (fig. 2). The HLB system has been extended to include ionic surfactants, some exceeding HLB 20; 
however, these are relative figures derived experimentally and not achieved mathematically (Haw, 2004). 
While Griffin’s work remains important and a useful starting point, HLB only describes the behaviour of 
surfactants in aqueous solutions and does not consider the environment (including salinity or temperature of 
the system) or other surfactant characteristics such as structure (Witthayapanyanon et al., 2008). HLB alone 
was not a useful predictor of surfactancy in this system.  
There have been several other proposed tools for predicting emulsions properties and guiding formulation. 
These include the hydrophile-lipophile deviation (HLD) and the phase inversion temperature (PIT) (Nguyen et 
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al., 2019; Salager et al., 1979; Shinoda and Arai, 1964). The HLD model considers the emulsion system more 
holistically than the HLB system, encompassing the system temperature and salinity, the effective alkane 
carbon number of the oil and the hydrophilic/phobic nature of the surfactant. However, it remains less widely 
used than the HLB system, possibly owing to the significant increase in complexity of calculations (which do 
not remove the need for extensive testing). Experience and experimentation are arguably the most important 
requirements in selecting surfactants for emulsion formulation (Salager et al., 2010).    
A common approach is to add surfactant to a system of known, fixed oil: aqueous fraction until emulsification 
is achieved. Surfactant is added in excess to improve emulsification. However, increased use of surfactant in 
this way may be undesirable in a number of applications, particularly in the pharmaceutical and biomedical 
industries where higher surfactant concentrations could denature proteins incorporated in the aqueous phase 
or cause cytotoxic and irritant effects in vivo.  
In this study, non-ionic surfactants from distinct families (Tergitol™, Brij®, Tween® and Triton™) were used to 
emulsify increasing oil fractions to create oil-in-water emulsions. Emulsion stability, and the kinetics of 
emulsion decay, were measured using a static multiple light scattering technique (Turbiscan™ LAB). Emulsion 
stability was used to rank surfactants for their ability to generate high internal phase oil-in-water emulsions in 
the test system. Surfactant HLB and functional groups were considered as variables.  
 
Principles of static multiple light scattering 
Stability was reported using the Turbiscan™ stability index (TSI). This non-destructive, non-invasive technique 
gives the stability of the sample over its whole selected height as a function of transmitted and backscattered 
light compared to the same measurements at the previous timepoint. Kinetic stability is built up over 
sequential scans. The pattern of change across the height of the sample gives a ‘fingerprint’ characteristic of 
the mode of destabilisation. TSI is defined in equation 1: 
TSI =  ∑
Σh|scani(h)−scani−1(h)|
H𝑖
           (eq. 1) 
where 𝑠𝑐𝑎𝑛𝑖 is the backscattering value at a given timepoint, 𝑠𝑐𝑎𝑛𝑖−1 is the backscattering value from the 
previous timepoint, h is the height of the scan and H is the total sample height from the first to the last scan. 
TSI is the sum of the differences between sequential scans and thus represents the stability of the sample over 
a defined timeframe. TSI reduces with increasing stability.  
This novel system of determining the oil fraction at which optimum emulsion stability occurs, the ‘oil carrying 
capacity’ (OCC) of the surfactant, is intended as a supplementary tool for surfactant selection in a system 




Equally, it may be used to optimise oil fraction ‘carried’ in the emulsion when a particular surfactant is 
required. It is a practical tool to be used in conjunction with other metrics, such as HLB, but its simplicity and 
















Fig. 1: Measuring kinetic stability using Turbiscan™ Lab static multiple light scattering technology. 
[A] A light source traverses the height of a glass cuvette. A pair of detectors read at 40 µm intervals. 
[B] A backscattering detector on the same side as the light source detects light reflected back from 
the sample; a transmission detector on the other side of the platform detects transmitted light. [C] 
The levels of transmitted and backscattered light reflect both the concentration of particles in a 
dispersion and the droplet diameter at different heights in the sample. Sequential scans display real-
time change in emulsion characteristics. Images sourced from the Formulaction Knowledge Centre 
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This work focuses on a range of commonly used surfactants used in with oil-in-water (O/W) emulsions. They 
all lie in the HLB range 9.8 – 17.6 (see table 1). The volume fractions of the oil (internal phase) range from 
classical emulsions (50, 60, 70% oil by volume) to high internal phase emulsions (HIPEs; 80 and 90% oil by 
volume). Emulsification and stabilisation of inverse (water-in-oil) emulsions falls outside the scope of the 
present work. Therefore, no lower volume fractions of oil were considered; neither were lipophilic surfactants 
with HLB below 10 (the only exception being Triton X-45 (HLB 9.8) which was included to create a full HLB 
series of Triton X surfactants).  
 
Particle sizing 
The size of the droplets of the internal phase is closely linked with the rheological properties of the emulsion, 
and thus the stability (Lee, 2006). Droplet size is also an important consideration in product design; either 
dictating pore or bead size in emulsion templating or influencing the bulk flow of materials like creams and 
lotions (Busby et al., 2002; Tessmar and Göpferich, 2007).  
Droplets of the internal phase are generally spherical. This minimises the surface area of contact between the 
continuous and internal phase and is most thermodynamically favourable. Assuming uniform droplet diameter 
of perfect spheres, the maximum volume fraction of the internal phase 74% (Cameron and Sherrington, 1996; 
Tai et al., 2001). Emulsions with an internal phase exceeding 74% total volume are called high internal phase 
emulsions (HIPEs). The spherical droplets become deformed into polyhedra and the continuous phase is 
compressed into thin films at the interface (Pal, 1999). The rheological properties change dramatically in HIPEs. 
HIPEs exhibit high storage modulus and yield stress under low shear, so droplet deformation is insufficient to 
result in bulk flow. Under high shear when the yield stress is exceeded, the emulsion changes from displaying 
elastic to viscous behaviour (Lee, 2006). These properties arise from the combined effect of some independent 
variables (internal phase volume fraction) and some dependent variables (interfacial tension, droplet size and 
range of droplet size).  
Measurement and refinement of droplet size is therefore an important consideration in emulsion formulation. 
The method is important to ensure that the emulsion is not distorted during measurement attempts. 
Application of emulsions to microscope slides allows excellent imaging and visualisation of emulsion decay, 
but the hydrophilic or phobic nature of the slide alters the emulsion at the interface and changes droplet size 
and dispersity.  
Light scattering is a commonly used technique to measure droplet size in emulsions and other dispersions and 
is well described (International Organization for Standardization, 2009; United States Pharmacopoeia, n.d.). 
The Turbiscan LAB Analyser uses static multiple light scattering to measure particle size. The principle 
advantage of this instrument is the capability to analyse HIPEs up to 95% internal volume fraction without 
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dilution (Abismaıl̈ et al., 2000). It uses data collected from a pair of sensors to record both backscattered and 
transmitted light at incremental heights of a sample-containing cuvette. Transmitted light is defined as the 
ratio of the intensity of light entering (𝐼0) and exiting (𝐼) a sample medium:  
𝑇 =  
𝐼
𝐼𝑜
                             (eq. 2) 
The backscattered light (BS) detected by the Turbiscan is inversely proportional to 𝑙∗, the mean free path of a 
photon travelling in a dispersion: 
𝐵𝑆 =  
1
√𝑙∗
                  (eq. 3) 
From Mie theory, 𝑙∗ is proportional to the mean diameter (𝑑) and inversely proportional to the volume fraction 
of dispersed phase droplets (Φ): 
𝑙∗(𝑑, 𝛷) =  
2𝑑
3𝛷(1−𝑔)𝑄𝑠
                     (eq. 4) 
Mie theory is a solution to Maxwell’s equations that, applied to emulsions, describes scattering of light by 
homogenous spherical particles (dispersed phase) of a different refractive index to that of the surrounding 
medium (continuous phase) (Acharya, 2017). The Turbiscan software enables computation of mean particle 
diameter given the volume fraction and the refractive indices of both the dispersed (internal) and continuous 
phases. 
The principles of Turbiscan measurement come from Mie Theory and Beer-Lambert law (eq. 5).  
𝐴 =  𝜀 x 𝑏 x 𝑐                    (eq. 5) 
where A is the absorbance (dimensionless), ε is the wavelength-dependent molar absorptivity coefficient (M-
1cm-1), b is the path length (cm), and c is the sample concentration (M). Absorbance is related to transmitted 
light as follows: 
𝐴 =  −log10 𝑇                    (eq. 6) 
While Mie Theory accounts for light scattering in a dispersion, Beer-Lambert law relates the absorbance and 
concentration of the sample medium. Together, they describe light travelling through a sample of mono-
disperse spheres through an absorbent medium.  
However, there are some limitations to Beer-Lambert law that translate to instrument limitations and should 
be considered during sample analysis. At high concentrations (0.01 M) Beer-Lambert law deviates from 
linearity due to the close arrangement of molecules. This proximity results in increased scattering, 
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fluorescence, changes in refractive index and changes in the absorbance coefficients due to electrostatic 
interactions between molecules.  
Some particle sizing instruments require dilution of samples to obtain accurate measurements in order to 
maintain linearity of Beer-Lambert law. Given the unique properties of HIPEs, dilution of these emulsions is 
not desirable in case it affects the measurement.  
Static multiple light scattering (fig. 1) offers a method of analysing real-time particle size and migration and 
the change over time. The method is not intrusive and does not require dilution and so was ideal for studying 




Tween® (20, 40, 80), Tergitol™ (15-S-7, 15-S-9, 15-S-15), Triton™ (X45, X100, X102, X114, X165, X405; X100 
reduced, X114 reduced), Brij® (58, O20), decane and MES hydrate and sodium chloride were purchased from 
Sigma Aldrich. Brij® O10 was obtained from Croda International (Table 1). 
MES/NaCl (25 mM/150 mM) was dissolved in water and adjusted to pH 7.4. This formed the aqueous phase 
for emulsions. All tested were performed at 37°C. 
Preparation of emulsions 
Stock solutions of surfactants were prepared in 7 ml polystyrene bijou by dispersing 0.1% (v/v) surfactant in 
decane so that surfactant scaled with oil fraction. These stock solutions were shaken briefly to disperse the 
surfactants before adding the deionised water. 4 ml mixtures were prepared in triplicate for each surfactant 
at various oil fractions (50, 60, 70, 80, 90% v/v oil-surfactant). Each sample was vortexed for 1 minute using 
WhirliMixer™ (Fisherbrand) to homogenise immediately prior to stability measurements. 
Turbiscan stability measurements 
3 ml of the sample was pipetted into a borosilicate glass cuvette, taking care to maintain a clean meniscus, 
and analysed using Turbiscan™ LAB Analyser (Formulaction, Toulouse, France) scanning every 30 seconds for 
a total of 15 minutes.  
Turbiscan stability index (TSI) was plotted for each surfactant as a function of oil fraction in the emulsion 
preparation, HLB, or time. Lower TSI indicates less change in the transmitted light, or less change in particle 
size and position.  
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The oil fraction at the lowest TSI after 15 minutes was identified as the ‘oil carrying capacity’ (OCC) of that 
surfactant. Further oil/buffer/surfactant mixtures were prepared at 5% oil fractions either side of this 
minimum (i.e. an initial minimum of 70% oil fraction would be tested then at 65% and 75% oil fraction).  
 
Refractive index 
Refractive index of the MES/NaCl buffer was measured using an Abbe 60/HR refractometer with W type prism 
and sodium lamp. Entering the refractive index of the aqueous and oil phases, along with the respective 
volume fractions in each case, to the Turbisoft software enables generation of an estimate of dispersed 
particle phase over time. 
The refractive indices of the decane and MES/NaCl buffer were recorded as 1.409 and 1.335, respectively. 




Particle size was determined using Turbisoft software using optical parameters. The refractive index of both 
the oil and aqueous phases was measured in triplicate using the Abbe 60/HW refractometer with W prism. 
Transmission level was determined by scanning a continuous phase control (MES/NaCl buffer) with the 
Turbiscan™. Volume fraction was equal to the amount of decane (internal phase) in each emulsion, ranging 
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Table 1: HLB scale of surfactants (adapted from the ICI Americas guide ‘The HLB System’ (ICI Americas, 






















C22H42O6.(C2H4O)n, n= ~20 
Polyoxyethylene sorbitan monopalmitate 
80 15 
C64H124O26 





Polyoxyethylene (10) oleyl ether 
 O20 15 
C18H35(OCH2CH2)nOH 
Polyoxyethylene (20) oleyl ether 
58 15.7 
C16H33(OCH2CH2)nOH 




(C2H4O)n C14H22O, n = ~5 
Polyethylene glycol 4-tert-octylphenyl ether 
 
X-100 13.4 
t-Oct-C6H4-(OCH2CH2)nOH, n= 9-10 
Polyethylene glycol tert-octylphenyl ether 
X-102 14.4 
(C2H4O)n C14H22O, n = 12 
Octylphenol ethoxylate 
X-114 12.3 
(C2H4O)n C14H22O, n = 7-8 
Polyethylene glycol tert-octylphenyl ether 
X-165 15.5 
(C2H4O)n C14H22O, n = 16 
Octylphenol ethoxylate 
 X-405 17.6 
(C2H4O)n C14H22O, n = 35 
Polyoxyethylene (40) isooctylphenyl ether 




Surfactant HLB Linear formula Structure 
Tergitol 
TMN-6 13.1 C11-15H23-31O(CH2CCH2O)7H 
Polyethylene glycol trimethylnonyl ether 
 
TMN-10 14.4 C11-15H23-31O(CH2CCH2O)9H 









(C2H4O)n C14H22O, n = ~5 





t-Oct-C6H4-(OCH2CH2)nOH, n= 9-10 




(C2H4O)n C14H22O, n = 12 
Octylphenol ethoxylate 
Ecosurf EH-9 12.5 
Ethylene oxide-propylene oxide copolymer 
mono(2-ethylhexyl) ether 
 
Table 3: Group B (‘alternative’) surfactants studied, arranged by family and HLB. These surfactants 
were segregated for their branched structure (Ecosurf, Tergitols) or as being reduced forms of 
equivalent ‘main’ surfactants (see Table 2) (Tritons).  
 
RESULTS & DISCUSSION 








Fig. 2: Stability of emulsions stabilised with 0.1% (v/v) surfactant at increasing oil fractions. Stability 
(TSI) was measured at 15 minutes after emulsification; lower TSI indicates higher stability. [A] ‘main’ 
surfactants are traditional options; [B] ‘alternative’ surfactants differ in that they are reduced or 
branched chain surfactants. Emulsions were tested in triplicate.   


















































































Surfactants studied can be divided into two distinct groups (figs. 2A and 2B) based on pattern of stability with 
increasing oil fraction. Group A (table 2) show maximal stability at or below 70% oil fraction. There was no 
common trend in stability with increasing oil fraction at fixed surfactant concentration (0.1% v/v). However, 
the difference in stability of emulsions at each oil fraction was significantly different between different 
surfactants (P<0.0001) (fig. 2A).  
Group B (table 3) show increasing stability with increasing oil fraction, even into the HIPE regime above 74% 
oil fraction.  
The TSI of emulsions stabilised with Triton X-45 (HLB 9.8) increased with each step change in oil fraction, 
indicating reduced stability with increased oil volume fraction. The surfactant HLB was below the required HLB 
of the decane oil phase (HLB 10-13) so the surfactant provided poor emulsion stability. As oil fraction 
increased, the surfactant was dispersed over greater surface area and stability further reduced. At 80% oil 
fraction, the TSI reduced – but stability also reduced. This discrepancy arises from the Turbiscan measurement 
principles. TSI is a kinetic measurement and relies on the differential light transmission/backscattering 
between each scan. Samples that decay too quickly – with the most rapid droplet deformation occurring 
before the first time point – register a lower TSI as a result. TSI measurements for less stable systems were 
always considered alongside bottle stability test observation.  
The other surfactants – in the HLB range 12-17 – show a different pattern of stability with increasing oil 
fraction. Stability increased (lower TSI) as oil fraction increased up to a certain point, after which stability 
reduced, often rapidly. This behaviour is characterised by a U-shaped curve with the minimum representing 
the optimum oil fraction for emulsion stability with each surfactant – the “oil carrying capacity” of the 
surfactant. 
Group B surfactants (table 3), such as reduced Tritons and branched Tergitols, showed a very strong pattern 
of increased stability (reduced TSI) with increasing oil fraction that continues into the HIPE regime (P<0.0001) 
(fig. 2B).   
The difference in stability in branched Tergitols (TMN-6, TMN-10) compared to Tergitol T-S-7, -9 and -15 
suggests a structural contribution, but the mechanism is unknown.  
Among Tergitols, the conventional surfactants span a wider HLB range (Table 2) than the branched variants 
(Table 3). Both Tergitol T-S-9 and Tergitols TMN-6 and NP-10 have HLB ~13, matching the experimentally 
determined required HLB range for decane. These results show a much greater dependence on other 
surfactant properties, such as structure, rather than HLB.  
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The pattern of behaviour is different with other classes of surfactant (fig. 2B). The oil carrying capacity metric 
is a method of distinguishing these classes of surfactant and identifying those suitable for stabilising HIPEs as 
opposed to lower internal phase emulsions (oil fraction <74%). 
 
Stability of emulsions made with different surfactant families, at different oil fractions 
A: Triton series      B: Tween series 
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C: Brij series      D: Tergitol series 
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Fig. 3: Stability of emulsions stabilised with 0.1% (v/v) surfactant at increasing oil fractions. Stability 
(TSI) was measured at 15 minutes after emulsification; lower TSI indicates higher stability. Emulsions 
are grouped by the family of surfactants used in each case: [A] Triton; [B] Tween; [C] Brij; [D] Tergitol. 
Graphs show mean and standard deviation; n=3.   
 
Among the surfactants in Fig 2A, the different surfactant families show different patterns of behaviour with 
increasing oil fraction. Emulsions containing Triton surfactants X-100, X-102, X-114 and X-405 all display 
maximum stability at 70% oil fraction (fig. 3A). With TSI<3, TX-102 and TX-114 were particularly effective at 
70% v/v oil fraction, though they are less effective at higher or lower oil: aqueous compositions. The use of 
different Triton surfactants was highly influential in the stability of the resultant emulsion (P<0.0001). Triton 
97 
 
X-45 shows a symmetrically opposite pattern of behaviour, arising from its low HLB, beneath the o/w 
emulsifying regime.  
Triton X-165 also failed to adequately stabilise emulsions in this test, despite an appropriate HLB (15.5). It 
should be noted that method (vortex) and time (1 minute) of mixing was standardised for the sake of direct 
comparison. However, vigorous shaking of Triton X-165 containing mixtures by hand did result in 
emulsification with good stability. Emulsification of X-165 mixtures was characterised by sudden transition to 
a highly viscous, opaque phase which gradually incorporated all liquid on further shaking. The extreme 
viscosity makes emulsification by vortex impractical; the vortex separates the phases rather than incorporating 
them to create an homogenous emulsion. With shear mixing or vortex, the denser viscous phase sank and did 
not incorporate with the less dense decane. Shaking lidded containers by hand forcibly reincorporated the oil 
phase and promoted further mixing until total emulsification was achieved. While this mixing effect was 
observed to with many surfactants, it was most pronounced with Triton X-165. 
Considering stability by family, where hydrocarbon tail length is constant, indicates that variation in HLB is 
dependent on variable carbon number of the hydrophilic head group rather than reduced lipophilic chain 
length.  
The Tween surfactants had comparable HLB (16.7, 15.6, 15) to Tritons but displayed poorer emulsion 
stabilisation. OCC of Tween 40 and 80 were 60%, but TSI>3 indicated poor stability even at optimum oil 
fraction. Tween 20 failed to adequately stabilise emulsions at any oil fraction; reduction in TSI at 80% oil was 
due to almost instantaneous phase separation after mixing. Most separation and droplet deformation 
occurred before the first scan started. 
All three Brij surfactants tested behaved comparably (fig. 3C) despite the range of HLB (15.7, 12.4, 15 for 58, 
O10 and O20, respectively). Brij 58 and O10 displayed OCC of 70%, while Brij O20 emulsions were most stable 
at 80% oil. Notably, O20 emulsions displayed stability (TSI<3) across a range of oil fractions, with 60-80% v/v 
internal phase systems all measuring stability with TSI<3.  
Tergitols 15-S-7 and 15-S-9 showed almost identical emulsion stability (fig. 3D) with OCC 70% and minimum 
TSI of 2.6 and 2.1 respectively (2 sf). The general pattern of behaviour was similar to that of Brij surfactants, 
with rapid destabilisation (increase in measured TSI) above the OCC. Tergitol 15-S-15 emulsions also behaved 
very similarly to T-S-7 and T-S-9 emulsions at lower oil fractions below the HIPE regime (fig. 3D). However, in 
high internal phase systems (>74%) T-S-15 emulsions showed a continued improvement in stability rather than 
the expected rapid emulsion breakage (**, P=0.0032). OCC was 90%, with TSI=1.1 (2 sf) indicating extremely 
good stability. T-S-15 is a larger molecule than either of the others, but the additional -CH may be shared 
between either of the 3 branches in any ratio so the relative size and shape change may be symmetrical or 
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distorted. Knowledge of the chain distribution would be useful in determining whether surfactant length or 
bulk was more effective at stabilising HIPEs.  
 
Effect of surfactant HLB on stability 
HLB is a qualitative measure of the contribution of the lipophilic (hydrocarbon tail) and hydrophilic (group 
group) of surfactants. Plotting TSI against surfactant HLB (fig. 4A) shows that surfactants across a range of HLB 
values – 12 to 15.5 – generated stable emulsions with TSI<3. The required HLB of the oil should not be 
considered as a precise figure, but rather as a guide with tolerance above and below depending on the specific 
surfactant used.  
Triton X-114 and Brij O10 (HLB 12.4) and Tween 80 and Brij O20 (HLB 15) are surfactants with identical HLB 
but with differing TSIs in the test emulsions (fig. 4B; fig. 4C). Triton X-114 and Brij O10 are structurally similar 
molecules. Although the degree of stability is increased in emulsions containing Brij O10, the OCC and pattern 
of behaviour across all oil fractions is comparable (P=0.844). 
However, Tween 80 and Brij O20 show different stability patterns in emulsions with increasing oil fractions. 
Tween 80 has OCC of 80% internal volume whereas Brij O20 has OCC 80%; the level of stability is significantly 
greater in emulsions with Brij O20 (**, P=0.0024) and the stability tolerance is greater across all oil fractions. 
In contrast, Tween 80 emulsions dramatically reduce in stability away from the OCC composition. In this case, 
the Tween and Brij molecules have very different structures (Table 2).  
The Tween surfactants head groups are large and bulky with limited rotation, whereas the Brij molecules are 
much narrower and almost linear. This may mean that Brij is able to pack more closely at the interface with 
less steric repulsion, enabling more effective coverage at the droplet surface and conferring enhanced 
stability.  
Separating the results by surfactant family (fig. 5) highlights the difference in behaviours between each 
surfactant family – likely, some form of structural contribution. Tritons (fig. 5A) show greatest stability 
between HLB 12-14, with stability reducing above this value. However, Tergitols with HLB 12-15.5 display 
emulsion stability with lower TSI at higher HLBs (fig. 5D). 
Tweens (fig. 5B) also have higher HLBs but provided least emulsion stability across all surfactants tested 
(excepting Triton X-45, HLB 9.8, which is below the accepted HLB range for o/w emulsifying).  
Brijs tested spanned a range of HLBs but despite this, showed similar stabilising ability at each oil fraction 
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Fig. 4: Effect of surfactant HLB on emulsion stability. Stability (TSI) was measured at 15 minutes after 
emulsification. All emulsions were made with 0.1% (v/v) surfactant. [A] shows the stability of 
emulsions made with Tritons, Tweens, Brijs or Tergitols as previously.  Results at HLB 12.4 and 15.0 
are circled as these have overlap with two different surfactants (illustrated separately in [B] and [C]. 
Emulsions were prepared with 0.1% (v/v) surfactant and increasing oil fractions from 50% to 90% 







A            B 
 
C            D 
Fig. 5: Effect of surfactant HLB on emulsion stability for emulsions prepared with different 
families of surfactant. Emulsions were prepared with 0.1% (v/v) surfactant: [A] Triton; [B] Tween; 
[C] Brij; [D] Tergitol, then the stability recorded 15 minutes after mixing in each case.    
 
These results all suggest a significant contribution of the surfactant structure to stability, However, there is no 
suggestion as to the specific features which work to enhance stability, or why. These numbers do not take into 
account branching or other conformations. In o/w emulsions, surfactants assemble at the interface and self-
orientate with hydrocarbon tails in the dispersed oil phase and hydrophilic head groups in the continuous 
aqueous phase. Droplet size affects the number of surfactants able to assemble at the interface, with the 
limiting factor being the circumference and radius of the droplet (limiting tail width and length, respectively).  






















































































































































Droplet size may also, to a small extent, affect the packing from hydrophilic head groups. Smaller droplets 
have reduced surface area in the dispersed phase. The convex droplet surface creates more space in the 
continuous phase than in the dispersed one so head group packing would be more affected than hydrophobic 
tails in the continuous oil phase.  
In an attempt to quantify relative contribution head and tail regions, surfactants were arranged by carbon 
number of the hydrophobic hydrocarbon tail group and hydrophilic head group to determine the effect of the 
hydrophilic surfactant tail on stability.  
 
Effect of increasing surfactant head group size at increasing oil fraction 
Emulsions containing 50%, 60% and 70% v/v oil fraction (those below the HIPE regime) show similar stability 
behaviour (fig. 6). Stability was generally better in 60% and 70% oil emulsions. The pattern is comparable with 
the results separated by HLB (fig. 5) but not identical. The stability at 90%, in the HIPE regime, was generally 
much lower, with the only exceptions being reduced and branched surfactants (Table 3). The tolerance in 
chain length for stability reduced, with only surfactants with 11-15 carbon tails (Tergitol 15-S-15 and Triton X-
10- reduced) achieving suitable stability (TSI<3). However, not all surfactants with this hydrocarbon tail length 
(or approximate hydrophobic tail: hydrophilic head, expressed by HLB) proved capable of stabilising 90% HIPEs 




Effect of increasing hydrocarbon tail length at increasing oil fraction 
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Fig. 6: Effect of surfactant hydrophobic tail length on emulsion stability at increasing oil fractions. 
Emulsions were prepared with 0.1% (v/v) surfactant and [A] 50% oil; [B] 60% oil; [C] 70% oil; [D] 80% 
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Fig. 7: Effect of surfactant head group size on emulsion stability at increasing oil fractions. Head 
group size was quantified by number of repeat units (n) such as   
Emulsions were prepared with 0.1% (v/v) surfactant and [A] 50% oil; [B] 60% oil; [C] 70% oil; [D] 80% 





Stability was generally similar across all oil fractions, with surfactants with approximately 9-15 repeated 
units of the head group having best stability at all oil fractions. Triton X-405 (HLB 17.6) was tested as a 
significantly larger variant of the other Triton molecules (having 35 POE units rather than the more typical 5-
15). Despite having HLB comfortably in the o/w emulsifying range, Triton X-405 emulsions displayed only 
intermediate stability (TSI~5). Triton X-405 emulsions displayed no variation in stability across any of the oil 
fractions tested, either above or below the HIPE threshold of 74% internal phase.  
Stability with surfactants of 20 carbon head groups 
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Fig. 8: Effect on emulsion stability of surfactants with 20 POE repeat head group units. Emulsions 
were prepared with 0.1% (v/v) surfactant and oil fractions from 45% to 80% (v/v). Subset graphs show 
the same data, split by surfactant family, over a range of oil fractions: [B] Brij 58 and Brij O20; [C] 






Of the surfactants studied, all Tweens and two of the Brijs had head groups with 20 repeat POE units. Stability 
was compared within and across these surfactant families with equal head group. Brij molecules are fairly 
simple and linear, whereas Tweens are much bulkier with the hydrophilic head group comprising four branches 
of variable length. The distribution of POE around the Tween molecule is therefore significantly different to 
that with Brij.  
While Brij surfactants were more effective stabilisers in the test emulsion system, the five surfactants 
displayed similar patterns in stability across increasing oil fractions below and in the HIPE regime (fig. 8A).  
Brij 58 and Brij O20 (16- and 18-carbon hydrocarbon tails; HLB 15.7 and 15.0 respectively) both showed 
intermediate emulsion stabilisation below the HIPE regime (fig. 8B). Brij 58 has an OCC of 70% oil fraction and 
stability reduced above this oil fraction. Brij O20 displayed good stability between 70% and 80% oil fraction, 
with OCC 80% v/v oil.  
The Tween mixtures displayed poor stability, failing to emulsify completely and then rapidly decaying after 
mixing (fig. 8C). Tween 20 (HLB 16.7) conferred slightly better stability than either Tween 40 (HLB 15.6) or 
Tween 80 (HLB 15.0, equal to Brij O20).  
This again shows a problem with overreliance on the HLB system for surfactant selection, as the highest HLB 
Tween gave best stability, but the lower HLB Brij (O20) was more effective and had high OCC, despite a 
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Fig. 9: Effect of surfactant hydrocarbon tail chain length on emulsion stability between straight 
chain (Brij) and branched chain (Tergitol) surfactants. Stability measurements were recorded 15 
minutes after mixing in each case.    
 
Brij surfactants have straight hydrocarbon tails and Tergitol surfactants have two-branched tails (Table 2). 
Tergitol 15-S-15 is approximately similar in size to the Brijs. The two smaller Tergitols (15-S-7 and 15-S-9) 
showed intermediate stability up to OCC, OCC at 70% oil, and then reduction in stability in the HIPE regime. 
The larger Tergitol, T-S-15, also has intermediate stability below the HIPE regime (TSI~3 at 70% oil fraction). 
Unlike the smaller Tergitols, stability continues to increase with increasing oil fraction into the HIPE range, 
with OCC at 90% oil. The behaviour is more typical of the bulkier Tergitols TMN-6, TMN-10, NP-10 (Table 3).  
The straight chain surfactants of the same approximate size, Brij 58 and Brij O10, also showed intermediate 
stability below the OCC (70% oil fraction). Above the OCC, in the HIPE range, emulsions with Brij surfactants 
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reduced in stability such that TSI was higher than the equivalent increments below the OCC. Emulsions 
containing Tergitol had less of a decrease in stability away from the OCC, possibly due to stabilising effect of 
the longer hydrocarbon tail.  
There may be a critical chain length for stability before the branching effect of the Tergitols has any enhanced 
stabilising effect in very high oil fraction emulsions. Tree roots, which are only effective anchors if they are 
deep enough in soil, are a useful analogy. Once they are deep enough, lateral spread will further improve 
anchoring. Surfactants may require a hydrophobic tail long enough to provide ‘anchorage’ in dispersed oil 
before hydrophilic head group size has a significant effect on emulsion stability.  
 
Effect of standard vs reduced surfactants  
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Fig. 10: Emulsion stability with standard and reduced surfactants at increasing oil fractions. [A] 
Triton X-100 (OCC= 70% oil) and Triton X-100 reduced (OCC= 80% oil); [B] Triton X-114 (OCC= 70% oil) 
and Triton X-114 reduced (OCC ≥ 90% oil).  
 
A       B 
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Effect of conventional vs reduced surfactants 
Triton X-100 and Triton X-114 are conventional surfactants (Table 2) and are also available in equivalent 
reduced forms (table 3), though these are less widely used. The reduced forms differ in that the reduced forms 
differ in that the head group of non-reduced surfactants is benzene-based, whereas in reduced surfactants it 
is cyclohexane-based (Tables 2 and 3). Both reduced surfactants displayed improved stability compared to the 
non-reduced form.    
Below their respective OCC, reduced and non-reduced Triton X-100 standard form showed very similar 
stability, with only a slight deviation at 60% oil fraction (fig. 10A). With TSI between 3 and 4, both surfactants 
formed and stabilised emulsions for short periods of time. In the HIPE range, emulsion stability varied between 
the two surfactants. Triton X-100 showed greatest stability (OCC) at 70% oil fraction, below the HIPE range 
(≥74%, whereas the reduced form had OCC at 80%. This differs from the other ‘alternative’ surfactants which 
had OCC at 90% oil fraction, the highest internal volume fraction tested. The mechanism of action of the 
reduced surfactant may be suppression of instability, rather than promotion of stability at the oil/aqueous 
interface. The reduced surfactant still showed excellent stability at 90% oil fraction, however. Triton X-100 
mixtures did not emulsify at 90% oil fraction and so are not presented. 
Triton X-114 and the X-114 reduced behave similarly. 90% emulsions formed with Triton X-114 but stability 
was poor; in the HIPE range above 74% oil emulsions destabilised quickly within the 15-minute analysis 
window. As with the Triton X-100/reduced pairing, Triton X-114 and the reduced equivalent showed very 
similar TSI measurements up to 70%. In all cases, stability was good with TSI<5. Above 70%, stability continued 
to increase in the reduced surfactant emulsion system with OCC 90%. The actual oil carrying capacity may be 
greater, but the Turbiscan is limited to analysing emulsions with internal volume fraction ≤95%.  
Although the reduced surfactants form more stable emulsions than their non-reduced counterparts, the 
stability approaching extremely high oil fraction (90% v/v) increased more slowly than other unconventional 
surfactants, such as Ecosurf or Tergitols (table 3). However, HIPEs can have extremely high viscosity which can 
impart a physical, as well as chemical, component to resist emulsion breakage. In scenarios where short-term 
emulsification is required (i.e. templating, where in the internal phase is removed, or transport, where is the 
internal phase must be recovered efficiently) this could be beneficial. The emulsion could be tuned to have 
good stability at the desired oil fraction over a particular timeframe, and then destabilise when the emulsion 
is no longer required and the internal phase needs to be removed.  
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Fig. 11: Particle size of emulsions containing reduced and equivalent non-reduced surfactants at 
increasing oil fractions. Particle size was calculated in Turbisoft software based on backscattered and 
transmitted light data and refractive indices of the continuous and dispersed phases. [A] Triton X-100 
(OCC= 70% oil) and Triton X-100 reduced (OCC= 80% oil); [B] Triton X-114 (OCC= 70% oil) and Triton 
X-114 reduced (OCC ≥ 90% oil).  
 
CONCLUSIONS 
The vast range and number of surfactants available makes selection of appropriate surfactants a lengthy and 
time-consuming task. Commercial protocols like the ICI Guidelines suggest screening surfactants by HLB. 
However, as demonstrated here and reported elsewhere in the literature, there are many other surfactant 
attributes which contribute to their efficacy in a given emulsion system. 
The HLB metric for surfactant selection is an accessible tool but has limited practical use in selecting 
surfactants for optimum emulsion stability. Identifying surfactants with appropriate HLB for the oil in the 
emulsion pre-selects a group of surfactants but within this group, surfactants will display a wide range of 
stabilising capability. Currently, this can only be determined experimentally. 
Emulsion stability is the result of the complex interplay between surfactant structure; method and speed of 
mixing; salinity and molarity of the aqueous phase; and the density and viscosity (empirical and differential) 
of the aqueous and the oil phases. No one metric is likely to be powerful enough to adequately describe all 
the contributing factors. However, a number of tools may be used concurrently to identify and select a number 
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of candidate surfactants which may then be tested thoroughly to assess practical emulsion stabilising 
capability in a given system.  
The ability to identify the oil carrying capacity, the volume fraction of the internal phase at peak emulsion 
stability, is a useful tool in emulsion design. It may either be used to select surfactants where a particular oil 
volume fraction is required, or it may be used to optimise the oil volume fraction for a given surfactant.  
Further work is required to elucidate the reasons for the different behaviours of the two classes of surfactant 
identified here (fig. 2), enabling easier identification of surfactants into one of the two classes of surfactant by 
OCC behaviour.  
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Particle size data 
Emulsions were initially analysed using single particle optical sizing (SPOS) using an Accusizer 780 (NICOMP 
Particle Sizing Systems, Santa Barbara, CA, USA). However, this technique required sample dilution which is 
not suitable for analysing highly concentrated HIPE oil-in-water emulsions. 
Particle size was then determined computationally using Turbiscan results, using a combination of 
backscattering and transmission data, and the refractive indices of the continuous and dispersed phases. Sizing 































































































































































With the exception of emulsions containing Triton X-165, all emulsions showed reducing droplet size with 
increasing internal phase volume fraction. This effect may be directly attributed to the surfactant as mixing 
method and rate was common to all samples. 
Tweens also showed a general reduction in particle size with increasing oil fraction. This is somewhat 
counterintuitive given that increasing oil fraction also correlated with reduced emulsion stability which 
commonly occurs by droplet growth. 
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The measurement of the very small droplets, smaller than those detected in Triton emulsions, may arise from 
residual, isolated droplets in the central measurement region after phase separation causing emulsion 
breakage and clearing.  
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As with other surfactant families, Brij emulsions showed a general reduction in particle size with increasing 
oil fraction. The larger droplets measured in the 65% oil Brij O10 emulsion (5% below OCC) is likely a genuine 
measurement, with larger droplets arising from a homogenous and stable emulsion with low tendency to 
separate during the test period. 
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3.2 Formulation and characterisation of oil-in-water emulsions to 
template highly porous protein structures 
 
ABBREVIATIONS 
DMEM  Dulbecco’s Modified Eagle’s Medium 
ECM  extracellular matrix 
ETPM  emulsion templated fibrin scaffold 
FBS  foetal bovine serum 
GTA  glutaraldehyde 
HIPE  high internal phase emulsion 
HLB  hydrophile-lipophile balance 
MES  2-(N-morpholino) ethane sulfonic acid 
MSC  mesenchymal stem cell 
O/W oil-in-water emulsions 
OCC oil carrying capacity 
PM0 foamed fibrin scaffolds 
polyHIPE scaffold templated from HIPE  
PS penicillin-streptomycin 
PVA poly vinyl alcohol 
SEM scanning electron microscope/graph 
TSI Turbiscan® Stability Index  
UTS Ultimate tensile strength 
________________________________________________________________________________________ 
ABSTRACT 
Emulsion templating is a versatile technique for creating porous materials. Emulsions can be used to create 
range of porous biocompatible materials such as polylactic acid, polymethyl methacrylate and 
polycaprolactone. These porous biomaterials have precise micro- and macro-architectures dictated by the 
emulsion template but have limited biologically relevance. Subsequent processing steps, such as surface 
treatment or functionalisation, may be required. 
The use of proteins (e.g. gelatin, collagen and fibrin) as the polymeric material allows the introduction of 
physiologically relevant chemistries to the construct. However, the surfactants needed to stabilise emulsions 
for templating are often aggressive and denaturing at the concentrations required, which can affect the 
macro-molecular structure.  
In this section, the manufacture of scaffolds by a facile emulsion templating process is described. Non-ionic 
surfactants were screened for their ability to stabilise emulsions at low concentrations (well below cytotoxic 
concentration). This was achieved by systematically increasing oil fraction of oil-in-water emulsions of decane 
and physiological buffer (MES/NaCl) and analysing short-term stability (in line with fibrin clot time) using static 
multiple light scattering. Oil fraction was gradually increased into the high internal phase system.  
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Surfactants capable of sustaining high internal phase emulsions (HIPEs) and therefore templating highly 
porous materials (polyHIPEs) were previously identified (Chapter 3.1). However, their biocompatibility was not 
assessed. Suitability of candidate emulsion systems was confirmed with templating. Fibrin scaffolds were 
found to have retained native fibrous structure, creating an intricate “basket weave” structure (confirmed 
with electron microscopy). Thromboelastometry confirmed no prohibitive effect of surfactant on fibrin 
formation. CCK-8 showed no evidence of cytotoxicity in either contact or leachable scaffold assays.     
________________________________________________________________________________________ 
INTRODUCTION 
Emulsion templating is a widely used method of creating biomaterial products, wherein two immiscible phases 
are mixed with surfactant to create a stable dispersion of spheroids. High internal phase (HIPE) emulsions, in 
which the dispersed phase comprises >74% total volume fraction (Cameron and Sherrington, 1996; Tai et al., 
2001), have been used to create extremely porous materials for many years – most commonly using 
hydrophobic synthetic polymers in a continuous oil phase (Bokhari et al., 2007; Carnachan et al., 2006; Cui et 
al., 2010; Hentze and Antonietti, 2001; Musgrave et al., 2017; Owen et al., 2016; Quell et al., 2017; Zhang and 
Cooper, 2002). Some oil-in-water (o/w) HIPEs have been used to create hydrophilic scaffold materials, 
polyHIPEs; however, to date, protein polymers have not been templated using such emulsions (Franks et al., 
2006; Sultana and Wang, 2008).  
Proteins – particularly those found in native extracellular matrix such as collagen – are attractive scaffold 
materials as they are biocompatible, biodegradable and offer biochemical, mechanical, and structural 
properties in line with physiological requirements. Proteins are often processed to purify, sterilise, or stabilise 
them for use. These processes render them may reduce risk of contamination or immunogenicity but can 
denature the protein and destroy the native hierarchical structure. When native protein is required, it is 
important to optimise the type and extent of purification and sterilisation processing to preserve the structure 
and biochemical function of the molecule. For example, treatment with surfactants such as SDS (ionic) or 
Triton X-100 (non-ionic) has been found to have no effect on collagen content in native tissue (Gilbert et al., 
2006; Song and Ott, 2011). Freeze drying, another method of sterilisation and stabilisation, has been shown 
not to alter the metabolic or biological properties of fibrinogen (Regoeczi and Stannard, 1969), though it is 
susceptible to degradation by enzymes and other means (Belew et al., 1978; Kopeć and Latallo, 1978).   
The emulsion system presents a challenge in templating proteins as the type and choice of surfactant is 
imperative not only to emulsion stability but also to protein integrity. Insufficient surfactant limits the stability 
of the emulsion and/or the volume of fraction of the internal phase. Surfactants required to generate sufficient 
emulsion stability for proteins to assemble and consolidate can delay formation or even damage or the native 
structure, especially because both tend towards interfaces and so are concentrated in in a small space 
competing for the interface (Norde and Lyklema, 1991; Wilde et al., 2004).   
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The charge of surfactants can be disruptive to proteins (Moosavi-Movahedi, 2005; Otzen, 2011; Song and Ott, 
2011), but even non-ionic surfactants, such as Tweens, are cytotoxic above a critical concentration as a result 
of the surface active/detergent properties. There are two ways to approach this problem. The first is to accept 
that the surfactant will denature the protein. This may be desirable in that the biochemistry of the protein is 
still present, but any fine structure/structural relevance to native ECM is lost. Additional top-down 
manufacturing steps, such as photo- or electron beam lithography, plasma treatment, or coating with 
adhesion proteins; or bottom-up approaches like self-assembly of copolymers on the scaffold surface, are 
required to add nanotexture to the scaffold (Viswanathan et al., 2012; X. B. Yang et al., 2001). These have been 
shown to enhance cell compatibility, migration and adhesion with the scaffold surface (Mann and West, 2002; 
Park et al., 2007; X. B. Yang et al., 2001). 
The second is to use synthetic polymers, particularly those with proven biocompatibility and regulatory 
approval such as PLLA, PGA, PCL and polyanhydrides (Abedalwafa et al., 2013; Nair and Laurencin, 2007). 
However, solubility presents an issue. Organic solvents may be required, increasing the environmental cost of 
the manufacturing process. As with scaffolds of denatured proteins, the microstructure will be templated by 
the emulsion but fine textures and nanotextures will be lacking (fig. 1).  
For this work, fibrin, a fibrous blood protein which forms blood clots in response to injury, was selected as the 
scaffold material (Chapter 2). To template fibrin scaffolds, its precursor molecule fibrinogen would be 
dissolved in the aqueous phase. Thrombin would then be added to catalyse conversion of soluble fibrinogen 
to insoluble fibrin fibres. The thrombin-fibrinogen system was interesting as previous work has shown that 
clot time and thrombin: fibrinogen ratio can affect the diameter and density of resultant fibrin (Blombäck et 
al., 1989; Blombäck and Okada, 1982). This offered an additional degree of control and ability to tune the 
scaffold material. However, clot time must be balanced against emulsion stability to ensure the fibrin 
templated the original emulsion with the intended droplet (pore) diameter and spacing.  
Thrombin distribution was an area of concern. It was thought that late addition of thrombin, after initial 
dispersion of oil and water phases but before complete emulsification, would offer the best chance of 







Styrene-DBV polyHIPE          
(Akay et al., 2004)                       
(no scale provided in source material) 
2‐ethylhexyl methacrylate-
DVB (90:10) polyHIPE 
(Sergienko et al., 2002) 
NIPAM-based polyHIPE 
(Pickering emulsion with 
PMMA beads)                     




polyHIPE (Paljevac et al., 2012) 
Polycaprolactone 
methacrylate polyHIPE (80:20 
chloroform: toluene)            
(Dikici et al., 2019) 
VBC-DVB polyHIPE stabilised 
with Span 80                            
(Barbetta et al., 2000) 
Fig. 1: Cross-sectional electron micrographs of emulsion templated scaffolds from literature.  
Scaffolds were templated via water-in-oil emulsions or Pickering emulsions (those stabilised 
with solid particle). High template fidelity creates scaffolds with close-packed spherical pores.  
 
Once formed, the emulsion must remain stable for at least the time taken for fibrin to form. Having previously 
identified non-ionic surfactants that are capable of short-term stabilisation of high internal phase emulsions 
(Chapter 3.1), the effect of incorporating biological buffer, fibrinogen and thrombin was next evaluated. 
Suitable HIPE surfactants are those above in red line in fig. 2, below. 
Another consideration was how the surfactant and protein might interact. Both have a tendency to assemble 
at the interface (Norde and Lyklema, 1991). In a HIPE system, surfactant and protein would be expected to be 
closely associated at the thin interfaces. This could potentially denature the protein or slow fibrin formation. 
Non-ionic surfactants with high “oil carrying capacity” were selected to allow their use in smaller 




































































































































































Fig. 2: Summary of oil carrying capacity of surfactants tested in previous experiments where 
the oil carrying capacity is the volume fraction of oil in the emulsion at which stability is greatest. 
Each emulsion contained 0.1% v/v surfactant and was tested in triplicate. Reported values 
represent stability at 15 minutes after emulsification. HIPEs are emulsions where the internal 
phase exceeds maximum spherical packing of the internal phase, i.e. 74% of the total volume.   
 
The aim was to generate a high internal phase emulsion capable of maintaining a stable droplet arrangement 
of appropriate diameter and spacing for cell and blood vessel ingress (fig. 3). Further, the emulsion must not 
denature the fibrinogen or thrombin and allow their interaction to form a native-like fibrin network at the 
oil/water interface.   
Emulsion stability was evaluated both macroscopically and using light scattering with a Turbiscan LAB analyser 
against increasing oil fraction. When translated to scaffold manufacture this produced high fidelity, highly 
porous scaffolds with close cell packing and even protein distribution, resulting in an interconnected structure 
with well-defined pores (confirmed by scanning electron microscopy). Droplet size was evaluated using light 
microscopy and was optimised for cell ingress and angiogenesis. 
The ability to create protein polymeric materials with well-distributed, delicate protein microstructure is of 
significance in development of scaffold materials for tissue engineering. Currently, polyHIPE materials are 
largely restricted to a small number of available hydrophobic biomaterials available using water-in-oil 
emulsions. This work demonstrated the capability to design well-characterised emulsions to accurately 
template protein materials such as fibrin, collagen, and alginate, which are commonly used in tissue 
engineering scaffolds. This method allows hierarchical scaffolds to be created in which the native protein 





 Optimal Achieved 
Pore size 
70 – 200 µm 
Cell ingress (Choi et al., 
2013; Marshall et al., 2004) 
50 – 200 µm 
Interconnect 
size 
25 – 35 µm 
Angiogenesis (Bokhari et 
al., 2007; Marshall et al., 
2005) 
20 – 40 µm 
Porosity 
≥ 74% 
Exceeds perfect sphere 
packing 
Up to 95% 
Fig. 3: Comparison of typical fibrin-based scaffold parameters with optimal values cited in the 
literature. The optimised scaffolds manufactured according to the method described in this report all 
meet (pore size; interconnect size) or exceed (achievable porosity) the cited values. Scale bar = 100µm. 
N.B. Up to 74% is not an optimal figure for porosity; simply the limit achieved (i.e. sub-HIPE) by authors 
describing scaffolds using native proteins by comparable methods.   
 
Initially, well-characterised common surfactants (including Tween-Span) were used to establish a working 
system with the relevant proteins and buffers. This was gradually modified by increasing oil fraction, moving 
to more efficient HIPE surfactants (fig. 2) when required. The emulsion systems were evaluated for stability 
and then protein- and cyto-compatibility. Volume fraction of oil was increased in a stepwise fashion from 50% 
v/v into the HIPE system up to 95% internal volume fraction. A systematic approach was used to achieve 
maximum oil fraction with minimum surfactant, while maintaining emulsion stability. The effects of mixing 
speed and method were evaluated as well as surfactant type and concentration. Non-ionic surfactants were 
used throughout as these were supposed to have a less denaturing effect on the structure and function of 









    
 
Fig. 4: Arrangement of the dispersed (internal) phase, continuous (external) phase and 
surfactant in an oil-in-water (o/w) emulsion. Monomers in the continuous phase polymerise to 
create a solid continuous matrix. The light micrograph shows a surfactant-stabilised o/w 




All water and buffers were autoclaved or sterile filtered, as appropriate, prior to use. All preparatory and 
formulation work was undertaken in a laminar flow hood to minimise risk of contamination. 2% bovine 
fibrinogen (w/v of clottable protein) and 5% w/v polyvinyl alcohol (PVA) (Mw 31,000-50,000 g/mol, 87-97% 
hydrolysed) were prepared by dissolving in MES/NaCl buffer (25 mM/150 mM, pH 7.4) at 37°C. 1 M calcium 
chloride solution was prepared in distilled water. Thrombin (pre-dialysed; frozen aliquots) was warmed to 37°C 
before use.  
Decane and surfactants (Tween 80; Span 80; ETOCAS 35-MH, ETOCAS 35 RB; Triton X-100, X-102, X-114, X-
165, CG-110; Brij O10) were used as purchased. Tween 80 and Span 80 were also mixed in various proportions 
to generate surfactant blends with appropriate required HLB to match decane (Table 1). 
  
Void space is determined 
by the volume fraction of 
decane (dispersed phase) 
Surfactant and dispersed 
protein both accumulate 
at the o/w interface  
Hydrophilic scaffold material (fibrinogen) is 
dispersed in the continuous (buffer) phase  
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Volume fraction HLB  
(hydrophilic mixtures) Tween 80 Span 80 
55 45 10.185 
60 40 10.72 
65 35 11.255 
70 30 11.79 
75 25 12.325 
80 20 12.86 
85 15 13.395 
90 10 13.93 
95 5 14.465 
100 0 15 
Table 1: HLB of different blends of Span 80 (HLB 4.3) and Tween 80 (HLB 15). Only hydrophilic blends 
(HLB >10) are shown as the intended use was o/w emulsions. The highlighted blends were found to 
have best stability and were included in early templating trials.  
 
Emulsion preparation 
Oil and aqueous phase were prepared as previous. Initial tests were performed according to ICI guidance (ICI 
Americas, Inc., 1984) and used 50% decane (v/v) and 1% (v/v) Tween 80/Span 80 in varying proportions to 
elucidate required HLB. Decane, buffer and surfactant were mixed at 5000 rpm using a high shear mixer with 
impeller blades (Caframo Ultra Speed BDC6015, Caframo Lab Solutions, Georgian Bluffs, Ontario, Cn). Vortex 
(Fisherbrand WhirliMixer) and hand shaking were used as alternative methods of emulsification. Oil fraction 
was systematically increased by increments of 5%. Different surfactants were trialled, and surfactant 
concentration reduced stepwise (1, 0.5, 0.1% (v/v)). Only formulations resulting in emulsification were 
progressed to the next stage of testing.  
Emulsion characterisation 
Emulsion stability was evaluated as described in Chapter 3.1. 3 ml samples were scanned every 30 seconds for 
15 minutes. Droplet size of the internal phase was evaluated by placing a sample of emulsion on a glass slide 




Scaffold preparation by emulsion templating 
Formulations which successfully emulsified and had TSI≤3 were selected for emulsion templating. This was 
approached systematically, starting with 50% internal phase, and gradually increased as the quality of 
emulsions improved. Brijs, Tritons and Tergitols were used in HIPEs to template polyHIPE scaffolds. Surfactants 
capable of stabilising HIPEs were previously identified and are shown as those with oil fractions at peak 
stability above 74% v/v (fig. 2). 
Briefly, the decane and surfactant were used as per the basic emulsion recipe. The MES/NaCl buffer aqueous 
phase (pH 7.4) also contained bovine fibrinogen (2% w/v clottable), thrombin and calcium chloride. The 
decane, surfactant, fibrinogen and calcium were mixed to emulsify before adding the thrombin and mixing for 
a further 30 seconds. Emulsification of early compositions was performed using the Caframo Ultra Speed 
BDC6015 impeller mixer. 
Emulsions were then transferred to 5x5 cm square weighing boats and incubated for 1 hour at 37°C. Scaffolds 
were cross-linked 1 hour each side with 0.2% glutaraldehyde solution, washed five times with 0.1% sodium 
borohydride and four times with deionised water. Some scaffolds were washed on each side in dilute excipient 
(0.2% w/v PVA, 1% w/v Tween, 1 M sorbitol or Tween/sorbitol). Scaffolds were then lyophilised overnight at -



















   
4. Cross link 1 hr each side 5. Reduce and wash 6. Freeze dry overnight 
Fig. 5: Overview of scaffold templating method during early development. The basic emulsion 
components (decane, aqueous buffer and surfactant) were added to a 50 ml syringe body with the tip 
removed and briefly pre-mixed before adding fibrinogen solution. The reagents were mixed until 
emulsified, by slowly raising and lowering the syringe while keeping the mixer blades submerged. 
Scaffolds were cast into weighing boats and incubated to allow fibrin to form before cross-linking. 
Sodium borohydride solution was used to remove excess glutaraldehyde solution and then removed 









2. fibrinogen  
 
3. thrombin  
 
+ 0.1% NaBH4 solution (4 washes) 
+ distilled water (4 washes)  
yellow/orange                white 










Thromboelastometry was assessed using a Stago STartMax coagulometer. All testing was performed at 37°C 
using pre-warmed reagents. Surfactants were added to fibrinogen solutions (2% clottable protein in 
MES/NaCl) at 0.1, 0.2, 0.5, 1.0 or 2.0% (v/v). 2 ml each solution was placed into a cylindrical cuvette containing 
a small steel ball bearing. The cuvettes were situated over the magnetic region of the coagulometer so that 
the ball bearings rotated around the base. 50 µl thrombin was then added to each sample and the time taken 
for a fibrin clot to form recorded. The clot time was determined as the point at which the viscosity had 
increased sufficiently to hold the ball bearing at a fixed position in the fibrin gel and resist the magnetic force 





RESULTS AND DISCUSSION 
Emulsion templating below the HIPE regime 
The ICI Americas guide suggests beginning emulsion formulation with a blend of Tween 80 and Span 80, widely 
used and well-characterised surfactants, to elucidate required HLB of the oil phase (ICI Americas, Inc., 1984). 
The required HLB, and most suitable Tween/Span blend (70:30 by volume, HLB 11.79) was previously identified 
(Chapter 3.1).  
The same strategy was applied to early attempts to template scaffolds with the decane/buffer system. Instead 
of varying surfactant, oil fraction was increased stepwise (fig. 6) to give a proof of concept and to test the 
bounds of the template method.  
Calcium chloride solution was added to fibrinogen and alginate (adapted from a confidential in-house method) 
dissolved in MES/NaCl buffer (pH 7.4). This was mixed with decane and the Tween/Span surfactant mixture in 
a 50 ml syringe body (fig. 5). Immediately on the addition of thrombin, the mixture was emulsified using an 
impeller mixer. The emulsion was cast into a flat-bottomed weighing boat, incubated to allow fibrin formation, 
cross-linked, washed and dried. The micrographs below (fig. 6) show cross-sections of the freeze-dried 
scaffolds under scanning electron microscope.  
These early scaffolds are characterised by thick, dense fibrin fibres and thick pore walls with few interconnects. 
This occurred partly because of the relatively low oil fractions (50%, 60%) and partly because of the poor 
stability afforded by Tween/Span in this system at 70% oil, close to the HIPE regime. The amount of surfactant 
was doubled to 0.2% in an attempt to improve stability, but this was unsuccessful. While fibrin formation 
appeared unaffected by the increase in surfactant concentration, the emulsion still destabilised rapidly and 
gave rise to a dense material with low porosity.  
At 50% oil fraction, discrete pores left by the oil droplets are visible, indicating the template was effective and 
the emulsion was stable during the time taken for fibrin to form at the interface. However, the low oil fraction 
gave less than optimal spheroid packing, producing thick mats of fibrin which would not permit ingress of cells. 
Additionally, the droplets at this oil fraction were quite large, producing pores ranging from 100 µm in 
diameter up to 500 µm and beyond.  
At 60% oil fraction, the porosity increased and droplet size reduced. The fibrin walls were thinner and separate 
fibres were distinguishable at high magnification. Thicker regions, such as the curved diamond at the furthest 
space between pores, comprised fibrin bundles rather than the mats observed at the thinner points. There 
was some evidence of interconnection between pores and much greater diffusional space between fibres. 
However, pores were less distinct, probably due to reduced emulsion stability giving less time for fibrin to form 




Microstructure of initial templated fibrin scaffolds 
0.1% surfactant blend (Tween 80/Span 80; 70:30, HLB 11.79) 
50:50 oil: aqueous 60:40 oil: aqueous 70:30 oil: aqueous 
   
   
Fig. 6: Cross-sectional electron micrograph images of emulsion-templated fibrin-based scaffolds 
with increasing porosity. The micrographs show magnified images (top row 2,500x; bottom row 
10,000x) of scaffolds produced with 50% oil, 60% oil, and 70% oil by volume fraction in the emulsion. 
This translates to approximately the same porosity in the templated scaffold. 70% oil emulsions were 
not stable throughout initial scaffold incubation, so surfactant concentration was increased to 0.2% 
v/v.  
 
The same properties were observed in the scaffold templated from a 70% oil fraction emulsion with the same 
concentration of surfactant (0.1%). Pore size reduced further but the emulsion stability was poor, resulting in 
separation of oil before the fibrin formation and scaffold consolidation had completed. This negatively 
impacted pore spacing and therefore wall thickness, as the emulsion decayed by particle migration and 
coalescence. Distinct fibrin fibres were visible, but they were clumped together owing to the rapid separation 
of the oil and aqueous phases. 
At low internal phase volume fractions, pore size and wall thickness were not adequate. At high oil fractions 
the emulsions were not sufficiently stable to maintain a template for fibrin formation.  
  
2µm 2µm 2µm 
2µm 20µm 20µm 
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Effect of increasing surfactant concentration on microstructure 
Surfactant concentration was increased in an attempt to improve emulsion stability. This was intended to 
promote the formation of smaller, more stable droplets and delay the onset of instability in higher oil fraction 
emulsions to allow time for fibrin formation around the oil droplets.  
Decane-MES/NaCl (70:30 by volume) emulsions were prepared as previously, with either 0.1% or 0.2% (v/v) 
Tween 80/Span 80 surfactant mixture added to stabilise.  
However, microstructural evaluation of cross-sectional freeze-dried samples showed no improvement in 
porosity, interconnectivity, or fibrin fibre arrangement in the 0.2% system (fig. 7). Conversely, scaffolds 
prepared with 0.2% Tween/Span showed equal or reduced porosity and minimal diffusional space. Fibrin fibres 
were evident but had amassed in dense sheets rather than a looser interwoven structure. 
With 0.1% surfactant, porosity was similarly low, suggesting that a similar volume of oil was held in the 
aqueous phase during templating. Emulsion separation by creaming was therefore unlikely. Fibrin fibres again 
formed in sheet-like structures, but individual fibres were visible within the sheets. This may suggest that the 
higher surfactant concentration (0.2%) slightly denatured the protein at the interface; however, both 
concentrations remained extremely low so this is unlikely.  
It was evident that increasing oil fraction would greatly improve the porosity, wall thickness and 
interconnectivity. Evidence of individual fibrin fibres at the thinnest parts of the pore walls (fig. 6, fig. 7 bottom 
left) showed that the fibrin sheet could be improved by templating from an emulsion with more closely packed 
oil droplets. Increasing oil fraction beyond the oil carrying capacity of the surfactant would lead to reduced 
emulsion stability and poorer template fidelity. Increasing surfactant concentration further could slightly 
improve stability, though previous work suggested the choice of surfactant was more important than the 
concentration (Chapter 3.1). Additionally, higher concentration of surfactant at a smaller interface (caused by 
closer packing of droplets in an emulsion with greater internal volume fraction) carries a higher risk of 
denaturing protein at the interface and either preventing fibrin formation or adversely affecting the native 
fibrous structure.  
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 Surfactant concentration (v/v) 









Fig. 7: Cross-sectional electron micrographs of fibrin-based scaffolds templated with emulsions 
containing 0.1% or 0.2% v/v surfactant. Emulsions and templated scaffolds were prepared as 
previously described. Emulsions contained 70% oil fraction and either 0.1% or 0.2% v/v Tween 








Effect of PVA and alginate copolymers on microstructure  








Fig. 8: Cross-sectional electron micrograph images of emulsion-templated fibrin-based scaffolds 
with increasing porosity containing either PVA or alginate (1:2 copolymer: fibrin). Scaffolds were 







An existing in-house method for preparation of fibrin scaffolds via a foaming method (confidential) used 
alginate as a copolymer and bulking agent. This served to improve the bulk strength and handling of the 
scaffold and provide stability especially between foaming and formation of a consolidated fibrin network.  
The same alginate was added to the templated scaffolds for the reason, to provide stability and increase 
integrity of the friable scaffold. Alginate is biocompatible and has a long history of use in the biomedical 
industry. Being significantly cheaper than fibrin, it is also an economically attractive option. 
However, while foamed scaffolds produced with fibrin-alginate have a delicate fibrous structure, the 
equivalent recipe produced thick, dense sheets when templated (fig. 8). After preliminary drying the scaffold 
had a gum-like texture, perhaps due to difficulty in removing liquid effectively. Examination of the 
microstructure shows extremely low porosity and almost no diffusional spaces. At 60% oil fraction and to some 
extent 50%, a small number of pores are visible. However, it is clear that the emulsion was not templated 
effectively. The alginate did not improve emulsion stability. At higher oil fraction (70%) there are no pores 
visible. In all cases, fibrin fibres were only visible in the thick walls where they had been exposed by a scalpel 
blade during sample preparation for microscopy. The alginate appeared to cloak the fibrin and form dense 
mats with low permittivity, rather than associated with individual fibres as intended. 
When alginate was substituted with the same amount of PVA, scaffolds at 70% oil fraction appeared 
superficially very similar to the equivalent fibrin-alginate scaffolds. However, instead of a gum-like texture the 
bulk scaffold was robust and springy to touch, suggesting promising viscoelasticity that would reduce brittle 
fracture of the dried scaffolds.  
At lower oil fractions, the scaffolds again displayed impermeable sheet-like pore walls with PVA coating the 
fibrin fibres. This could be suggestive of an imbalance between the PVA and fibrin. Some pores were visible, 
and some interconnects where the fibrin had not formed walls at the closest contact point to the adjacent 
pore.   
The low oil fractions used produced emulsions with fewer, larger droplets. The spacing between droplets was 
therefore greater than optimal, leaving space for thick walls to form. Given that alginate did not coat fibrin 
fibres in this way in comparable scaffold produced by foaming, it could be assumed that the coating and 
resultant sheet formations occurred either because of the excessive pore spacing, the tendency for polar 
molecules (i.e. alginate), zwitterions like proteins and amphiphilic polymers (PVA) to assemble at the oil-water 
interface – theoretically with a higher interfacial affinity than fibrin – or a combination of the two. Poor stability 
of the emulsion at greater oil fractions created faster breakage (for example, by creaming or coalescence) 
which would serve to further increase spacing between droplets. 
More stable emulsions of greater oil fraction, above 74% (in the HIPE regime), were required to produce 
effective porous materials. 
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Different surfactants were trialled for improved stability at higher oil fractions (Chapter 3.1). Briefly, Brijs, 
Tritons and Tergitols were more effective than the Tween/Span mixture at stabilising emulsions at and above 
70% oil fraction. Having established proof of concept with this system, future work replaced Tween/Span with 
more effective surfactants. 
 
Effect of mixing speed on emulsion stability 
Increasing mixing speed increases shear, producing smaller droplets and improving stability by imparting more 
energy into the system. Particle size was previously investigated using Turbisoft software in conjunction with 
the Turbiscan™ static multiple light scattering analyser (Chapter 3.1).  
Fibrin scaffolds were manufactured as previously but with alginate removed and replaced with equal volume 
of MES/NaCl buffer, and Triton X-165 in place of Tween/Span to enable better stability. The mixtures were 
emulsified using either the impeller mixer (Caframo Ultra Speed BDC6015, Caframo Lab Solutions, Georgian 
Bluffs, Ontario, Cn) or vortex (Fisherbrand WhirliMixer) to emulsify immediately after addition of thrombin. 
The impeller mixer was used at maximum speed, 5000 rpm, to create the highest shear rate. The vortex mixing 
rate was not quantified but is constant with the mixing vessel is applied at fixed pressure. It is significantly 
greater than the highest mixing speed possible by the impeller mixer.  
After manufacture, scaffolds were freeze dried and the cross-sections examined under electron microscope. 
Void diameter was quantified in Image J (fig. 9). Each graph represents cumulative void diameter from three 
sample. Voids were determined as any resolvable gap visible in a 1000x magnified SEM image. Voids therefore 
include pores at the largest end of the scale (10s-100s µm), interconnects (typically 10s µm) and diffusional 
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Fig. 9: Effect of increasing surfactant concentration and mixing speed on microstructure and pore 
geometry of fibrin-based scaffolds. [A] void diameter frequency distribution of scaffolds made with 
different mixing speed and surfactant (Triton X-165) concentration showed that [D] vortexing created 
a very high number of small diffusional voids compared to [C] lower rate mixing, whilst reducing 
surfactant [B] maintained comparable porosity but greatly increased the number of interconnects and 





































































































The scaffold made with 0.1% Triton X-165 surfactant and mixed at 5000 rpm (fig. 9B) describes the typical 
manufacturing case. The scaffold had a porosity of 90% with well-distributed fibrin fibres creating a basket-
weave structure. Pores were rounded and tightly packed and had a small size distribution. The smaller, more 
frequent voids recorded on the histogram include diffusional gaps (<20 µm) and interconnects (20-60 µm). 
The large number of these voids indicate a highly permeable, open-pored structure. 
Increasing surfactant concentration tenfold to 1% (v/v) showed a dramatic effect on both microstructure and 
pore geometry (fig. 9C). The oil fraction was maintained at 90% so nominal porosity was equal to [A], but the 
void size distribution was much greater with a small number of very large pores. These were beyond the scale 
useful to cells for signalling and environmental signalling and are not desirable. Additionally, the reduced 
internal surface area created dense, thick fibrin walls with reduced texture and greatly reduced 
interconnectivity and number of diffusional gaps. chemistry. These modifications and their modification are 
described in Chapter 3.3. 
Theoretically, increasing the mixing speed will reduce the droplet size to a fixed minimum for each emulsion 
system, and the energy input will enable the emulsion to reach the most thermodynamically favourable state. 
Therefore, the higher surfactant system was trialled with increased mixing speed to try and reduce the number 
of very large pores. Indeed, mixing by vortex did dramatically reduce void size and created a normal 
distribution of void diameters (fig. 9D). However, the emulsion produced was extremely fine and average pore 
diameter was below the threshold for useful interconnect size (fig. 3). The pores were too small to support 
either cell migration angiogenesis. Additionally, the high-speed vortex damaged the protein and destroyed the 
fibrous structure. The fibrin formed in smooth sheets rather than fibrous meshes, reducing diffusional gaps. 
Together, these histograms highlight the reduction in porosity and increase in pore size distribution to include 
very large outliers when surfactant concentration is increased (fig. 9A). Increasing mixing speed to vortex 
showed a dramatic shift to the left, with a very large number of pores with diameter about 5 µm and almost 
all pores in the range 1-15 µm. These were all in the diffusional gap range (fig. 3) and had little other function 
as they were too small to allow ingress of cells or blood vessels.  
A more moderate increase in mixing speed may be useful; however, this is below the upper range of the 
impeller mixer. It is not possible to reduce the rate of the vortex in a controlled or reproducible manner.   
Mixing speed was investigated in more detail using only the impeller mixer. Brij O10, Triton X-100 and a 
mixture of Tween 80/Span 80 (75:25) were used as stabilising surfactants at three different oil volume 




   sub-HIPE     HIPE   




70 75 80 
Brij O10 Triton X-100 T-80/S-80* Brij O10 Triton X-100 Triton X-100 
1000  11.30 3.189 6.424 14.24 3.571 2.483 
2000  2.945 2.758 3.686 13.67 2.601 2.225 
3000  3.013 8.763 6.146 8.677 2.723 2.493 
4000  4.266 3.637 5.860 2.440 3.213 9.886 
5000  2.886 2.705 2.801 8.341 2.398 5.128 
Table 2: Turbiscan stability index (TSI) of emulsions containing 0.1% (v/v) surfactant and either 
70% (sub-HIPE) or 75% (HIPE) decane (v/v) 15 mins after mixing. Surfactant, buffer and decane 
were mixed in the body of a 50 ml syringe with a Caframo impeller mixer. Surfactants tested 
were Brij O10 (HLB 12.4); Triton X-100 (HLB 13.4); Tween 80/Span 80 (75:25) (HLB 12.33). TSI is 
given to 4 significant figures. 
Stability was measured using the Turbiscan™ static multiple light scattering analyser and expressed using the 
Turbiscan stability index (TSI) which reflects the change in transmitted and backscattered light across the 
height of a sample over a period of time (Chapter 3.1). A higher value of TSI reflects poorer stability; a lower 
value reflects greater stability. However, because TSI measures rate of change, emulsions which break 
instantly after mixing ceases can display low TSI values.  
Below the HIPE regime, at 70% oil fraction, emulsions containing Brij O10 demonstrated very poor stability 
when mixed at 1000 rpm but significantly improved in stability from 2000 to 5000 rpm mixing speeds (Table 
2, fig. 10). The significant change (p<0.0001) in stability between emulsions mixed at 1000 rpm and those 
mixed at all other speeds suggests that above 1000 rpm, the shear rate imparts sufficient energy to the system 
to emulsify effectively and produce an even dispersion of droplets more resistance to breakage by migration 
or aggregation.  
When oil fraction increased to 75%, just above the HIPE transition, emulsions containing Brij O10 gradually 
increased in their stability from 1000 to 3000 rpm (Table 2, fig. 11). At 4000 rpm peak stability was achieved. 
Interestingly, the stability then reduced at 5000 rpm. Samples were only mixed for 1 minute in order to make 
effective comparison between conditions and repeats. It is therefore possible that mixing speed was sufficient 
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to produce a stable emulsion, but mixing time was not. This is a feature of HIPE systems where the oil is 
emulsified gradually. The first part to emulsify is dense and sinks, making further emulsification more difficult.  
Brij O10 did not emulsify mixtures containing 80% v/v oil phase. 
Mixtures containing Tween 80/Span 80 only emulsified at 70% oil fraction (Table 2). Stability was better when 
mixed at 5000 rpm but there was no clear trend with mixing speed from end point TSI. However, the stability 
data over time (fig. 10) showed very similar profiles for all samples in the first five minutes after mixing. By 15 
minutes, samples mixed at 2000 rpm and 5000 rpm showed lower TSI than those mixed at 1000, 3000 or 4000 
rpm. Macroscopic evaluation of the sample cuvettes. Showed that the emulsion prepared at 2000 rpm had 
broken during analysis. However, whereas the other samples broke by coalescence in a homogeneous 
manner, the 2000 rpm samples only partially separated by creaming. The emulsion underneath the separated 
oil remained, and so TSI reduced rapidly then plateaued when the emulsion adjusted after creaming. For this 
reason, it is important to consider TSI only one tool to measure emulsion stability. It should not be considered 
without macroscopic observation and raw transmission and backscattering data to show the method and 
extent of destabilisation.     
Emulsions containing Triton X-100 formed at 70, 75 and 80% oil fraction. At 70% oil fraction, stability was 
generally good and comparable at all mixing speeds except 3000 rpm. As with Brij O10, this can be explained 
by the fact that mixing speed may be sufficient while mixing time is not. This was supported by macroscopic 
evaluation of the sample in the cuvette. However, in both cases it is interesting that this occurred at an 
intermediate mixing speed.  
At 75% oil fraction, just into the HIPE regime, all Triton-containing samples emulsified easily and remained 
macroscopically stable throughout analysis (Table 2). Turbiscan™ analysis showed a small change in stability 
(fig. 11) but this was not sufficient to cause visible change to the turbidity or extent of the emulsion. 
At 80% oil fraction, Triton-containing samples mixed at 1000, 2000 and 3000 rpm failed to emulsify and rapidly 
separated after mixing. This produced misleadingly low TSI values (Table 2). At 4000 rpm, an emulsion did 
form but degraded rapidly. A more stable emulsion formed on mixing at 5000 rpm. However, this did not 
match the stability achieved at lower volume fractions. 
This experiment suggested Tritons as an interesting candidate surfactant family for this emulsion system. The 
ability to stabilise HIPEs showed promise. Three possible barriers to effective emulsification were proposed: 





Fig. 10: Stability profile of emulsions stabilised with [A] Brij O10, [B] Triton X-100 and [C] Tween 
80/Span 80 at different mixing speeds. Emulsions contained an oil fraction of 70% decane and 0.1% 
v/v surfactant. Tween 80/Span 80 were used in a ratio of 75:25 (HLB ~12.3), the optimal ratio for 
stabilising decane/buffer solutions based on previous experimentation. Emulsion samples were 
scanned every 30 seconds for 15 minutes after preparation and mixing. Mean results are plotted for 
each time point; n=3. One-way ANOVA showed significant effect of mixing speed on emulsion stability 
with each of the three surfactants (****, p<0.0001).   
 
Mixing time was set at 1 minute for these tests for ease of comparison between samples. For basic 
formulation, mixing was performed until emulsification was achieved to resolve this problem.  
Using the impeller mixer was an efficient and reproducible method of mixing; however, for HIPEs which 
emulsify in parts, it is not an appropriate method. Once emulsification begins, the initial dense emulsion at 
the bottom of the mixing vessel is difficult to reintroduce without losing oil through the top of the vessel. 
Instead, high shear mixing was achieved by placing the constituent emulsion materials in a small lidded 
container and shaking vigorously. Collision with the container walls at close confines effectively distributed 
the oil throughout the container. This facilitated better and faster emulsification of the remaining oil. 
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The Triton family of surfactants comprises many similar surfactants with increasing hydrophilic chain size. 
Given that Triton X-100 was an effective emulsifier at the HIPE transition, it was posited that a more 
hydrophilic Triton surfactant may be more effective at stabilising HIPEs with higher volume fraction.  
 
 
Fig. 11: Stability profile of emulsions with variable decane/buffer composition at different mixing 
speeds. Emulsions all contained 0.1% v/v Triton X-100 and were prepared with an impeller mixer to 
emulsify. Turbiscan measurements were taken every 30 seconds for 15 minutes after mixing. 
Emulsions containing 75% and 80% (v/v) decane are HIPE systems. Mean results are plotted for each 
time point; n=3. One-way ANOVA showed highly significant effect of mixing speed on emulsion 
stability above and below the HIPE transition (74%), at 70% and 80% oil fractions (****, p<0.0001) 






Effect of the addition of PVA on emulsion stability 
 
Fig. 12: Stability of emulsions stabilised with [A] Brij O10, [B] Triton X-100 and [C] Tween 80/Span 
80 at different mixing speeds, with and without PVA. 5% stock PVA solutions (in MES/NaCl buffer) 
were added to give an overall concentration of 0.1% in the emulsion. Surfactants were added at 0.1% 
(v/v) with respect to the total emulsion volume. TSI is reported for stability of emulsions measured 15 
minutes after mixing. 
 
PVA demonstrated interested mechanical properties when added to the fibrin scaffold. When added in low 
concentrations it had no detrimental effect on the microstructure (Chapter 3.3). However, early trials with 
PVA showed a tendency to form sheets at the interface and coat the open fibrous structure created by the 
fibrin (fig. 8). PVA is an amphiphilic molecule and will therefore tend towards accumulation at an interface. It 
was thought that the addition of PVA to the aqueous phase, as well as improving scaffold properties, may have 
an additional stabilising effect on the emulsion.  
This was not the case in Tween/Span emulsions. Samples with and without PVA failed to emulsify when mixed 
below 4000 rpm. At 5000 rpm, the PVA did improve stability (not reflected in the TSI data because, as 
previously described, TSI is misleadingly low for very unstable emulsions).  
For emulsions containing Brij O10, which did emulsify, the addition of PVA showed no significant change in 
emulsion formation time or stability. This was also the case for emulsions containing Triton X-100.  
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These results demonstrate that PVA would not significantly affect stability of the emulsion, which must be 
adequately stabilised by a combination of non-ionic surfactant and mixing speed and method. However, they 
also show that there would be no deleterious effect if PVA was added in order to improve properties of the 
templated scaffold. 
 
Effect of surfactant concentration on fibrin formation time 
Thromboelastometry testing was preformed to ensure the choice and concentration of surfactant in the 
emulsion would not adversely affect fibrin formation from fibrinogen and thrombin. The time taken for a fibrin 
clot to form from fibrinogen (2% w/v clottable protein in MES/NaCl) and thrombin in the presence of Ca2+ 
ions and surfactant at various concentrations was measured using a thromboelastometer (Stago STartMax). 
The fibrinogen: thrombin (4:1) ratio used was the same as for standard scaffold manufacture. The clot time is 
determined as the point at which the fibrin gel forming becomes sufficiently firm to resist the movement of 
an embedded steel ball bearing in a magnetic field. A sample containing no surfactant was used as a negative 
control. Each combination was tested in duplicate. 
The surfactants used vary in HLB (Brij O10=12.4, Triton X-100=13.4, Triton X-165=15.5, Tween 80=15). The 
Tritons and Brijs are capable of stabilising decane-based emulsions; the Tween is not an adequate surfactant 
for this system but was tested as it has documented cytotoxic effects at higher concentrations. 







Effect of surfactant on fibrin gel time
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Fig. 13: Effect of surfactant and surfactant concentration on coagulation time of 
fibrinogen/thrombin. Neither presence nor choice of non-ionic surfactant was found to have 
any significant effect on fibrin gel formation time. Tween 80/Span 80 in a ratio of 3:1 (HLB 12.3) 
was the only formulation with significantly reduced gel time compared to the control (0.1% **) 




Below: Cuvettes showing the steel ball bearing held in a fibrin gel. [B]: Less stable emulsions, or 
systems with a slow clot time, separated in the cuvette. The lower section was denser and more 
opaque. [C]: in more stable emulsions, less separation occurred and the resultant gel was less 
dense but comprised a greater portion of the total test volume. The gel appeared cloudy, rather 
than translucent (fig. 13B) because the gel in the stable emulsion system trapped oil droplets 
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Less stable emulsions tended to separate before the fibrin clot formed (fig. 13B). This was clearly 
distinguishable by the appearance of a transparent layer of oil at the top of the cuvette. The denser aqueous 
phase, containing fibrinogen and thrombin, sank to the bottom and formed the fibrin clot. Depending on the 
rate of destabilisation and the fibrin clot time, the two phases could separate completely, as shown above, or 
partially, giving rise to a gradient of gel strength. In this case, fibrin clots were densest at the bottom of the 
cuvette, close to the ball bearing. 
In more stable emulsions, the oil phase remained dispersed during fibrin formation. The clot was therefore 
dispersed throughout the cuvette instead of accumulating in a dense gel at the base. The coagulometer works 
by timing gel formation until it is sufficiently strong to resist and stop the movement of a circulating ball 
bearing. The different fibrin densities formed in stable and unstable emulsions were therefore a concern for 
quantifying clot time; however, even the diffuse gels were able to slow the movement sufficiently to trigger 
the coagulometer. However, the pitfalls of this test highlight the importance of considering a range of data 
(clot time, mechanical strength, microstructure) in conjunction when evaluating scaffold design parameters.  
Surfactants are key to forming stable emulsions with a specified mean droplet diameter. Ionic surfactants can 
interact with proteins and denature them, impairing or destroying the native structure. Even non-ionic 
surfactants display a degree of cytotoxicity. There are two factors at play: one being the surfactant 
concentration and the other being the HLB. The concentration must be sufficiently high to stabilise the 
emulsion, but low enough to avoid protein interference or degradation. At optimal HLB, the surfactant will 
display equal affinity for the aqueous and oleic phases of an emulsion. In a perfect system, the surfactant will 
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be fully engaged at the interface and will not interact with protein. Selecting a surfactant that displays slightly 
more lipophilicity may further reduce risk of protein interaction by physically moving the surfactant deeper 
into the oil phase and away from the protein in the aqueous phase, but this would be detrimental to the 
emulsion stability.  
In this case, all of the surfactants tested formed emulsions at all concentration. As previously discussed, the 
Tritons and Brij were selected for their superior stabilising power at higher oil fraction. Tween was used as a 
useful back-reference and because it is a well characterised, commonly used commercial surfactant. None of 
the surfactants tested, at any concentration, increased the coagulation time beyond a reasonable length of 
time (i.e. coagulation always occurred within 2 minutes which is well within the stability time of the emulsion 
and thus template). There were no clear patterns between concentrations or surfactants. 
 
CONCLUSIONS 
As an adherent protein key to the wound healing process, fibrin is an excellent candidate material for a skin 
tissue engineering scaffold. It self-assembles into strong fibres from fibrinogen and thrombin. Varying their 
ratios allows tunable fibre diameter and mesh density. Artificial cross-linking of fibrin (in this case, with 
glutaraldehyde) imparts mechanical strength to the scaffold and also prolongs its residence in vivo by resisting 
proteolytic degradation. This enables the scaffold to persist for a clinically useful timeframe while the 
regenerating and remodelling tissue gradually takes over the mechanical and structural contributions from 
the scaffold. Fibrin fibres form the base of the hierarchical structure and differentiate the scaffold from other 
materials. If the protein’s native structure is damaged (due to artificial processing, or accidental or incidental 
denaturation) the structural functionality is lost. 
Emulsion templating was selected as a method of producing tightly prescribed and reproducible three-
dimensional scaffolds while retaining fibrous fibrin structure. Emulsion templating offers advantages over 
other methods of creating porous materials. Unlike foaming, control over porosity, pore size, pore size 
distribution and wall thickness are possible. The structures generated are more organic in shape than those 
typically created by additive manufacturing, where a simple pattern is often repeated to build the structure. 
Electrospinning offers a method of generating spun fibres down to the nanoscale with good control, but the 
use of high voltages and aggressive solvents limits the use of native proteins as a scaffolding material. 
Additionally, creating complex and controlled 3D structures is not possible by this method alone. Melt 
moulding requires high temperatures which denature proteins, removing native structures. Use of particle 
leaching creates tightly packed, highly porous structures with small size distribution and good control over 
pore size, but removal of the porogens often requires complex or aggressive post-processing that again 
precludes the use of native proteins.  
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While emulsion templating is a commonly used process and has been widely used for a long time, the most 
common methods use an inverse water-in-oil emulsion. The chemicals and processing conditions used are 
aggressive and better suited to synthetic polymers rather than proteins. Oil-in-water emulsions stabilised with 
ionic surfactants, or surfactants at high concentrations, are similarly denaturing and preclude the use of 
proteins in their native form. To our knowledge, the method described above is unique in allowing for HIPE 
templating of a protein in its native form (≥74% porosity). Furthermore, owing to the limitations of other 
methods described here, our technique may be the only method for producing such high porosity materials 
with native proteins. 
In the work presented, emulsions were refined to produce homogeneous emulsions with stability in excess of 
fibrin clot time. This allowed the fibrin network to consolidate around the oil droplets at optimal diameter and 
dispersion. Surfactants were screened for their ability to stabilise high internal phase emulsion (>74% v/v) up 
to 95% oil fraction, enabling generation of very highly porous scaffolds. Droplet packing was very tight in the 
HIPE regime, so pore walls were thin and improved diffusional and interconnection voids.   
Identifying suitable surfactants with high oil carrying capacity allowed their use at lower concentrations (0.1% 
v/v). At this concentration, no detrimental effect on fibrin formation time or microstructure was observed. 
The density of droplets in the dispersed phase is varied by changing the ratio between the continuous and 
dispersed phases. Here, dispersed phase ratio was increased in small increments, using different surfactants 
to maintain stability at higher oil fractions. In this way, oil phase was gradually increased from 50% (fig. 6) to 
90% (fig. 9).  
Mixing speed was optimised to obtain oil droplets and thereby pore sizes conducive to cell and blood vessel 
ingress (fig. 3). Emulsion droplet size can be controlled and varied by altering the interfacial tension between 
the oleic and aqueous phases. Homogenisation of an emulsion system, for example by shear mixing, reduces 
droplet size to a minimum after which no further decrease is observed. The smallest droplets are achieved by 
mixing at the highest speed for the shortest time, until the theoretical minimum droplet size is achieved, then 
the mixing time has no further effect (Prinderre et al., 1998; Solans et al., 2005). However, mixing by vortex 
was shown to destroy fibrin structure and produce pores too small to allow cell ingress. Instead, mixing at 
5000 rpm with an impeller mixer produced a narrow range of droplets of optimal diameter.   
The minimum droplet size is governed by interfacial tension and the availability of surfactant in the emulsion 
system. Homogenisation promotes droplet formation by distributing surfactant throughout the system to 
enable assembly around a greater number of interfaces. This can also be achieved by, or in conjunction with, 
increasing the concentration of surfactant.  
This work enabled creation of a prototype fibrin-based scaffold with appropriate microstructure (porosity, 
interconnectivity, wall thickness) from a stable, non-denaturing emulsion. Successful drying and subsequent 
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storage of the scaffolds confirmed that the oil phase was successfully removed from the scaffold during the 
washing process. This is important for prolonging shelf life and ensuring cytocompatibility. 
As a result of the experiments described here, a final scaffold composition of 2:1 fibrin:PVA, templated from 
a 90% oil fraction emulsion containing 0.1% Triton X-165, was selected. With the emulsion composition 
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3.3 Manufacture and characterisation of novel fibrin-based 
hierarchical polyHIPEs  
ABBREVIATIONS 
CCK-8 cell counting kit 
DMEM Dulbecco’s Modified Eagle’s Medium 
ECM extracellular matrix 
EtOH ethanol 
ETPM emulsion templated fibrin-based 
scaffold 
FBS foetal bovine serum 
GFP-MSC fluorescently labelled mesenchymal 
stem cell 
GTA glutaraldehyde 
HIPE high internal phase emulsion 
MES 2-(N-Morpholino) ethanesulfonic acid 
MMP matrix metalloproteinase 
O/W oil-in-water emulsion 
PBS phosphate buffered saline 
PEG polyethylene glycol 
PM0 foamed fibrin-based scaffold 
polyHIPE scaffold templated from HIPE 
PS penicillin-streptomycin  
PVA polyvinyl alcohol 
SEM scanning electron microscope/graph 




Emulsion templating is a versatile technique for creating porous materials with well-defined porosity, pore 
diameter, pore size distribution and the degree of interconnectivity between these pores. Hydrophilic or 
hydrophobic monomers may be dispersed into the aqueous or oleic phase, respectively. Synthetic 
biocompatible polymers such as PMMA, PLLA and PCL can be templated using water-in-oil emulsions. The 
resultant porous biomaterials have precise micro- and macro-architectures arising from the emulsion template 
but lack biologically relevant structures. These may be added in subsequent manufacturing steps. Using 
proteins (gelatin; collagen) as the polymeric material allows the introduction of physiologically relevant 
chemistries to the biomaterial. However, the surfactants required to stabilise emulsions for templating are 
aggressive and denaturing for proteins, altering their structure.  
This experimental section describes scaffolds manufactured by a facile emulsion templating process that does 
not use organic solvents and minimal non-ionic surfactant (well below cytotoxic concentrations). Template 
fidelity is good, allowing repeatable small batch manufacture of scaffolds with tuneable porosity, pore size 
and pore size distribution. Electron microscopy of the scaffolds reveal the fibrous protein structure is 
preserved, creating an intricate “basket-weave” structure down to the nanoscale and removing the need for 
subsequent processing. Further, the scaffolds show mechanical properties, cyto-compatibility and angiogenic 





Emulsion templating is a widely used and highly versatile method of introducing porosity (Kimmins and 
Cameron, 2011; Zhang and Cooper, 2005) whereby immiscible phases (typically oleic and aqueous-based) are 
mixed to form a dispersion of droplets (the dispersed phase) in a continuous phase (Hentze and Antonietti, 
2001; Tadros, 2013). An amphiphilic molecule, such as a surfactant, may be added to promote stability of the 
emulsion (Hentze and Antonietti, 2001).  
A water-in-oil emulsion (w/o) has oil droplets dispersed in an aqueous continuous phase. An oil-in-water 
emulsion (o/w) has aqueous droplets dispersed in an oleic continuous phase (Tadros, 2013). Hydrophobic 
polymers, such as the commonly-used styrene/divinylbenzene co-polymer system, dissolve in the oil phase to 
form a scaffold matrix around the dispersed aqueous phase in ‘inverse’ w/o emulsions (Silverstein, 2014).  
Alternatively, the polymer may be dissolved into the dispersed phase (i.e. a hydrophobic polymer in an o/w 
emulsion) to form micelles or template microbeads. These polymer microbeads may be used to deliver a 
variety of substances in vivo, such as proteins, drugs and DNA/RNA  (Ho et al., 1994; Kulkarni et al., 2011; 
Tessmar and Göpferich, 2007). 
High internal phase emulsions (HIPEs) allow greater yield of templated beads (if the polymer forms in the 
dispersed phase), or highly porous templated scaffolds (where the polymer forms in the continuous phase). 
Additionally, the interfacial nature of the HIPE phase gives stability to the formed structure (polyHIPE) during 
the manufacturing process. 
Some oil-in-water polyHIPEs have been used to create hydrophilic scaffold materials, including some protein 
biomaterial scaffolds. However, these use processed or denatured proteins (such as gelatin) as a base material 
(Barbetta et al., 2005). To date, native-structured protein polymers have not been templated using polyHIPE. 
This section focuses on emulsion templating using o/w emulsions with hydrophilic materials in the continuous 
phase. 
The emulsion system presents a challenge in templating proteins: surfactants required to generate sufficient 
emulsion stability to support the protein framework during consolidation can denature proteins and hinder 
this process. 
In the work presented, protein polyHIPE emulsions were manufactured and characterised using an optimised 
emulsion system. A range of surfactants (Brijs, Tritons, Tweens, Spans and Tergitols) were studied for 
emulsifying decane (dispersed phase) in physiological buffer. Emulsion stability was evaluated using light 
scattering with a Turbiscan LAB analyser against increasing oil fraction. Internal phases of up to 95% volume 
fraction were achieved in an optimised system. When translated to scaffold manufacture this produced high 
fidelity, highly porous scaffolds with close cell packing and even protein distribution, resulting in an 
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interconnected structure with well-defined pores (confirmed by scanning electron microscopy). Droplet size 
was optimised for cell ingress and angiogenesis. 
Iterative design and characterisation of the emulsion system allows control of the diameter, number and 
packing of droplets within the dispersed phase. This approach offered a rapid and effective screening method 
for protocol design for templating of protein polymeric materials.  
Fibrin has been widely investigated as a scaffold for a diverse range of tissue engineering applications including 
engineering of small blood vessels and heart valve prostheses; cartilage; bone and skin, as well as a carrier for 
transplanted stem cells (Bensaıd̈ et al., 2003; Geer et al., 2002; Jockenhoevel et al., 2001; Perka et al., 2001; 
Swartz et al., 2005; Yasuda et al., 2009). The use of fibrin composite tissue engineering constructs, with 
materials such as fibrin-agarose, fibrin-collagen, fibrin-alginate, fibrin-PCL, fibrin-PLLA-PLGA and fibrin-
polyurethane has also been described (Carriel et al., 2012; Collen et al., 2003; S. B. Lee et al., 2003; Lesman et 
al., 2011; Levenberg and Lesman, 2014; Ma et al., 2012, 2003; Schagemann et al., 2010; Serbo and Gerecht, 
2013; Shikanov et al., 2009; Swieszkowski et al., 2007; Weinberg, 1989). 
The strength of fibrin adhesion derives from its ability to bind to cells (de la Puente and Ludeña, 2014) either 
directly, via integrin receptors, or indirectly via ECM proteins such as fibronectin (binding to fibroblast and 
phagocyte receptors) (Makogonenko et al., 2002) and vitronectin (binding to collagen and endothelial cell 
receptors) (Preissner and Jenne, 1991).  
Fibrin has been used as a haemostatic agent for over 100 years (Loeb, 1909). Its therapeutic use was inspired 
by its native action in the coagulation cascade, and it is used to rapidly seal a wound and prevent blood loss in 
extreme scenarios, such as battlefield injuries (Borst et al., 1982; Granville-Chapman et al., 2011; Vournakis et 
al., 2003). This versatility in application may derive from the characteristic structure of fibrinogen, and the 
different ways of producing fibrin from fibrinogen (using autologous, allogeneic, xenogenic or recombinant 
fibrinogen and polymerising with thrombin or snake venom (Linnes et al., 2007; Stocker et al., 1982). 
In normal physiology, the persistence of fibrin constructs – blood clots – is regulated by the interplay between 
the coagulation and fibrinolysis cascades (Clark, 2003; Standeven et al., 2005). Regulation of artificial fibrin 
scaffolds is likewise tuneable by mechanical, chemical, or enzymatic means. The number, diameter and density 
of fibrin fibrils affects degradation rate; as does the biochemical environment, including proteolytic enzymes.   
One problem with the use of fibrin for implantable biomaterials is its rapid degradation in vivo. Protease 
inhibitors like aprotinin or tranexamic acid can delay proteolytic degradation, prolonging the persistence of 
implanted fibrin constructs as required to support the repairing tissue (de la Puente and Ludeña, 2014; 
Jockenhoevel et al., 2001).  
Having identified and evaluated a number of surfactants capable of stabilising a high internal phase emulsion 
(Section 3.1) at sufficiently low concentration to avoid denaturation of fibrinogen in the aqueous phase 
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(Section 3.2), the next step was to fine-tune the emulsion to generate desirable properties in the templated 
scaffold. The optimised method developed preserves fibrin’s hierarchical fibrous structure and differentiates 
the scaffold from other protein scaffolds where native structural functionality is lost during processing.  
The fibrin fibres around the oil-templated pores form a connected series of niches for cell residence. The size 
of these pores is critical to permit cell and blood vessel ingress. Good interconnectivity – a consequence of the 
basket-weave structure as well as high porosity and very close pore packing – enables cell migration and 
communication and also supports angiogenesis. This is vital for the development and survival of the 
regenerating tissue. Rapid angiogenesis will help accelerate the cellular response. Scaffold structure and pore 
size is dependent upon the size and packing of oil droplets in the precursor emulsion. A key objective was to 
ensure template fidelity from the optimised emulsion and the resultant scaffold by balancing emulsion stability 
with unimpaired fibrin formation.  
Initial templated scaffolds (fig. 3, Section 3.2) suffered insufficient porosity, giving rise to large, unconnected 
pores and thick pore walls. Excessive fibrinogen concentration also produced thick walls between pores, and 
densely packed fibres will few diffusional spaces. Scaffolds with higher porosity were difficult to manipulate 
and often tore during manufacture. A secondary aim was to improve mechanical properties of highly porous 
scaffolds to allow thinner pore walls with more diffusional space. It was hypothesized that addition of another 
polymer with viscoelastic properties could act to support lower density fibrin fibres and promote bulk elasticity 
of the scaffold to improve handling.  
The ability to create protein polymeric materials with well-distributed, delicate protein microstructure is of 
significance in development of scaffold materials for tissue engineering. Currently, polyHIPE materials are 
largely restricted to a small number of available hydrophobic biomaterials available using water-in-oil 
emulsions. This work demonstrated the capability to design well-characterised emulsions to accurately 
template protein materials such as fibrin, collagen and alginate, which are commonly used in tissue 
engineering scaffolds. This method allows hierarchical scaffolds to be created in which the native protein 







All water and buffers were autoclaved or sterile filtered, as appropriate, prior to use. All preparatory and 
formulation work was undertaken in a class I HEPA filtered laminar flow hood to minimise risk of product 
contamination. 2% bovine fibrinogen lyophilised powder (w/v of clottable protein) was prepared by dissolving 
in MES/NaCl buffer (25 mM/150 mM, pH 7.4) at 37°C with minimal agitation to prevent foaming. Calcium 
chloride solution (1 M in distilled water) and stock polyvinyl alcohol (PVA) (Mw 31,000-50,000 g/mol, 87-97% 
hydrolysed) solution (5% w/v in MES/NaCl, dissolved overnight at 37°C with periodic agitation) and thrombin 
(pre-dialysed, in frozen aliquots) were warmed to 37°C before use. Decane and surfactants were used as 
purchased. 0.8% (v/v) glutaraldehyde solution was prepared by adding 8 ml Grade I glutaraldehyde (25% in 
H2O; Sigma Aldrich) to 800 ml absolute ethanol and 200 ml 0.1 M MES (aqueous solution, sterile filtered, pH 
7.4). Glutaraldehyde solution was prepared freshly for each of the two washes, no  more than 10 minutes 
before use. 
Suitable surfactants include Triton X-100, X-102, X-114, X-165, X-100 reduced, X-114 reduced, N-101 reduced; 
Brij 58, O10, O20; Tergitol 15-S-7, 15-S-9, 15-S-15, TMN-6, TMN-10, NP-10; Ecosurf EH-9. 
MES monohydrate crystals were purchased from Fisher Scientific (Loughborough, UK); all other materials were 
purchased from Sigma Aldrich, Inc. (Gillingham, Dorset, UK).   
Emulsion preparation 
Emulsions were prepared separately for each 5x5 cm scaffold; each with a volume of 22 ml. Decane formed 
the oleic phase (90% v/v). The aqueous phase (10% v/v) comprised fibrinogen, thrombin (in a 4:1 ratio), 
calcium chloride and PVA all dissolved in a MES/NaCl buffer solution (pH 7.4). For each scaffold, 20 µl 
surfactant was dispersed in 20 ml decane in a 50 ml universal tube. 5 µl calcium chloride solution, 625 µl 
MES/NaCl buffer and 100 µl 5% PVA solution were added and shaken vigorously. 1 ml warmed fibrinogen 
solution was added, and the tube was shaken vigorously until the contents emulsified fully (determined by 
dramatic change in viscosity and opacity). 250 µl warmed thrombin was added and the mixture was shaken 
immediately and vigorously for 30 s.   
 
Scaffold manufacture 
The final emulsion was poured into a square-edged weighing boat which was tapped to remove air bubbles. 
The weighing boat was covered to reduce evaporation and incubated for 1 hour at 37°C.  
The scaffold was incubated for 1 hour at room temperature with 25 ml cross-linking solution (abs. ethanol, 0.1 
M aqueous MES solution (pH 7.4) and glutaraldehyde (25% aqueous solution) in a ratio of 100:25:1). The 
149 
 
scaffold was flipped over the process repeated for another hour with fresh cross-linking solution. During cross-
linking the scaffolds turn from white to yellow (colour intensity is dependent on concentration of 
glutaraldehyde and fibrinogen present). Residual glutaraldehyde was consumed by a series of 5 reducing 
washes using 0.1% sodium borohydride in distilled water. The solution was changed and the scaffold flipped 
over after each wash. This process was repeated for a further four washes with distilled water, flipping the 
scaffold and replacing with fresh water each time. The scaffolds were then washed in 0.2% aqueous PVA 
solution (w/v) for 5 minutes each side before draining. Scaffolds were then lyophilised overnight at -40°C under 




Three scaffolds per condition, and three samples per scaffold were tested (nine samples per condition). The 
scaffold samples were cut to approximately 8x3 mm, mounted in cross-section and sputter coated on stubs. 
Micrographs were taken with a Zeiss Supra 55 VP scanning electron microscope (aperture 20 µm; current 5 
kV). Each sample was imaged at three different sites. Void size and size distribution (including all measurable 
voids) was evaluated using the measure function in Image J. The images used for analysis were all 1000x 
magnification micrographs, as these images contain clear resolved structures of interest at both pore and 
interconnect level. 
Pore and interconnect sizes are measured manually from SEM micrographs using Image J. The largest round 
shapes that can be resolved as assigned as ‘pores’; the smaller structures within these are assigned 
‘interconnects’. Immeasurably small distances (using this method, at appropriate magnification to resolve 
pores) are designated diffusional gaps (space between fibrin fibres as opposed to templated structures) and 
are not recorded owing to their small size and high frequency. 
Cyto-compatibility  
Cylindrical samples were cut with an 8 mm biopsy punch (n=3) were cut from two scaffolds (six samples per 
condition). These were washed twice with 70% EtOH, twice with PBS and once with DMEM. GFP-MSC-hTERT* 
were seeded (p12, 50,000 cells/well) onto the hydrated scaffolds and a plate control with 150 µl 
DMEM+FBS+PS. At 24 h (acute response time) and 120 h (chronic response time), 300 µl DMEM/CCK-8 (10:1) 





Cyclic compressive testing was performed on bulk hydrogels of the same composition as the aqueous phase 
of the fibrin-PVA scaffolds. Each gel was formed into a disc of approximately 1 cm in diameter and 3 mm deep. 
Testing was performed on an Instron UTM 5942 using a 5 N load cell for a total of five cycles.  
Freeze-dried scaffolds were cut to 10 mm wide strips (approximately 50 mm long and 3 mm wide). Small pieces 
of dry paper towel were folded over either end to provide additional grip and prevent slippage. The ends of 
the scaffold were secured leaving a gauge length of 40 mm. Testing to failure was performed in triplicate for 
each scaffold using an Instron UTM 5582 (100 N load cell, crosshead speed 8 mm/minute). 
Scaffold degradation (hydrolytic and enzymatic) 
6 mm discs were cut from each scaffold. To measure hydrolytic degradation, scaffold samples were incubated 
at 37°C in sterile PBS. Enzymatic degradation was measured by incubating scaffold discs at 37°C in PBS with a) 
0.25% trypsin, b) 0.125 U/ml plasmin and c) MMP-1, MMP-2, and MMP-9 (each 0.2 µg/ml). Each of the 
solutions for the enzymatic degradation assay were changed daily. For both enzymatic and hydrolytic 
assays, discs were removed and freeze-dried at the following time points: 7, 14, 21 and 28 days (hydrolytic) 
and 1, 3, 5, 7, and 10 days (enzymatic). Each test was performed in triplicate. Degradation was reported as 
percentage change in mass from day 0 to the time point.   
Δ mass (%) =100 (W0−WtW0)         (eq.1) 
Equation 1 (from Grizzi et al (26)) expresses the change in mass over time where W0 is the initial dry mass 
and Wt is the mass of the same sample, removed from the test solution at time t and lyophilised before 
weighing. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 8.1.2. Significance was evaluated using one- 
or two-way analysis of variance (ANOVA), as appropriate, with Tukey’s post-hoc multiple comparison tests. 
Levels of significance were assigned as follows – * where p<0.05; ** where p<0.01; *** where p<0.001 and 





RESULTS AND DISCUSSION 
Comparison of emulsion templated and foamed scaffolds of similar protein composition 























































































Void diameter (µm) 
Fig. 1: Cross-sectional electron micrograph images and void diameter frequency charts of fibrin-
based scaffolds produced by (A) foaming method and (B) emulsion templating. Foaming creates a 
high degree of porosity but offers no control over pore size or size distribution and therefore lacks 
reproducibility. Lack of pore size control is shown in the histogram with a wide distribution of void 
diameters recorded. Additionally, foaming can produce very dense regions of protein (shown in the 
higher magnification image). There are few interconnects or smaller voids. Emulsion templating offers 
more control over pore size, with a more uniform pore size distribution. Total void frequency is 
significantly higher in the templated scaffold owing to better interconnectivity and many more small 
voids (“diffusional gaps”). 
 
Emulsion templating offers better control over droplet size and wall thickness compared to other methods 
such as foaming (fig. 1). The foamed scaffold had regions of high porosity but was very heterogeneous. The 
foaming method created a somewhat interconnected network between the pores generated by coalescing 
bubbles. Variability in porosity and wall thickness were governed by dispersal of foaming agent through mixing 
homogeneity. If the foaming agent is not dispersed uniformly dense regions of material form. In vivo these 
would provide no functionality and may exacerbate the inflammatory response and could lead to M1 
macrophage attack (reducing scaffold persistence) or fibrous encapsulation (Merritt et al., 1979; Sheikh et al., 
































































Formation of hierarchically structured templated scaffolds  
The pore size in templated scaffolds is governed by the size of oil droplets in the internal phase. With fixed 
surfactant type and concentration, oil and aqueous phases and energy of mixing, thermodynamics dictate that 
the same approximate size of droplets will form each time (Fontenot and Schork, 1993). Steric repulsion of the 
surfactants govern pore spacing, and fibrin(ogen) content prescribes the fibre density that will form around 
the pores. In the HIPE system, interfacial forces become dominant due to the border effect described by 
Plateau’s laws (Kravchenko et al., 2018). An emulsion must be sufficiently stable to maintain droplet size and 
spacing during the fibrin formation time. The curved triangular spaces between droplets, which may be 
approximated to I-beams, confer compressive strength to the emulsion and templated systems. 
          
Fig. 2: Droplet proximity and internal pressure push scaffold material away from the point of 
contact. This becomes an interconnect.  
 
In this case, template fidelity may be assumed. Porosity is therefore governed directly by the volume fraction 
of the oil internal phase and is also easily controlled. These features allow the emulsion templated scaffold to 
be faithfully reproduced within and across multiple batches. 
Unlike porosity, interconnectivity is not directly governable but may be controlled to a degree. It arises from 
the closeness of the pores and the quantity of material forming the walls. The degree of interconnectivity is 
greater in scaffolds with tightly packed pores and the minimum material to support the structure. At the 
closest point of contact between two pores, the internal droplet pressure pushes the material to either side 
of the contact point and leaves a connecting space (fig. 2). The materials described here have varying 
interconnect diameters but consistently high degrees of interconnectivity, creating an open-celled structure 
within the scaffold (fig. 3). 
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Fig. 3: Cross-sectional scanning electron micrograph showing geometry of optimised emulsion-
templated scaffold. [A] Cumulative frequency from three sites analysed from the same scaffold. Mean 
pore size 102.35 µm, SD=74.83; mean interconnect size 35.05 µm, SD=15.34; mean diffusional void 
size 7.13 µm, SD=1.96. All measurable voids were quantified at the widest point using Image J (1000x 
micrograph). Pores were determined as the largest resolvable round structures on the image; 
interconnects are the smaller gaps within them. Very small gaps resulting from spaces between fibrin 
fibres, as opposed to template shape, were designated as diffusional gaps. Only the larger diffusional 
gaps were measured as most were too small to measure accurately by this method. Fig. 3(B) shows a 
typical cross-section of a freeze-dried scaffold (Zeiss Supra 55 VP; 5 kV, 1000x magnification).  
 
Optimising fibrinogen concentration 
Fibrinogen content in the aqueous phase was initially calculated based on an existing in-house method for 
manufacturing fibrin-based scaffolds by another method (not disclosed). This proved successful with sub-HIPE 
oil fractions (50-70% v/v; previously reported in Chapter 3.2) but at higher oil fractions produced dense 
polyHIPE materials which frequently tore during manufacture owing to excessive bulk.  
The concentration of fibrinogen in the aqueous phase of the HIPE was halved, maintaining proportions of 
thrombin and calcium chloride, to produce more delicate structures (fig. 4(B)). Reducing the protein 
concentration resulted in thinner yet more robust scaffolds with excellent handling properties (wet and dry) 
as well as increased permittivity and interconnectivity as illustrated in the cross-sectional SEM images.  
The precursor emulsion must contain sufficient fibrinogen to form fibrous networks around the largest of the 
pores that can adequately support their own weight when the template is removed. Fibrinogen solutions 
interconnect pore 
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become extremely viscous above 5% (w/v, clottable protein). 10% was found to be the highest useful 
concentration with the method and equipment described here.  
   
Fig. 4: Effect of fibrin concentration on scaffold architecture. A higher fibrinogen concentration 
results in the formation of a dense fibrous network of fibrin resembling a mat. Template fidelity is 
good at pore level, but there are few interconnects and diffusional gaps. Any additional materials such 
as co-polymers settle between the fibres and further reduce permeability (visible in 5000x image). At 
reduced fibrinogen concentration, template fidelity is preserved but the fibrin network is more 
diffusive and individual fibres are evident. Interconnectivity is greatly increased. Diffusional gaps are 
also far more prevalent. 
 
The fibrinogen volume was limited by the total emulsion volume (i.e. the size of scaffold desired) and the 
volume fraction occupied by oil (i.e. the desired scaffold porosity) as well as any other materials to be included.  
A higher fibrinogen concentration ensured more fibrin coverage around the oil droplets and better mechanical 
strength. Lower fibrinogen concentration gave a more diffusive, fibrous basket-weave structure which in turn 
gave better diffusivity, permeability, and pore interconnectivity These features are all important scaffold 
design considerations so fibrinogen content must be modulated to achieve the optimum balance.  
The high-fibrinogen scaffold was easier to manufacture owing to the improved mechanical strength. Fibrin 
formed rapidly and was therefore more forgiving of emulsion instability. Template fidelity was good, with 
tightly packed pores of similar sizes in the region 50-200 µm. However, the walls were very dense, resulting in 
reduced interconnectivity and permeability. Additionally, with the fibrin fibres are so closely associated, the 
  










































PVA co-polymer tended to cover groups of fibres rather than individual strands and further closed up the 
diffusional gaps (fig. 4(A), 5000x).  
When fibrinogen concentration was too low, the scaffolds collapsed during manufacture, suggesting the fibrin 
was insufficient to surround larger pores. These are not pictured as they could not be preserved through to 
drying. Reducing the fibrinogen concentration from the high concentration (10% w/v clottable protein) to 5% 
then 2% w/v produced a scaffold which was readily handleable throughout manufacture. Template fidelity 
was as good as in the high-fibrinogen scaffolds, with tightly packed rounded pores. The sparser distribution of 
protein around the interface resulted in a more open structure with much greater interconnectivity and more 
diffusional gaps for the same meso-porosity. Under higher magnification, individual fibrin fibres were clearly 
visible (fig. 4(B)). These were sufficiently closely arranged to impart strength, but well-spaced enough that the 
PVA co-polymer did not coat them and seal up the smallest voids. 
 
























Fig. 5: Effect of fibrin: PVA ratio on scaffold micro-architecture. Fibrin scaffolds without PVA are 
fragile and brittle but have a delicate basket-weave hierarchical structure (5000x, top row; 500x, 
bottom row). Interconnectivity is high, with high permeability from diffusional gaps. 1:1 fibrin: PVA 
has greatly reduced interconnectivity and diffusional gaps. The PVA glues together neighbouring fibrin 
strands, reducing the hierarchical structure. At and above fibrin content of 2:1 fibrin: PVA the bundling 
of fibrin fibres by PVA is still present, improving resilience and handle-ability, but the underlying 




200µm 200µm 200µm 200µm 200µm 







Fig. 6: Behaviour of bulk fibrin/PVA hydrogels under cyclic compressive loading. Bulk hydrogels of 
2:1 fibrin: PVA show an elastic response with good recovery between loading. This testing is 
qualitative and is shown only for a single sample to demonstrate typical behaviour.  
 
Addition of PVA to enhance elastic behaviour  
Native fibrous fibrin produces scaffolds with optimal microstructure, but they behave in a brittle manner at 
macro-scale and can be fragile to handle. Scaffolds must be sufficiently robust to withstand manufacture, and 
to be cut, positioned, and stapled or sutured into place in clinical use. PVA was incorporated as a co-polymer 
to increase bulk elasticity of the scaffold. As previously described, aqueous component volumes are limited by 
the desired porosity and associated oil fraction, so a working solution of 5% w/v PVA was used. At 1:1 fibrin: 
PVA, the PVA was found to coat closely arranged fibrin fibres and draw them into thick bundles. While this did 
improve elasticity and handleability, it disrupted the microstructure by reducing nano-texturing and 
diffusional gaps. At meso-scale, reduced interconnectivity and diffusivity were evident (fig. 5).  
Halving the PVA ratio to 2:1 gave a comparable improvement in elasticity but with less detriment to the 
microstructure. Although there was some association of fibrin fibres, diffusional gaps and interconnects 
remained evident. The structurally and biologically relevant hierarchy remained but the mechanical behaviour 
was much improved, so the 2:1 composition was deemed optimal.  
At 5:1 and 10:1 fibrin: PVA, the microstructure was not significantly affected by the addition of PVA. However, 
the macro-scale mechanical properties were similarly unaffected so there was no benefit of PVA addition at 
these levels.  
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2:1 fibrin: PVA represents a concentration of 0.2% w/v PVA in the emulsion mixture. Even at this level, elasticity 
of the scaffold was increased. Bulk hydrogels of 2:1 fibrin: PVA, in discs of approximately 10 mm x 3 mm, were 
tested in their hydrated state under cyclic compression. The 2:1 material showed excellent recovery between 
each cycle, with closely similar stress-strain and recovery curves being produced each time (fig. 6). The linear 
slope on the ascending side is characteristic of elastic behaviour. The descending slope of each cycle represents 
the viscous component and is likely associated with the displacement and re-association of water with the 
hydrogel. The displaced water is visible in the second image of the compressed gel, and just visible drawing up 
the left edge of the right-hand image where compressive force has been released. 
 



















Fig. 7: Effect of PVA on scaffold micro-architecture when used as an excipient. Fibrin-based scaffolds 
washed with aqueous solutions of PVA (Mw 31,000-50,000 g/mol, 87-97% hydrolysed) were freeze-
dried and imaged in cross-section. 0.2% v/v PVA supports the scaffold structure during freeze-drying, 
with hierarchical void diameter and individual fibres visible. Interconnects, diffusional gaps, and fine 
fibrous structure are reduced in scaffolds washed with 0.6% v/v PVA. The effect intensifies at and 
above 1.0% PVA where the PVA coats and masks the underlying protein structure.  
 
Incorporating PVA as an excipient (0.2% w/v aqueous solution) prior to lyophilisation was initially used to 
protect the delicate microstructure under drying pressure (50 mTorr). Although not required for this purpose, 
it was found improve elasticity and general handling of both the dried and re-hydrated scaffold. The effect 
was comparable to when PVA was added to the emulsion mixture. When used as an excipient, the PVA is not 
an integral part of the scaffold and is likely to be washed out during rehydration and sterile washing before 
placement on a wound. However, it could improve handling by clinicians up to that point, allowing it to be 
positioned over a wound and cut to shape more easily.  
200µm 200µm 50µm 50µm 
10µm 10µm 50µm 50µm 
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Cross-sectional micrographs show that the microstructure was unaffected by washing with PVA at 0.2% w/v, 
determined as the optimal concentration for improving mechanical behaviour without detriment to the 
microstructure (fig. 7). The basket-weave structure, interconnectivity and diffusional gaps were clearly 
evident. Increasing the concentration to 0.6% w/v gave a comparable improvement in elasticity and handling, 
but the PVA closed up the fine microstructure by forming sheet-like structures over the fibrin. At 1% and 2% 
this was worsened with thicker deposition, even causing the formation of artefacts like globules and thick 
strands of PVA.  
 
Scaffold cyto-compatibility 
Two identical scaffolds (D3, D4) from different manufacturing batches (0.1% surfactant, 90% porous, 2:1 fibrin: 
PVA, 2% fibrinogen) were tested with triplicate samples from each.  A scaffold (“PM0”) with the same wall 
material and comparable porosity and pore size, manufactured via a foaming method (confidential), was used 
as a 3D control. This material is known to be non-cytotoxic, verified with both in vitro and in vivo assays. 
Surfactant (in this case, Triton X-165) was added to the same volume of media to give a concentration of 0.1% 
v/v, equivalent to the concentration used in the emulsion to template the scaffold. This was used to test 
inherent surfactant cytotoxicity.  
At 24 hours in culture, cell count was comparable between the two scaffolds but 3/5 the count on the 2D plate 
control. 24 h was selected as a time-point relevant for acute toxicity. However, by 120 h cell count on the 
scaffold had increased to be comparable with the 2D plate control. This would suggest there was no toxic 
response as cell numbers would not be expected to recover to such a degree. It is possible that the reduced 
cell population in the scaffolds at 24 h is due to the cells expending energy exploring and colonising the 3D 
environment rather than proliferating. 
The difference in absorbance between the templated scaffolds (D3, D4) and the foamed scaffold (PM0 e) in 
the 24 h leachable assay was not significant.   
In the contact assay, there was no significant difference between the two templated scaffolds at either 24 or 
120 h. However, the reduced absorbance of the templated scaffolds compared to the foamed scaffold was 
significant at 24 h (D3*; D4**). The difference in absorbance between the unbound surfactant and all scaffolds 
was highly significant (****), suggesting that the surfactant used for templating, although cytotoxic in itself, is 
largely removed during washing and poses low risk of cytotoxicity during application.   
This initial result suggests no cyto-toxic response at either acute (24 h) or chronic (120 h) exposure time.  
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Fig. 8: Cyto-compatibility of fibrin-based scaffolds based on 120 h culture in direct contact. Cell 
number was calculated from a standard curve, based on fluorescence of CCK-8 (1:10 dilution in 
DMEM) at 450 nm. PM0e is a foamed fibrin-based scaffold of comparable composition to D3 and D4. 
0.1% Triton X-165 in DMEM was used as a control well (“TX-165”). Both (identical) emulsion-
templated fibrin-based scaffolds (D3, D4) showed reduced cell count after 24 h in culture compared 
to the plate control. However, by 120 h cell numbers on the scaffolds had recovered close to plate 
control. Cell count increased on the ETPM (D3, D4) 116% and 131% between 24 h and 120 h. Increase 
in cell count on the plate control in the same timeframe was 57%.   
 
Mechanical testing 
The additional strength provided by cross-linking fibrin makes the scaffolds more robust and easier to handle. 
It also brings the soft gel closer in strength to native skin tissue. It is widely reported that cells can sense and 
respond to the substrate stiffness. The mechanical properties of a scaffold can influence both stem cell 
differentiation and morphology, so it is important to match closely with native tissue (Freed et al., 2009; 
Hollister et al., 2002; Hutmacher, 2001). Matching scaffold strength to the native tissue also helps promote 
integration, as the implant will behave in a more contiguous manner. Cross-linking also increases resistance 
to proteolytic degradation so the scaffold can persist in vivo for a clinically useful timeframe. 
In vivo, cross-linking of newly-formed soluble fibrin fibrils by activated coagulation factor XIII stabilises the 
fibrils to form a strong, elastic insoluble clot  (Standeven et al., 2005). The same effect may be achieved in 
artificial fibrin constructs by chemical cross-linking with reagents such as genipin (Dare et al., 2009; Linnes et 
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al., 2007), glutaraldehyde (McManus et al., 2006) or carbodiimides such as EDC in NHS buffer (Grasman et al., 
2012); or by photo crosslinking with the aid of a ruthenium catalyst (Bjork et al., 2011).   
It was expected that increasing glutaraldehyde concentration would increase Young’s modulus (and ultimate 
tensile strength in line with this as the material is elastic). However, there was little difference in modulus 
between 0.2% and 0.4% v/v glutaraldehyde. 0.8% v/v produces significantly higher Young’s modulus, but 
higher concentrations showed modulus reducing to very low values. UTS showed a slightly different trend, but 
in both cases 0.8% glutaraldehyde concentration was optimal (fig. 9). 
  
Cross-linking creates shorter length bonds between fibrin molecules, resulting in contraction of the bulk 
scaffold. It was hypothesised that more cross-linker would result in more contraction, so scaffolds were 
measured along the x and y axes after the first and second cross-linker washes and then again after the 
scaffolds were reduced, washed, and freeze-dried. Generally, the scaffolds did contract between the first and 
second cross-link. 






























Fig. 9: Tensile behaviour of fibrin-based scaffolds cross-linked with glutaraldehyde at various 
concentrations. Tensile testing of rectangular strips of freeze-dried scaffold samples showed an 
intermediate (0.8% v/v) glutaraldehyde concentration gave highest ultimate tensile strength (UTS) 
and Young’s modulus compared to higher or lower concentrations. The large error bar arose from 
sample slippage in the vertical testing clamps.  
 
Interestingly, the contraction from ‘as cast’ (5x5 cm) reduced after freeze drying to a very small decrease. It is 
possible that the reduction in the hydrated state is not due to cross-linker so much as hydrostatic pressure 
from the surrounding solution. Scaffold shrinkage showed no dependence on cross-linker concentration 
except at 1.6%, and reduction in the final dried scaffold was minimal (fig. 10(B)).    
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Tensile testing of scaffolds cross-linked with 0.8% glutaraldehyde showed elastic behaviour to failure 
(indicated by the straight ascending slopes on the graph). All three repeats failed at the same strain (~1.7). 
Stress varied between sample, with the first replicate exhibiting more soft behaviour than the second, but 
these were broadly in agreement (fig. 10(A)). This could suggest that the lowest glutaraldehyde concentration 
is sufficient to crosslink the fibrin, or that most of the mechanical strength comes from the fibrin and not the 
additional crosslinking. The tension imparted from the HIPE structure itself – where the interfaces may be 
approximated as I-beams, or a classical honeycomb structure – may also contribute to mechanical strength as 
reduce the role played by glutaraldehyde crosslinking (Kravchenko et al., 2018).  
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Fig. 10: Effect of glutaraldehyde cross-linker concentration on (A) tensile strength and (B) surface 
area of fibrin-based scaffolds. Young’s Modulus is consistently low (~0.1 MPa) for all cross-linking 
concentrations except 0.8% glutaraldehyde (GTA). Ultimate tensile strength (UTS) increases with 
glutaraldehyde concentration up to 0.8% GTA but then reduces. Glutaraldehyde cross-linking causes 
moderate shrinkage at all concentrations (fig. 10 (B)); however, the reduction in area from as-cast 
dimensions is much less notable after the scaffolds have been freeze-dried. 
 
Hydrolytic degradation 
The scaffolds are likely to be washed in PBS before application to a wound. Once applied and secured to the 
wound, the scaffold will be hydrated with plasma and wound exudate. Wet degradation studies were 
performed to assess the predicted longevity of the scaffolds when used in vivo. In order to be useful as surgical 
skin scaffolds, the materials must be a) robust and handleable when hydrated to facilitate placement on the 
wound, and b) able to retain structure for a clinically useful timeframe. This must be at least 3 days, while 
growth factors recruit dermal cells and circulating monocytes to the wound (Falanga, 2005, 2004; 
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Kourembanas et al., 1990), but the scaffold should persist for several weeks in order to provide structural 
support during remodelling to promote regeneration rather than scarring (Gurtner et al., 2008).  
The first, simpler test used sterile buffered PBS. With physiological pH and no enzymes present, any 
degradation was attributable to hydrolysis. Triplicate samples from various scaffolds were incubated in PBS at 
37°C. Samples for each time point (1, 4, 7, 14, 21, 28 days) were removed, dried, and weighed. Change in mass 
was compared to the original dry mass of each sample. Scaffolds with different composition were formulated 
with the same standard emulsion (90% v/v decane, 0.1% v/v Triton X-165 surfactant) but with either only fibrin 
or 2:1 fibrin: polymer. Matriderm® (bovine collagen/elastin; Dr. Suwelack Skin & Health Care, Billerbeck, 
Germany) and Integra® Dermal Regeneration Template (shark glycosaminoglycans and bovine collagen; 
Integra LifeSciences, Plainsboro, NJ, USA) were used as commercially available and widely used control 
materials.  
Of the materials tested, the two collagen-based materials were the only ones to lose mass over time. Integra®’s 
silicon backing was removed for the degradation test. Without it, the collagen matrix degraded within 24 
hours. No material was recoverable to dry and weigh for any time point.  
Matriderm® remained intact and handleable but consistently reduced in mass between each time point. The 
reduction in mass was significant compared to the porous fibrin scaffold (day 1, P=0.0460; day 4, P=0.0180; 
day 14, P=0.0008; day 21, P=0.0479; day 28, P=0.0049). 
All the fibrin-based scaffolds behaved very differently. The appearance and handling were unchanged 
throughout the study. Dry mass increased in many cases, suggesting that the PBS hydrated rather than 
hydrolysed the scaffold (fig. 11). 
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Fig. 11: Change in mass of scaffolds of various compositions incubated for 28 days in sterile PBS. The 
assay was adapted from ASTM 1635. Triplicate samples were made for each time point and the mass 
taken of the dried scaffold. (A) 90% porous emulsion-templated fibrin scaffolds alone or with PVA, 
alginate or PEG added to the aqueous phase of the emulsion were compared with commercial 
products Matriderm® and Integra®. Integra® dispersed before the first time point and could not be 
recovered for weighing. (B) Glutaraldehyde cross-linking density for 2:1 fibrin: PVA scaffolds showed 
no significant difference between 0.2% and 1.6% v/v.  
 
A similar study was performed for 2:1 fibrin: PVA scaffolds manufactured as previously but with different cross-
linker concentrations. The starting glutaraldehyde concentration was 0.8% v/v, taken from an existing in-house 
protocol for fibrin formation. It was expected that increasing cross-linker concentration would prolong scaffold 
longevity and reduce hydrolytic degradation. However, while most samples in this study did lose dry mass over 
time, the difference in degradation between the cross-linker concentrations was not significant at any time 
point except Day 7 (0.4% and 0.8% GTA*, P=0.0308; 0.4% and 1.6% GTA*, P=0.0103). Cross-linker 
concentration in this case can therefore be selected to optimise mechanical properties (fig. 9) rather than 




The different fibrin-based scaffolds were tested with Matriderm® and Integra® in a second study, in which 
various enzymes were added to the PBS to better represent the wound environment during the healing and 
remodelling processes. Non-specific enzymes were used owing to the different materials used in each scaffold 
(i.e. collagenase would be expected to degrade collagen-based Matriderm® and Integra® more efficiently than 
fibrin-base scaffolds). Concentrations of these enzymes were based on values reported in the literature (Lim 
et al., 2018; Lobmann et al., 2002; West and Hubbell, 1999). 
MMPs, secreted by fibroblasts in the wound, are actively involved in the degradation of the wound bed and 
then of scar matrix components throughout healing and remodelling (Rohani and Parks, 2015; Tarnuzzer and 
Schultz, 1996). MMPs are consistently reported to be increased in chronic wounds and are therefore an 
interesting and relevant enzyme to explore for scaffolds intended for treating ulcers (Lobmann et al., 2002).  
Degradation in Trypsin (fig. 12 (A)) 
Matriderm® degraded rapidly in the trypsin solution and was only recoverable on day 1. On day 1, Matriderm® 
had degraded significantly more than Integra®, the other collagen-based scaffold (P=0.011) and the fibrin-
based scaffolds (P≤0.0001). 
Unlike in PBS alone, Integra® retained some integrity over the course of the study. However, mass loss was 
the greatest of any of the scaffolds across all enzymes tested. Given the hydrolytic degradation results, this 
may have arisen from interaction with the PBS rather than being specifically attributable to the enzymes. All 
other scaffolds showed a modest reduction in dry mass over time. The loss in mass between day 0 and days 1, 
4 and 10 was highly significant (P≤0.0001). Integra® degraded significantly more than all the fibrin-based 
scaffolds at all time points, with the most dramatic difference in mass lost occurring on day 1 (P≤0.0001 
compared to all fibrin-based materials). 
The degradation of all the fibrin-based scaffolds was comparable across all time-points. The addition of either 
PVA, PEG or alginate made no significant difference to the scaffold longevity in this test. 
Degradation in MMP mixture (fig. 12 (B)) 
As before, Integra® showed the most dramatic loss in mass over time (P≤0.0001 compared to all other scaffolds 
at all time points). Again, this degradation may be hydrolytic in nature rather than enzymatic.  
Matriderm® performed much better in the MMP solution compared to Trypsin. While mass was lost 
consistently day-on-day, the samples were retrievable and measurable at the end of day 10. The degree of 
degradation was higher than for the fibrin-based scaffolds, particularly the 2:1 fibrin: PEG scaffolds (day 7, 
P=0.0213; day 10, P=0.0015).  
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Change in mass was variable for the fibrin-based scaffolds, with material blend giving loss and gain in mass at 
various time points. There was no significant difference between any of the fibrin-based scaffolds. The only 
material that showed no significant change in mass at any time point was fibrin: PVA. Samples were moved to 
a desiccator for 24 h and re-weighed to ensure all water was removed from the samples but the results were 
unchanged and so appear to be genuine.  
 
Degradation in plasmin (fig. 12 (C)) 
In the plasmin solution, samples of the fibrin-only scaffold generally gained mass over time. The other fibrin-
based scaffolds showed significant changes in mass over time, mainly due to the fact that in some cases mass 
gain was recorded. Again, this was verified with re-weighing following 24 h in the desiccator.  
Matriderm® and Integra® behaved in a more expected manner, both consistently losing mass over time with 
a time-dependent response. Matriderm® was slightly slower to degrade, with no significant loss of mass on 
day 1, but loss on subsequent days was much greater (P≤0.0001, 0.0003, 0.0002 respectively).  
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Fig. 12: Change in mass of scaffolds of various compositions incubated for 28 days in [A] 0.25% 
trypsin, [B] MMP cocktail and [C] 0.125 U/ml plasmin. The MMP mixture comprised 0.2 µg/ml of 
each of MMP-1, MMP-2, and MMP-9. Graphs show mean and standard deviation; n=3. All ETPM 
scaffolds containing other polymers were in a ratio of 2:1 fibrin: polymer. The change is mass was 
largely insignificant. In many cases the dry mass increased over time, possibly as a result of the 
polymers retaining water from the degradation solutions. No bulk degradation was noted in any of 
the fibrin-based scaffolds. Integra® scaffolds degraded rapidly in all conditions. Matriderm completely 
disintegrated in Trypsin [A] within 3 days but degraded more slowly in MMP and plasmin solutions. 
A          B                 C 
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As in the other solutions, Integra® degraded the most at all time points, with a large reduction in mass at each 
(P≤0.0001).  
Given the variable results with fibrin-based scaffolds, it is difficult to draw specific conclusions about 
proteolytic stability. The test could be repeated with larger samples and more concentration enzyme solutions. 
With Integra® and Matriderm®, it is clear that these collagen-based materials were robust in PBS, but again 
enzymatic activity was less clear. The test could be repeated with a buffered solution in which these scaffolds 
are more stable.  
 








70 – 200 µm for cell ingress (Choi 
et al., 2013; Marshall et al., 2004) 













25 – 35 µm for angiogenesis 
(Bokhari et al., 2007; Marshall et 
al., 2005) 
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Fig. 13: Comparison of typical fibrin-based scaffold parameters with optimal values cited in the 
literature. The optimised scaffolds manufactured according to the method described in this report all 





Emulsion templating offers advantages over other methods of creating porous materials such as 
electrospinning, foaming or other gas-based methods. Control over the critical design parameters - 
porosity, pore size, pore size distribution and wall thickness - is achievable. The structures generated are 
more organic in shape than those typically created by additive manufacturing, where a simple pattern is 
often repeated to build the 3D structure. 
High internal phase emulsions (≥74%) allow for creation of highly porous structures at ambient or 
physiological temperatures, depending on the system design. Use of non-ionic surfactants at low 
concentrations avoids damage or denaturation of proteins, allowing the templated scaffold to retain 
native protein structure and properties. Some surfactants are more suited than others to this particular 
application (addressed in a separate report). 
Retaining native protein properties is intended to offer biological recognition when implanted in vivo, 
particularly when using ECM proteins such as fibrin or collagen. They are recognisable by cells and readily 
and safely metabolisable.  
Moreover, the thin fibres forming the hierarchical structure provide traction rails for migrating cells in the 
same way that electrospun fibres do. Templating also provides an engineered hierarchical 3D structure 
which is lacking in aerated scaffolds formed by foamed or gas bubbled or electrospun scaffolds. This level 
of control is possible by a methodical approach, first designing an emulsion of appropriate internal phase 
volume fraction, droplet size and stability before optimising scaffold materials and their concentrations. 
In this way, protein fibre density, pore size and interconnect density are easily tunable and reproducible 
between batches. 
While operating parameters in aeration and spinning methods can be modified to influence air bubble 
number and diameter, or fibre diameter, porosity and spacing are ultimately determined by processes 
which cannot be controlled. In contrast, HIPEs have droplet sizes that can be controlled by mixing speed, 
oil fraction and surfactant choice. Thermodynamics dictate that spacing and diameter will be reproducible 
under the same conditions. If the emulsion is stable, the scaffold will be templated by the emulsion and 
therefore have a controllable and reproducible structure. 
The method described here achieves the high porosity and interconnectivity of HIPE templating with the 
nanostructure of the native protein preserved in the final scaffold. This is an advantage over current 
methods where the HIPE regime limits material choice to synthetic materials or denatured proteins. 
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Additional processing steps are required in both cases to create fine nano-structured surfaces to enhance 
cell interaction, for example creating engineered structured topographies by microcontact printing or 
various lithography strategies; unstructured topographies by chemical etching or phase separation, or 
surface treating by plasma deposition (Chandrasekaran et al., 2011; Dalby et al., 2007; Norman and Desai, 
2006; Viswanathan et al., 2012b). Materials like gelatin have poor mechanical integrity but contains an 
amino acid sequence (Arg-Gly-Asp) which promotes cell migration and adhesion. Surface deposition of 
such materials on a scaffold substrate combines the structure and mechanical integrity of the substrate 
material with the biological properties of the protein coating at the surface where cells interact with the 
material (Chandrasekaran et al., 2011). However, this second processing steps adds to the duration, cost, 
and complexity of manufacture.  
This method also greatly increases the porosity and reduces the density achievable with native protein-
based scaffolds. Typically limited to hydrogels, we present the possibility of engineering complex highly 
porous scaffolds. To our knowledge, the method is unique in allowing HIPE templating of a protein in its 
native form. Furthermore, owing to the limitations of other methods described here, our technique may 
be the only method for producing such high porosity materials with native proteins and the necessary 
control and repeatability for commercial application and regulatory approval. The method described in 
this report is robust and repeatable and generates scaffolds with properties in line with the requirements 
widely reported in the literature.   
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3.4 Assessing scaffold angiogenic potential using the chick 
chorioallantoic membrane (CAM) assay 
ABBREVIATIONS 
CAM chick chorioallantoic membrane 
ETPM emulsion templated scaffold 
H&E haematoxylin and eosin 
HH Hamburger-Hamilton  
PBS phosphate buffered saline  
PVA poly vinyl alcohol 
REM rapid eye movement 
SEM scanning electron microscope 
Three Rs    Reduction, refinement, and 
replacement of animals in research
_____________________________________________________________________________________ 
ABSTRACT 
Biomaterial scaffolds must be evaluated for their cytotoxic, functional, and proliferative effects on cells. 
Some of this can be performed in in vitro studies with cultured cells, but these models are limited and 
cannot adequately replicate complex features of in vivo models (notably blood supply and 
immune/inflammatory response). In vivo studies carry economic and ethical burden as well as increased 
variability between repeats. The chick chorioallantoic membrane (CAM) assay, which exploits the rapidly 
developing capillary plexus of a fertilised egg in the early stages of embryonic development, offers a 
compromise between the in vitro and in vivo systems.  
Frequently used to study tumorigenesis and evaluation of angiogenic growth factors, the CAM assay may 
also be used to compare angiogenic potential of biomaterial scaffolds. While results are reported in the 
literature, detailed methods and protocols are frequently withheld.  
Here, the CAM assay was used to evaluate angiogenic potential of fibrin-based polyHIPE scaffolds 
compared to commercial scaffolds Matriderm™ and Integra® Dermal Regeneration Template. Fibrin, 
fibrin-PVA and fibrin-alginate scaffolds with 90% porosity were also evaluated against non-porous films of 
the same composition to examine the materials’ structural contribution to angiogenesis. Blood vessel 
development was monitored throughout the study and Drabkin’s haem count used to assess haem in the 
excised scaffolds at the conclusion.  






Even with scaffolds that are biocompatible and facilitate the migration of cells into and though the 
construct, the longevity of these exploratory cells is not guaranteed. Residence time is dictated by the 
availability of nutrients and oxygen, as well as removal of waste. This is especially true of a wound 
environment where high proliferation and differentiation rates are required. A rapidly forming and robust 
vasculature throughout the scaffold is essential to support the cells from an early stage and ensure the 
continued performance of the implanted scaffold. Impaired graft vascularisation may lead to infection, 
localised necrosis or rejection of the implanted material (Hendrickx et al., 2010; Sahota et al., 2004).  
Historically, cell and vascular penetration of biomaterial scaffolds has been restricted to a couple of 
millimetres, which is therefore a limiting design factor on scaffold dimensions but also on the application 
of the material. A thin construct has limited use for replacement of repair of thick, dense tissues which is 
why many commercial materials are focussed on dermal replacement (the dermis is only 0.6-0.7 mm thick 
(Chopra et al., 2015; Oltulu et al., 2018) so the materials could conceivably replace the full thickness).  
Successful graft materials must provide a framework for new and repairing vasculature (Oliver et al., 
1983). Porous materials are highly desirable as skin scaffold. Their interconnected cavities provide space 
for neovascularisation and angiogenesis as well as aiding supply of nutrients and chemical stimuli, and 
removal of waste from the regenerating tissue (Busby et al., 2001; Thomson et al., 1995; Whang et al., 
2000). A highly porous material further allows increased and more uniform infiltration of cells (Brauker et 
al., 1995; Carnachan et al., 2006; Glowacki et al., 1983; Klawitter and Hulbert, 1971; Lu et al., 2012; 
Mooney et al., 1991; Nade et al., 1983; Whang et al., 2000).  
To support vascularisation, fibrin scaffolds must have pores with appropriate pore- and interconnect 
diameter were found to allow existing capillaries to penetrate and newly formed tips to further invade 
(Linnes et al., 2007).  The literature cites a wide range of ‘optimal’ pore diameters which appear to be very 
specific to the particular material and application in each case. Marshall et al found that poly (2-
hydroxyethyl methacrylate) scaffolds with pores of 35 µm diameter, implanted in mouse skin, showed 
enhanced angiogenesis compared to comparable scaffolds with either smaller or larger pores (Marshall 
et al., 2005). However, a year earlier the same group had stated that pores of 70 µm diameter were more 
effective at promoting vascularisation throughout the scaffold (Marshall et al., 2004). PLGA scaffolds with 
very large pore diameter, ≥200 µm, have been shown to promote the formation of low density networks 
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of larger blood vessels whereas smaller pore diameter (<200 µm) promotes the formation of high density 
networks of smaller blood vessels following implantation in nude mice (Choi et al., 2013).  
Interconnectivity and interconnect diameter is equally important as this facilitates the passage of blood 
vessels through the scaffold. Indeed, interconnect diameter may be more important than pore diameter 
for vascularisation by promoting the proliferation, adhesion, and migration of endothelial cells through 
the scaffold. This has been demonstrated using HUVECs cultured in β-tricalcium phosphate (β-TCP) discs 
(Xiao et al., 2015). Β-TCP scaffolds with larger interconnect diameters have been shown to exhibit 
improved vascularisation over those with smaller interconnect diameter, up to a maximum of 400 µm 
beyond which no significant difference is observed (Bai et al., 2010). The collective evidence suggests a 
minimum cut-off diameter for angiogenesis, possibly dictated by the diameter of endothelial cells which 
assemble to form new blood vessels (approximately 5-20 µm, dependent on location) (Garipcan et al., 
2011). Above this critical diameter, the blood vessels have room to mature into thicker, more robust 
capillaries which are likely to occur at lower density.  
In addition to ensuring biocompatibility and microstructure are conducive to vascularisation, biological 
strategies may be employed in tandem to further improve blood vessel ingress into the scaffold. This may 
be achieved with cells or biochemical or pharmacological agents. Scaffolds can be dosed with growth 
factors or gene vectors which are released into the wound as the polymer carrier degrades. Scaffolds may 
be seeded with vessel-forming endothelial cells prior to implantation so that the building-blocks for 
neovascularisation are already in place (Frueh et al., 2017). Disadvantages to biological vascularisation 
strategies include the increased cost and processing time created by added complexity, as well as 
increased challenge in safe storage and transportation of the prepared materials. The biological 
component is also likely to increase the risk-based class of the scaffold and change its designation to a 
combination product, which makes the regulatory approval process more convoluted.   
There are two methods by which new blood vessels form: angiogenesis and vasculogenesis. 
Vasculogenesis describes the direct formation of blood vessels by differentiation of angioblastic precursor 
cells in situ. Angiogenesis describes the formation of new blood vessels from pre-existing ones (i.e. sprouts 
from existing capillaries and venules) (Risau, 1997). In this case, the scaffolds are intended for use as 
dermal skin templates where they would be placed into fresh wound beds. The wound bed already has 
established blood vessels with sprouting ends, so in this environment neo-vascularization would be 
expected to occur via angiogenesis.  
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Rapid vascularisation of a potential skin scaffold material is therefore essential to its success. Assessment 
of the angiogenic potential of candidate materials is an important criterion during scaffold development. 
Here, the chick chorioallantoic membrane (CAM) in vivo ‘bridge’ assay was used as a high-throughput 
technique for assessing angiogenesis in a 3D functional capillary bed.  
 
CAM development and relevance 
The CAM assay provides a useful bridge system between in vitro and in vivo models for investigating blood 
supply in biomaterial structures. In vitro models lack endothelial structures and 3-dimensional complexity, 
while in vivo models are overly complex with many extraneous variables when testing for a specific 
response (here, angiogenesis). There is also a risk of a lack of consistency and reproducibility between 
animals (Moreno-Jiménez et al., 2016). Finally, some animals may not tolerate implantation with materials 
designed for human use and bias the test with an immune response that would not be seen in human 
models. 
The CAM is a respiratory organ that fuses with the shell and provides gaseous exchange with the outside 
environment to support the developing embryo. Importantly, the CAM is very highly vascularised, 
containing a dense plexus of capillaries, and highly branched blood vessels of many sizes. The largest of 
these are latterly accompanied by an extensive lymphatic network (Taizi et al., 2006). Rapid capillary 
proliferation continues until day 11 post-fertilisation and then progresses slowly until final vasculature 





Fig. 1: Schematic diagram of a fertilised chicken egg showing the location of the chorioallantoic 
membrane in (A) longitudinal and (B) transverse view. The chorioallantoic membrane forms by 
the fusion of the chorion and the allantois on day 4 or 5 post fertilisation (Fuchs and Lindenbaum, 
1988). Images adapted from (Gabrielli and Accili, 2010; Valdes et al., 2002). 
 
The allantois emerges from the ventral wall at about 3.5 days after fertilisation. It grows rapidly from day 
4 until day 10, during which time it fuses with the adjacent chorion to form the chorioallantoic membrane 
(CAM). The CAM is only fully differentiated on day 13 (Hamburger and Hamilton, 1992; Moreno-Jiménez 
et al., 2016; Nowak-Sliwinska et al., 2014). In order to capture the entire duration of angiogenesis and 
blood vessel maturation in the growing CAM, CAM assays for the study of biomaterials typically coincide 
with days 4 – 14 of development. However, on about day 14 of development the embryo makes complex 
movements to get into position for hatching. For this to happen the central nervous system has to be 
highly developed, by which time the embryo would be sensate. The assay was therefore designed to 
terminate at the end of day 13 or at the very latest early on day 14, in line with ethical guidelines to 
terminate before two-thirds gestation (Tong et al., 2013). 
Chick embryos lack a functional immune system until approximately day 15 of development (Ribatti, 
2010). The lymphoid system is not fully developed until the late stages of incubation (leading up to 
hatching on or around day 21 post-fertilisation), and bursal lymphocytes do not appear until between 
days 12-15 of embryonic development (Glick, 1979). IgM, which also originates in the bursa, is not 
identified until day 14 of development (Kincade and Cooper, 1971). This is the first immunoglobulin 




to day 14 of development (Tîrzui and Seres, 2010).  
Thus, the CAM is a naturally immune-deficient host system when used in the early stages of development. 
After this time, the foreign test samples may incite an inflammatory response which may be detrimental 
to the wellbeing of the embryo; and secondly, the inflammatory response may provoke angiogenesis, 
making it difficult to assign vascular development confidently to material or inflammatory response 
(Nowak-Sliwinska et al., 2014; Ribatti, 2012).  Before day 15, biomaterials and/or cellular materials can 
therefore be implanted and tested without species-specific restrictions (Dohle et al., 2009).  
 
The CAM assay 
The CAM assay makes use of the early rapid vessel formation. Substances to be tested are placed on the 
CAM and the interaction and infiltration of the new vessels with the materials is observed. Increased 
angiogenesis would indicate a more angiogenic material; more infiltration further suggests that number, 
size, and spatial arrangement of pores in the material is conducive to angiogenesis. This information is 
extremely useful in biomaterial scaffold design and suggests whether prototype materials would be 
capable of supporting cell in vivo or whether redesign is required. 
In the CAM assay, a fertilised egg develops blood vessels that are easily visualised, accessed and 
manipulated (Dohle et al., 2009). The superficial layers of the CAM are transparent to most visible 
wavelengths, so the vasculature can be visualised by light and/or fluorescent microscopy (Nowak-
Sliwinska et al., 2014). The small window cut into the shell in the established in ovo method can obstruct 
visualisation of the whole CAM. Visualisation can be further improved using an ex ovo method where the 
egg is displaced from the shell into a petri dish, allowing unimpeded viewing. Ex ovo culture has been 
associated with low embryo viability as the yolk typically ruptures either on cracking the egg, or during 
culture (as a result of excessive distension of the yolk on a flat surface) (Auerbach et al., 1974; Nowak-
Sliwinska et al., 2014; Ribatti et al., 2000). Most loss occurs during the first three days in ex ovo culture, 
after which survival rates dramatically improve (Auerbach et al., 1974).  
Test substances (in this case, small scaffold samples) are placed carefully around the capillary plexus at 
the start of embryo development. As the CAM grows and matures, it rapidly vascularises. The interaction 
with these blood vessels and the various test materials over time is observed. A more angiogenic material 
has greater interaction with the capillary plexus (more blood vessels resident, more branch points etc.). 
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As the assay is hosted in a developing organism, the stage of development must be carefully monitored 
during progression of the assay to avoid causing any undue disturbance. A timeline of assay progression 
is shown against Hamburger-Hamilton stages for chick embryo (fig. 2).  
There are various protocols described, with varying levels of detail, in the literature. In the work described 
here, these protocols were evaluated, and aspects of several protocols were adopted and trialled during 





















Fig. 2: Timeline of chick embryo development, based on Hamburger-Hamilton stages (Hamburger and Hamilton, 1992), alongside key stages from 
the CAM assay protocol. Figure adapted from Tong et al (Tong et al., 2013). The stages before Hamburger-Hamilton (HH) 2, in which an embryo 
forms from a germ, are described by Eyal-Giladi and Kochav (Eyal-Giladi and Kochav, 1976).  
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36 white eggs (Gallus gallus domesticus, Dekalb white) were purchased from Henry Stewart & Co. Ltd. 
(Norfolk, UK). Eggs were refrigerated until required. Mean weights per batch were 63.05g ± 0.62, 
59.24g ± 2.96 and 58.98g ± 2.83.  
Emulsion templated scaffolds (“ETPM”) were manufactured according to the method described 
previously. All emulsions comprised 90% (v/v) decane and 0.1% (v/v) Triton X-165 surfactant. 
Fibrinogen: thrombin ratio was 4:1. Fibrin scaffolds with alginate or PVA contained 2:1 fibrin: 
copolymer.  
Films were produced with the same polymer composition as each of the ETPM scaffolds (fibrin only, 
and fibrin-PVA and fibrin-alginate in a ratio 2:1). These were prepared in the same way as the aqueous 
phase of emulsions for the ETPM with the same order and timing of reagent addition and same 
method and duration of mixing. The films were cast in 5 cm2 weighing boats, tapped to remove air 
bubbles and freeze dried alongside the ETPM over a 16-hour cycle to 50 mTorr, -40°C (VirTis Genesis 
25ES, SP Scientific). Scaffolds and films were manufactured in triplicate, in a ‘clean’ environment to 
reduce contamination. This entailed autoclave sterilisation of all solutions and sterile filtration of 
thermo-sensitive solutions, then conducting mixing and casting in a category I laminar flow cabinet. 
Pronova UP VLVG alginate was purchased from NovaMatrix Ultrapure Biopolymer Systems. 
Matriderm™ (Dr. Suwelack Skin & Health Care, Billerbeck, Germany) and Integra® Dermal 
Regeneration Template (Integra Life Sciences, Plainsboro, NJ, USA) were purchased through 
Northwick Park Institute for Medical Research. All other reagents and consumables were purchased 
from Sigma Aldrich.  
 
Ethical considerations 
Chicken embryos are not considered protected species under current Home Office regulations; 
however, a series of measures were implemented in line with the ‘three Rs’ (refinement, reduction, 
and replacement) principles originally proposed by Russell and Burch in the 1950s (Balls and 
Straughan, 1996; Guhad, 2005).  
Eggs were sourced from a DEFRA regulated supplier. They were either put into immediate use or 
refrigerated on receipt to retard development. Fertilised eggs may be safely refrigerated for up to one 




The optimal span of temperature during incubation is very narrow to maintain healthy and viable 
embryos (Webb, 1987). 
The use of ex ovo CAM allowed total visualisation of the whole organism. While monitoring blood 
vessel interaction with the scaffolds, chick development was simultaneously tracked according to the 
Hamburger-Hamilton stages (figure 2). Length of incubation in reared eggs and chicks is a function of 
the level and stability of incubation temperature (Reed and Clark, 2011). In this study, with a controlled 
common environment, all embryos were expected to develop according to the same approximate 
time frame. Visual development tracking by Hamburger-Hamilton staging corroborated expected 
development stage with assay progression. 
Early gestational chick embryos are immune-deficient so introduction of extraneous materials 
(especially xenogeneic material) should elicit no immune response and have no adverse effect on the 
embryo (Dohle et al., 2009; Glick, 1979; Kincade and Cooper, 1971; Tîrzui and Seres, 2010). 
Additionally, samples were introduced onto the CAM before the embryos became tactile, and the 
assay concluded before embryos developed visual or auditory sensation. All embryos should therefore 
have no sensory awareness of any procedures taking place. 
The embryo is innervated during the development stages covered by a typical CAM assay, but the 
CAM itself is not. With careful placement and manipulation of test samples, the embryo should 
experience no pain (Moreno-Jiménez et al., 2016). 
All materials were sterilised with 70% ethanol/autoclaving (as appropriate) prior to use, to minimise 
the risk of contamination to the ex ovo embryo. Egg shells are partially permeable, and application of 
ethanol or detergents significantly reduces embryo viability (Dohle et al., 2009). The eggs were instead 
cleaned using chlorhexidine gel then cleansed with distilled water and dried thoroughly.  
The scaffolds were manufactured under ‘clean’ conditions to reduce introduction of contaminants 
and/or endotoxin. Matriderm™ and Integra® are supplied sterile. Prior to use, all scaffolds were 
washed in 70% ethanol and then thoroughly washed with PBS to sterilise. Preliminary in vitro cultures 
with scaffolds prepared in this way showed no adverse response. 
The size and positioning of scaffolds around the CAM were considered for statistical relevance 
(biological repeats) and reducing the number of eggs required, while ensuring the scaffolds were 
distinct and separate with no interaction between samples.  
Measures were implemented throughout to minimise mechanical trauma to the embryos. Eggs were 
rotated for 3 days prior to evacuation from the shells. The embryo resists the rotation and migrates 




experienced by the embryo (Dohle et al., 2009). Increased survival rates (more than 50% higher) are 
reported using this method. Scaffolds were placed around the edge of the CAM to avoid disturbing 
the embryo or rupturing capillaries.  
Eggs were checked at least daily during incubation. Non-viable embryos (assessed by absence of foetal 
heartbeat) were immediately isolated and terminated in line with Home Office regulations to protect 
the remaining embryos. All embryos were terminated at the end of the assay early on day 13 of 
development (before Hamburger-Hamilton stage 40).  
 
Finalised method 
This protocol was initially based on the method described by Dohle et al. (2009) and modified 
iteratively.  
On receipt, eggs were checked for hairline fractures, mechanically cleaned with dry paper towel, and 
refrigerated until required (up to one week). Before use, the eggs were cleaned with chlorhexidine gel 
and dried thoroughly before weighing. They were then positioned in the pre-conditioning incubators 
on their longitudinal axes and the upper surface marked. The eggs were incubated at 37.5°C, 60-62% 
humidity with the incubator (RCom KingSuro Max 20, Autoelex Co. Ltd., Juchon, Korea) rotating 
through 60° every hour.  
After 72 hours each egg in turn was removed from the incubator and the underside (opposite the 
mark on the upper surface) was tapped sharply against a scalpel blade. Surgical scissors were inserted 
through the fracture and used to grow the incision through shell and membrane. Finger pressure 
contained the albumen in the shell. Holding the egg just above an octagonal-based weighing boat 
(cleaned with 70% ethanol), the egg was evacuated into the boat. Each boat was lidded with an 
inverted weighing boat, offset to expose the corners. Four kim wipes, folded in half, were placed in a 
100 cm2 square weighing boat, and sprayed with distilled water. The lidded weighing boat was placed 
in the larger weighing boat then immediately incubated at 37°C, 80-85% humidity (HERAcell VIOS 160i, 
Thermo Scientific).  
The next day, all scaffolds and films were washed in 70% ethanol then three times in sterile PBS. All 
were equilibrated in fresh, sterile PBS at room temperature while eggs were examined. Non-viable 
embryos, determined by absence of heartbeat (at this stage only visible as a red pulse), were removed 
and destroyed. A sterile 8 mm biopsy punch was used to make circular samples of the hydrated films 
and scaffolds. Using a pre-determined matrix, four scaffolds per egg were positioned at the edge of 




used, with three scaffolds per material condition. Each sample and egg were photographed after 
placement. Eggs were then returned to the incubator for a further 8 days.    
All eggs were checked daily for viability. The kim wipes were sprayed with fresh water daily, or as 
required, to maintain overall incubator humidity of 80-85%. Each egg was removed and photographed 
on days 1, 3, 5, and 7. At each timepoint, the embryo and each sample were imaged at 7.5x 
magnification with a camera attachment (GXCAM-9, GT Vision Ltd. Stansfield, UK; Nikon SMZ745T 
stereomicroscope).  
Early on day 9 after sample placement, eggs and scaffolds were imaged as previously. All accessible 
samples were gently excised with forceps, using a scalpel to remove excess albumen where necessary. 
Each sample was deposited into the well of a 24 well plate. Embryos were destroyed immediately after 
sample excision.  
The haem content of the excised scaffolds was assessed by Drabkin’s assay, using the protocol 
provided by the manufacturer (Sigma Aldrich, available online). Samples were not treated with 
anticoagulants or calibrated to take account for lipids, abnormal plasma proteins or erythrocyte 
stoma. Briefly, excised scaffolds were placed in 24-well plates and incubated with 2 ml Drabkin’s 
reagent for 30 minutes at room temperature. Absorbance on the spectrophotometer was set to 0 
using distilled water as the reference. The samples were removed before measuring the absorbance 
of each well at 540 nm. A standard curve was prepared using reconstituted human haemoglobin (100 
mg/ml to 6.25 mg/ml). 
Angiogenic potential of materials was assessed by counting blood vessels penetrating the samples on 












Fig. 3: Preparation of eggs for ex ovo culture in the CAM assay. Embryos were orientated to 
the upper surface of each egg over 72 hours in a rotating incubator. Each egg was cracked 
with a single tap to underside followed by propagation with surgical scissors, using finger 




Of the eggs that were delivered fertilised and with shells intact, survival rate after transfer to ex ovo 
culture was over 70%. Some embryos died in the first 24 h of culture, typically those with rapid, 
shallow pulse immediately after evacuation. Viability in culture reduced over time, principally owing 
to yolks slowly leaking. Viability on days 1, 3, 5 and 7 after sample placement was 61.3%, 54.8%, 51.6% 
and 32.3% respectively. On the final day of the assay 29% of the batch remained viable. At all stages, 
embryos progressed as expected according to the Hamburger-Hamilton development stages. 
The developing embryo shown in fig. 4 is characteristic of healthy embryos at each time point. At day 
0 after cracking, the embryo was only visible by its pulse. The capillary plexus grew rapidly until it 
covered the air interface. At this point, capillaries began to mature, growing in diameter and 
interconnectivity. There was some evidence of remodelling during the maturation process. Scaffolds 
were initially positioned on top of the capillary network at the outer edge. However, the yolk 
distended as the embryo grew and consumed the contents, occasionally forcing the scaffolds off the 





  Day 0 Day 1 Day 3 
   
Day 5 Day 7 Day 9 
   
Fig. 4: CAM development at time points after sample placement. The yolk sac is displaced 
and consumed over time by the growing embryo. At day 0, the embryo was only detectable 
by its pulse. In the following 24 hours the head and spine became evident, and after 72 hours 
the head body and limbs were all visible. The thin capillary network grew rapidly in line with 
embryo development. After 5 days (incubation day 9; approximately HH stage 35) the capillary 
plexus reached full surface coverage and blood vessels matured in diameter, depth, and 
connectivity. 
N.B. Scaffold C2 (right side of weighing boat) is not visible in the images from day 3 onwards. 
The sample adhered to the capillary plexus and was subducted into the albumen after the 































































































D a y  3
D a y  5
D a y  7
D a y  9
 
Fig. 5: Number of blood vessels interacting with scaffold samples. Each timepoint represents 
the number of days after sample placement on the CAM (incubation day -4). Interacting blood 
vessels were defined those entering and exiting around sample circumference. Mean values 
and standard deviations reported; n variable owing to loss of samples and embryos (as 
reported in Table 1). Two-way ANOVA showed no significant differences between samples or 
time points. 
 
Most test materials perform comparably with the commercial comparators Matriderm™ and Integra®. 
The 90% fibrin ETPM scaffold performed particularly strongly, with greater blood vessel interaction 
than either commercial product on assay days 5, 7 and 9 (incubation days 9, 11 and 13). Prior to assay 
day 5, the capillary network in all cases was still growing; from day 5 onwards the entire surface of the 
culture dishes were vascularised and the capillaries moved from exploration and expansion to 
consolidation and maturation. In general, all samples showed increased blood vessel interaction over 
time. Some (fibrin ETPM, d9; fibrin-PVA ETPM, d9; fibrin-alginate ETPM, d7; fibrin film, d9; fibrin-
alginate film, d7) showed a reduction at a single timepoint. Especially with the day 7 reduction, this 




with the samples. The recovery in number at day 9 supports this theory. Another, less likely, possibility 
is that number of interacting blood vessels reduced due to conformational changes in the capillaries. 
This could occur with tortuous capillaries bending close to the perimeter of the sample.  
Notably, Integra® was the only material to show consistent reduction in the number of interacting 
blood vessels across each time point. At day 3, the number of interacting blood vessels was the highest 
of all samples, but this declined over the course of the assay. The remaining blood vessels in the vicinity 
did not appear to have increased in diameter, suggesting the reduction in number was not offset by 
maturation of the major vessels.  
In contrast, the number of blood vessels interacting with Matriderm™ samples increased day-on-day 
with the greatest increase occurring between days 5 and 7 after sample placement. This time point is 
of interest as it marks the change from exploratory blood vessel growth over the air interface to 
maturation. An increase in blood vessel interaction from day 5 onwards is therefore more likely to be 
indicative of a material influence rather than random growth. 
Among the fibrin-based materials, there was no significant difference in the number of blood vessels 
counted either between the same materials at different timepoints, or different materials at the same 
timepoint. No advantage of any one material over another was apparent. The fibrin-only scaffold 
showed increased blood vessel interaction compared to fibrin-PVA and fibrin-alginate scaffolds, but 
the difference was not statistically significant. There was no discernible difference in the performance 
between the three different fibrin-based films. A slight reduction in interaction was expected in the 
alginate- and PVA- containing samples as these are not native blood proteins, like fibrin. It is possible 
that the response may be different or more pronounced for materials of human-origin fibrin in a 
human in vivo test, rather than bovine fibrin in a chick assay.   
The fibrin films showed a greater number of blood vessels interacting compared to their 3-dimensional 
scaffold counterparts. However, this number is likely to be misleading as the films were more 
transparent and allowed greater visualisation, making it difficult to separate interacting vessels with 
non-interacting blood vessels below the sample. The results cannot therefore separate between 
material and structural contribution to angiogenic potential. 
While the comparative results are not compelling, it should be noted that both Matriderm™ and 
Integra® have a long history of clinical use and have amassed a body of clinical and supporting 
academic evidence that suggests both in vivo efficacy and integration with host tissue. This would only 





  90% porous ETPM Non-porous film Commercial product 








1 22, 32, 36 22, 32, 36 22, 32, 36 22, 32, 36 13 13 13 8, 13 
2 11    11  11  
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1     21, 34 21, 34 21, 34 21, 34 
2 16, 30 19, 29 16, 30 19, 29 16, 30 19, 29 16, 30 19, 29 
3 7, 28 7, 28 17 17 28 7, 28 7, 17 17 
Table 1: Explanted scaffolds per egg on culture days 5, 7 and 9. Samples were extracted at 
assay endpoint or after death of the embryo. Embryos that failed before the capillary plexus 
covered the surface of the culture well (incubation day 9, culture day 5) were destroyed 
without collecting scaffolds.  
 
Quantification of haem present in explanted scaffold samples 
Scaffolds were excised after the final blood vessel count on culture day 9 (incubation day 13) prior to 
termination. A Drabkin’s assay was performed on these excised scaffolds to quantify haemoglobin 
present as a secondary output measure. In theory, any haemoglobin present in the samples must 
originate from embedded blood vessel fragments. Their presence confirms infiltration, unlike direct 
imaging which cannot distinguish between blood vessels interacting with samples from those simply 
passing underneath.  
Both measures are useful to a degree, as vessels passing directing underneath the sample without 
penetrating may still be influenced in some way. The direction could be attributable to chemotactic 
properties of the material (positive response), or simply coincidental, or even a repulsive response by 
blood vessels eschewing the material but retaining their path by going above or below. 
The Drabkin’s assay revealed a low concentration of haemoglobin present in all samples. It should be 




and so concentrations at the low end of the manufacturer’s suggested calibration range were 
expected.  
Nonetheless, the results (fig. 6) are surprising for their discrepancy with the number of interacting 
blood vessel (fig. 5). Matriderm™ samples had among the highest number of interacting blood vessels 
at day 9. This is broadly in agreement with the result of the Drabkin’s assay. However, the fibrin ETPM 
scaffolds, fibrin-PVA films and fibrin-alginate films which displayed similarly high levels of blood vessel 
interaction in the CAM assay were found to contain the lowest levels of haem by Drabkin’s 
quantification (<0.07 mg/ml). This may be due to the difficulty in extracting the samples cleanly from 
the albumen. The fibrin-based scaffolds and films are all elastic in behaviour. Blood vessels are also 
highly elastic, and the albumen ‘matrix’ was highly viscous by the end of culture. There was resistance 
from all three components during sample harvesting. It is also possible that many of the blood vessels 
observed interacting with samples, particularly with the transparent films, were passing adjacent and 
below the samples. Films were retrieved largely intact without signs of tearing, which supports this 
supposition.  
Although the fibrin-PVA and fibrin-alginate scaffolds showed reduced numbers of interacting blood 
vessels, the mean haem detected was greater than in fibrin only scaffold samples. It is difficult to draw 
positive conclusions from the results, but they do not show any detrimental angiogenic effect when 
PVA or alginate are used to replace some of the fibrin.  
The addition of PVA, particularly, has been shown to significantly improve the mechanical properties 
of the fibrin-based scaffolds. PVA is similarly attractive from an economic stance: cost per gram is 175 
times less than that of bovine fibrinogen and 290 times less than that of human fibrinogen. However, 
it is imperative that the in vivo performance is not compromised. Establishing equivalence in 
biocompatibility, cell interaction and angiogenic potential is essential. These early results are 
promising, but larger scale testing, as well as whole animal models, are required to confirm equivalent 










































































































































































































Fig. 6: Cyanmethemoglobin (mg/ml) detected using Drabkin’s Reagent at 540 nm 
(R2=0.9995). Scaffolds were excised with forceps immediately prior to termination to minimise 
risk of contamination with blood from neighbouring severed blood vessels. [A] box-and-
whisker plot showing median, upper, and lower quartile and upper and lower values; [B] mean 
and standard deviation. Two-way ANOVA revealed no statistically significant difference 
between samples. *Dashed line shows limit of detection (LOD =  ?̅?b𝑖 + 𝑆bi  where ?̅?b𝑖  is the 







Biomaterial scaffolds of myriad materials and structures are reported in the literature. The importance 
of rapid vascularisation and angiogenic potential of these materials is equally well known. Insufficient 
vascularisation can lead to graft failure, rejection or necrosis (Hendrickx et al., 2010; Sahota et al., 
2004). Confirming angiogenic potential of candidate biomaterials is therefore essential to their 
success. The fibrin-based scaffolds tested here went through an iterative design process to generate 
spatial structure parameters (porosity, interconnectivity, wall thickness, etc.) in line with reported 
literature values prior to evaluating angiogenic capacity.  
The mouse aortic ring model and whole animal testing are alternative methods for testing biomaterial 
angiogenic potential. The CAM was selected as it offered a dynamic living system, mimicking the rapid 
physiological response during the wound healing cascade, but allowed higher throughput than use of 
animal models. Chick eggs are more readily available than research animals, and their lack of immune 
system and tactile sensation during scaffold placement ameliorate ethical concerns.  
The CAM assay is widely used and reported for use studying tumorigenesis. However, methodologies 
are often sparse. Despite the large body of literature describing scaffold manufacture, the number of 
works reporting angiogenesis results is relatively small. This may go some way to explaining why 
products described as promoting rapid tissue integration fail to live up to clinical expectation.  
 
Method development 
The ex ovo CAM assay is well described in recent literature, and several groups describe the use of 
such culture for decades with degrees of success. It is generally accepted that ex ovo culture is more 
challenging than in ovo culture and embryo viability may be reduced. However, many groups describe 
various approaches that seek to attenuate this loss, and viability rates of ~70% have been cited.   
The biggest losses consistently occurred, unavoidably, on delivery. Safely evacuating the eggs was the 
second barrier to survival. Whilst rotating the eggs did successfully orientate embryos to the upper 
surface of the egg, the yolk did not similarly migrate. Yolk rupture during cracking was the most 
common cause of mortality either immediately after cracking or during culture, depending on the 
extent and rate of the leak. The yolk solidified at the air interface, reducing the surface area for 
gaseous exchange.  
Viability continuing to reduce throughout the assay (after transfer to ex ovo culture) was contrary to 




rates by increasing ambient humidity and using alternative methods for evacuating embryos. Size of 
the embryo at evacuation was a strong indicator for survival. The largest carried a much higher 
mortality rate than smaller embryos with smaller and less developed capillary networks.    
Despite reduced viability, ex ovo culture was selected for the larger test area, enabling the use of more 
scaffold samples per egg and a larger field of vision. Successful ex ovo culture is dependent upon a 
reliable method of extracting the egg contents intact and then recreating the shell environment in 
culture. The shell provides a partially permeable barrier, a calcium reservoir, and a structural support 
for the developing embryo. All three components must be replicated ex ovo. Here, embryos were not 
developed beyond Hamburger-Hamilton stage 40 so skeletal development was not a major concern 
and calcium supplements were not used. In place of a permeable membrane, embryos were incubated 
with tightly regulated humidity, temperature, and air supply. In terms of structural support, embryo 
viability is highly dependent on maintaining the shape of the yolk sac. In a flat culture dish, the yolk 
distends and ruptures, drowning the embryo. Some protocols suggest cracking the eggs into a 
hammock formed by securing film by the rim of a plastic cup (Cloney and Franz-Odendaal, 2015). This 
method effectively recreates the curvature of the intact egg, but the cups are not stable and are liable 
to fall.  
The method used here was initially based on that described by Dohle et al. (2009), with some 
modifications. The Dohle group describe a tightly prescribed method for cracking the shell with a 
triangular pyramidal stirring bar in a defined and repeatable manner, which resulted in a 50% increase 
in embryo survival ex ovo (Dohle et al., 2009). This method was used during the pilot study, but the 
stirring bar was found to produce a small series of cracks that were insufficiently cohesive to create a 
neat fracture surface. In subsequent attempts, the stirring bar was replaced with a scalpel blade, 
followed by initial fracture with a scalpel blade followed by propagation with surgical scissors. This 
method proved most successful at piercing the shell and thick outer membrane and resulted in the 
greater viability (fewest egg yolks ruptured). 
Most reported protocol cite an incubation humidity of 60-65%. Maintaining humidity is important to 
prevent the albumen and yolk drying out, however, excessive humidity may cause embryos to drown. 
In these experiments 65% humidity was found to be too low. 80-85% humidity improved embryo 
survival rates and visibly reduced drying and volume loss of the albumen. The use of damp kim wipes 
under each dish, suggested by Cloney and Franz-Odendaal (Cloney and Franz-Odendaal, 2015), proved 








Fig. 7: Embryo mortality arising from [A] catastrophic yolk rupture, [B] slow rupture after 2 
days in culture and [C] low humidity (60-65%). Mortality was detectable by [D] blood 
accumulating at the periphery of the capillary plexus, [E] whitening of the vessels and embryo. 
Images taken with iPhone, without magnification.   
 
FUTURE WORK 
In principle, angiogenesis should be enhanced in a cellularised scaffold compared to the same acellular 
scaffold because the resident cell would secrete their own cytokines and growth factors to enhance 
angiogenic potency (Frueh et al., 2017). In situ secretion of these factors is likely to have greater effect 
than dosing scaffolds with isolated growth factors as cell secretions would be more physiologically 
relevant and not suffer from loss of viability during manufacturing and processing or sterilisation 
techniques.  
Additionally, if the implanted cells are endothelial or progenitor cells capable of differentiating into 
endothelial lineages, they may be able to form blood vessels in the scaffold interior. This could 
accelerate graft vascularisation compared to relying on vascularisation solely arising from existing 
vessels in the wound bed and periphery.  
Implanting xenogeneous cells in an exogenous scaffold into a chicken egg is unlikely to be a useful 







be no inflammatory response but equally there would be no additional benefit. The immune response 
is an important consideration and should be included in output measures. Additionally, enhanced 
positive response possible from allogeneic or autologous cellularisation could not be monitored. It 
would therefore be more appropriate to study angiogenic potential of cellularised scaffolds during 
advanced animal clinical trials, after confirming efficacy with acellular scaffolds in the same model. 
The results of such a study would be a useful cost-benefit analysis to determine whether the added 
complexity, time, and cost of cellularising scaffolds translated to clinical benefit.  
 
CONCLUSIONS 
The CAM assay is a useful model for studying angiogenesis in biomaterial samples, allowing 
unimpeded real-time visualisation of the developing vascular network and material interaction. The 
assay allows higher throughput testing than conventional in vivo models. However, it is not without 
difficulties and egg viability is highly dependent on patience and experience. This may help explain the 
variability in protocols and parameters cited in the literature. 
The CAM assay was intended to test three principal hypotheses:  
1) use of a native blood protein, fibrin, would show greater angiogenic potential compared to 
similarly structured materials of heavily processed proteins (collagen/GAGs; Matriderm™ and 
Integra®);  
2) reduction of fibrin content in favour of biocompatible but non-bioactive polymers (PVA) would 
reduce angiogenic potential; 
3) 2-dimensional films would show reduced blood vessel interaction compared to highly porous 
(90%) 3-dimensional scaffolds of equivalent composition.  
It was hypothesised that ETPM scaffolds would equal or exceed performance of commercial 
competitors owing to a combination of superior material and structural properties. Examination of 
the microstructures (reported previously) revealed ETPM scaffolds to have a much more open, 
interconnected structure than either Matriderm™ or Integra®. The results reported above could 
suggest that ETPM scaffolds behaved comparably with Matriderm™ and Integra® in terms of blood 
vessel interaction.  
Surprisingly, there was no significant difference in blood vessel interaction between materials of 
different structure (3-dimensional scaffolds versus equivalent 2-dimenional films) or composition. 




a framework to promote capillary ingress during wound healing (Collen et al., 2003). The templating 
technique used to manufacture the fibrin-based scaffolds described here maintained the native 
protein structure and should preserve this functionality. PVA is not bioactive, so fibrin-PVA materials 
were expected to have less of an angiogenic response owing to reduced fibrin concentration.   
However, the results are not sufficiently compelling to make firm conclusions. While the number of 
samples and eggs tested is sufficient for statistical significance, only one batch of eggs survived to 
assay completion, so no technical repeats were achieved.  
The output measures could be improved to help refine data and increase confidence in the results. 
Counting blood vessels in a 3-dimensional model is complex and subjective. As the CAM develops, 
particularly beyond development day 8 (culture day 5), blood vessels remodel and develop in layers. 
It is difficult to determine whether vessels are interacting with the scaffold or passing underneath. 
Some protocols aim to counter this problem by only including vessels that are seen to enter and leave 
the scaffold, but unless the material is transparent this approach is not robust. The capillaries are 
dendritic and tortuous, so it is almost impossible to extrapolate with any confidence.  
Locating the scaffolds during CAM growth and yolk consumption was also challenging. Scaffolds stick 
to the viscous albumen and thus move as the egg contents change conformation. This problem was 
slightly ameliorated with increased ambient humidity, as it prevented albumen drying at the interface. 
Some scaffolds subducted underneath the yolk sac as it flattened – particularly those where the initial 
capillary plexus was not central on the yolk at the time of scaffold placement. Additionally, the highly 
porous scaffolds became saturated with egg material (albumen, etc.) and became virtually 
indistinguishable over time. Imaging could be improved by use of contrast agents. Inks and dyes must 
first be trialled for biocompatibility to avoid biasing the study. Another option is fluorescent labelling 
of the scaffold during manufacture, for example, binding an agent like Alexa Fluor 594 to fibrinogen 
concurrently with thrombin addition.  
Quantification of haem was intended as a more robust measure to supplement blood vessel count. It 
should help assess whether the blood vessels were active (some were observed to retract and remodel 
during the CAM assay) and consider capillary diameter and circulation capacity. However, precise 
extraction of the scaffolds was challenging and may have reduced the quality of the results. Scaffolds 
were removed with forceps. However, the high viscosity of the albumen at the end of the assay meant 
that vessels, which are elastic in nature, preferentially adhered to the albumen matrix rather than the 
scaffold. Surgical scalpels were used to cut away excess albumen around the edge of the scaffold, 
helping to keep blood vessel fragments in the excised scaffold. Some blood may have drained out of 




the Drabkin’s assay is intended for liquid samples only. It may be possible to use some means of 
digesting the scaffold and albumen, perhaps by a mild acid digestion approach, but this would take 
extensive development and refinement to ensure homogenous samples with haem left intact for 
analysis.  
Fixing the tissue would, however, be a useful approach to preserve capillary architecture. Sectioning 
and imaging samples, either staining with H&E or perhaps immunohistochemistry, would give a 
detailed 3-dimensional picture of the capillary plexus and its interaction with the scaffold. This would 
be particularly useful in conjunction with scaffold dyeing or other tagging as the scaffold would be 
clearly defined, making interaction by blood vessel count in and out of the scaffold a more robust 
measure. While labour intensive, this method would yield high-quality results and is highly 
recommended for future use.   
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4. Conclusions  
 
The aim of this project was to design and develop a skin tissue engineering scaffold, with particular 
application in the treatment of chronic wounds and serious burns. There are many products available 
that claim to promote healing of these wounds, and indeed there are many case studies of successful 
treatment with products such as Matriderm®, Integra® and Biobrane®. However, there remains an 
unmet clinical need for products which are able to ‘regenerate’ damaged skin; that is, to repair the 
appearance, composition, and function to equal surrounding undamaged skin.  
Tissue engineering research has offered promising solutions in the shape of stem cell or gene therapy, 
or targeted delivery of growth factors, drugs, or extracellular vesicles. While targeted delivery may be 
achieved, retention in the wound environment is a challenge. Scaffolds offer an implantable ‘niche’ 
for cultured autologous cells or particular controlled doses of other therapies. The rate of release away 
from the immediate scaffold environment can be mediated by porosity and degradation rate. 
Emulsion templated allows creation of scaffolds with tunable, accurate and reproducible porosity and 
pore size. For the body of work described in this thesis, porosity was increased to 90% to maximise 
the internal area for cells and blood vessels while maintaining structural integrity and mechanical 
strength. Pore size was designed match values described in literature to encourage rapid colonisation 
by fibroblasts from the wound periphery and sprouting ends of neighbouring blood vessels to sustain 
resident cells. 
Early results show cytocompatibility and the ability to support ingrowing vasculature, as demonstrated 
in the chick chorioallantoic membrane assay. Before clinical or commercial use the scaffolds should 
be tested more rigorously with higher throughput in vitro assays and large animal models to positively 
confirm biocompatibility, lack of immunogenicity and appropriate degradation profile.  
Cell therapies are often prohibitively expensive and specialised for most healthcare providers. The 
scaffold produced here was designed will both outward migration of cultured cells and ingress of 
healthy native cells in mind. In all the experiments described, the scaffold was freeze-dried after 
manufactured and stored until use. This dramatically It is also a useful consideration for scaled-up 
commercial manufacture, as batches may be made in advance and stored until required. There is no 
need for cold-chain storage during shipment. However, heat treatment of the scaffolds was not tested 
so the fibrin may be sensitive to extreme heat (above 37°C; for example, in a shipping container). 
The ability to retain cells or other therapeutic agents in the wound environment also improves the 




successful treatments. Each of these is associated with hospital care, standard dressings and physical 
therapy and rehabilitation. Improving outcome with fewer surgeries would be hugely beneficial to 
patients by reducing the time spent in operative or postoperative care. 
While the project was initially conceived as an exercise to design a scaffold for stem cell therapy – for 
the reasons outlined above – the engineering of the scaffold and the precursor emulsion itself was the 
focus of research. This decision was not consciously made but reflected available materials as well as 
expertise and research interests. 
As the project evolved, formulation of an appropriate emulsion system became a larger area of 
research than anticipated. Significant time was spent trying to understand the factors contributing to 
emulsion stability and how to manipulate them without adversely affecting the protein scaffold. Oil 
carrying capacity was an unexpected discovery made during the systematic evaluation of surfactants. 
It proved a useful tool in accelerating surfactant selection for scaffold templating, but it has potential 





5. Future work 
Scaffold design 
Enhanced clot formation control 
Alternative fibrinogen splicing, arising spontaneously in nature, produces an elongated γ-chain (γ’). 
This alternatively spliced variant normally circulates as γA/γ’ (as opposed to γA/γA with conventional 
splicing). The γ’ variant has been shown to exhibit looser protofibril packing and larger pores, together 
producing less stiff fibres. The fibres assemble in 3D networks differently, with more heterogeneity in 
diameter and spacing. Importantly, γA/γ’ are more resistant to lysis (Allan et al., 2012; Domingues et 
al., 2016). 
Cross-sectional SEM images of the scaffolds described in this project show structures more 
characteristic of the γA/γ’ variant. However, this has not been confirmed. It would be interesting to 
do so and to attempt formation of scaffolds with structures characteristic of the γA/γA type. This 
should produce scaffolds with better mechanical strength but poorer resistance to hydrolytic 
degradation. The ability to tune γA/γA : γA/γ’ for optimisation of mechanical and degradation 
properties would be very useful. 
Thrombin concentration is widely known to impact clot strength as well as fibre diameter and density 
of the 3D mesh (Blombäck, 2000; Weisel, 2004). The concentration of thrombin used here was 
relatively low, producing fewer, thicker fibres with fewer branch points. It would be useful to increase 
thrombin concentration and investigate the effect of the change in fibre number, diameter, and 
number of branch points on the mechanical and degradative properties. The effect on cell adhesion 
and rate and extent of locomotion should also be studied. Fibre diameter and spacing in electrospun 
artificial membranes has been shown to affect the proliferation, orientation and integration of a 
variety of cell types with the scaffold, including fibroblasts, Schwann cells, neurons and dendrites, 
mesenchymal stem cells and smooth muscle and bone cells (Gupta et al., 2009; Jin et al., 2012; 
McCullen et al., 2007; Nam et al., 2007; Sun et al., 2007; Wang et al., 2013; Zhou et al., 2015). The 
same would be expected in a fibrin network. The fibrin scaffold poses a more interesting question as 
the electrospun membranes are commonly either 2-dimensional or very thin (50-200 µm, or 30 µm 
for single layer membranes)(Bhattarai et al., 2004; Pan et al., 2014; Pu and Komvopoulos, 2014; Riboldi 







In vitro assays 
Designing and characterising the emulsion system consumed a significant amount of project 
resources. In vitro tests were scaled back as a result. Although the final scaffold properties conform 
to values presented in the literature as being optimal for cell ingress and proliferation, this should be 
verified with culture of relevant cell types (dermal fibroblasts, endothelial microvascular cells, and 
mesenchymal stem cells). It would be useful to investigate the material and structural contributions 
of the scaffolds on metabolic activity (MTT; live/dead), adhesion and production of ECM components 
(immunofluorescence and colorimetric detection; qPCR; ELISA; Western blot analysis).  
PVA, alginate and PEG were added to improve the mechanical properties of the scaffold and also to 
reduce the cost per unit area. Fibrinogen and thrombin are considerably more expensive that the 
other polymers, particularly when using the human proteins that would be needed for a clinical 
product. Inclusion of the other polymers makes the scaffold more economically viable. However, while 
the mechanical and structural effects of adding these materials were evaluated, the biological effects 
were not. Again, the effect on cell viability, adhesion, and differentiation (of primary MSCs) should be 
assessed for different material combinations at different ratios. 
CAM assay repeats 
The CAM assay was repeated multiple times owing to unexpected equipment failures and method 
fallibility. The final method worked well in our laboratory; however, the results obtained were 
inconclusive. It would be useful to repeat the assay with a technical repeat, as originally intended, as 
a larger sample size would give more confidence in the results. 
Counting the number of blood vessels interacting with a small disc in a deep, translucent medium is 
difficult to perform accurately and objectively. Future assays, therefore, should use histology (H&E 
and immunohistochemistry) to give a better indication of blood vessel interaction with the scaffold. 
Fixed samples would be much easier to handle without tearing either the scaffold or the vessels when 
removing from the viscous albumen. Sectioning to expose the scaffold would allow simple counting of 
blood vessels interacting with the material by eliminating the planes above and below (difficult to 
achieve by eye alone). H&E staining would increase contrast; immunohistochemistry could identify 
the new blood vessels from the ones made redundant during remodelling. Again, this is very difficult 





In vivo studies 
In vitro assays are useful ways of predicting cell behaviour, particularly during the design and 
development stage, but are limited models of the complex whole animal system. Animal studies 
should form two stages: firstly, basic biocompatibility testing to ensure the fundamental safety of the 
material. Once this is confirmed, longer-term studies can assess the efficacy of the scaffolds at healing 
a) acute (surgical excision) and b) debrided full thickness burn wounds compared to current clinical 
products (Matriderm, Integra and Biobrane scaffolds). This two-stage procedure is similar to the 
testing process required by the FDA for testing safety and efficacy of implantable materials. 
Using small animals allows a larger number of repeats, but less biologically relevant results for human 
use. Pig studies are more expensive, but more samples may be applied to a single animal and the pig 
is the best non-primate model for humans. Ultimately, the materials could be submitted for human 
clinical trials to be tested for safety and efficacy in healing surgical and burn wounds and chronic 
ulcers. 
 
Preparation for commercial transfer 
Batch size 
The scaffolds described in this thesis have been optimised at lab scale, with a typical batch comprising 
8-10 scaffolds, 5x5 cm2. Scaffolds have been manufactured at 10x10 cm2 (a typical commercial scaffold 
size), but batch size was reduced owing to size constraints of the fume hood and laminar flow cabinet.   
To make the scaffolds commercially viable, the scaffolds must be manufacturable at 10x10 cm (or 
above) in larger batch sizes. The washing and drying stages are very time consuming and so the ability 
to produce a large number of scaffolds in a single batch would drastically improve the efficiency of the 
process and reduce operational costs.  
Manufacturing time 
Currently, all scaffolds are freeze dried prior to use. The freeze-drying process was shortened during 
process optimisation, but the complete freezing and drying cycle still takes 16 hours. For some freeze-
dried products, the freeze drying is used as the mode of generating porosity and thus is an integral 
part of the process. In this case, the porosity is generated by the emulsion template and freeze drying 
is used simply to preserve the structure and to remove moisture, prolonging shelf-life. However, the 
results of the short-term hydrolytic degradation assay (Chapter 3.3) indicate that the scaffolds are 




for longer periods – for example, 1 to 2 years – it may be possible to eliminate the drying process 
completely and simply package the sterile scaffolds in a pouch with saline. Integra® Dermal 
Regeneration Template (Integra LifeSciences) is currently packaged in this manner. The long-term 
hydrolytic stability of the scaffolds in saline should be assessed, as should the bioburden after two 
years’ storage in ambient conditions. The scaffold microstructure (e-SEM) and mechanical properties 
(tensile and compressive) of the non-dried scaffold should be compared to a typical freeze-dried 
scaffold that has been washed and rehydrated in saline as though for clinical application. If 
comparable, the freeze-drying step may be removed, reducing manufacturing time by half. 
Process automation 
Process automation would be a useful step towards commercialisation, freeing up labour time for 
characterisation and batch testing. The most obvious opportunity for optimisation is the emulsion 
mixing. Vortex mixing and shear mixing yielded inferior results to hand shaking for manufacture at lab 
scale. However, behaviour is likely to be different at larger scale owing to the increased distance 
between the mixer and the vessel walls changing the shear dynamics. Other methods of mixing should 
also be attempted. It may also be possible to generate a single large volume of emulsion from which 
a whole batch of scaffolds could be cast. This would certainly create good reproducibility within 
batches. If the emulsion mixing process was robust and repeatable then batch-to-batch variability 
could be minimised. This is an important point to prove during the regulatory assessment process. 
The washing processes could also be at least partially automated. The rig shown below is a possible 





     
Fig. 1: Proposed rig for automation of the scaffold washing process. Automation has the 
potential to accelerate manufacture time, increase batch size capability and minimise 
handling. Reduced scaffold handling during manufacture decreases risk of damage to the 
scaffolds (increasing viable yield per batch) and risk of contamination introduced by 
laboratory personnel. 
 
‘Next generation’ product modifications 
Cellularised scaffolds 
The scaffolds described here have thus far been characterised and discussed as an acellular product. 
Many of the commonly used clinical scaffolds are acellular; it is the ECM protein composition that 
gives some biological relevance. Adding cells adds significant cost, complexity (in manufacture, 
storage, delivery, safety, and regulation) and time to market. Autologous cells must be harvested then 
expanded and cultured in the scaffold. Transporting the cellularised scaffold from the lab to the 
patient while guaranteeing both sterility and viability is challenging. Clinical use of cellularised 
scaffolds is therefore likely to be limited to ‘centres of excellence’ where hospitals contain dedicated 
clean rooms and CL2 laboratories for cell culture and the surgical team is experienced with 
combination products.  
The use of cellularised scaffolds must therefore be justified by in vitro and in vivo assays to confirm 
superiority over the acellular material. Increased rate of cell ingress and colonisation of the scaffold, 




vasculature is a current limitation of tissue engineering scaffolds. If insufficient, any resident cells are 
likely to experience reduced viability.  
Histology from in vivo implantation of acellular and cellularised (with autologous fibroblasts or 
mesenchymal stem cells) could be used to assess extent and maturity of vasculature at different time 
points. Histology would also reveal the presence of various ECM products secreted by cells and the 
organisation of these products in the wound. Cellularised scaffolds would be expected to show 
enhanced vascularisation, cell colonisation and ECM deposition owing to the contribution of the 
implanted cells in addition to wound periphery fibroblasts. This should be confirmed, and cost/benefit 
analysis performed compared to acellular materials. 
Fibrin decoration 
As evidenced from its physiological role as a clotting protein, fibrin is a naturally sticky protein. Unlike 
other biomaterials which must be treated with laminin or fibronectin to improve adhesion, fibrin may 
be directly decorated with therapeutic agents. Fibrin scaffolds are therefore an interesting vehicle for 
delivery of growth factors, extracellular vesicles, etc. to the wound environment. These could be used 
as additional biochemical cues to accelerate the wound healing response or to influence the type of 
healing. This could be a useful tool in promoting regeneration over scarring and less organised or less 
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